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Abstract 
 
 
The transcription factor SRF (Serum Response Factor) regulates expression of 
target genes in response to changes in actin dynamics, by virtue of association with 
the Myocardin Related Transcription Factor (MRTF) family of transcription 
cofactors. MRTF-A senses changes in actin dynamics via direct G-actin binding to 
its RPEL domain. While bound to actin MRTF-A continuously shuttles between the 
nucleus and cytoplasm, but localises to the cytoplasm due to a high export rate. 
Because MRTF-A is exported by Crm1 in an actin dependent manner, dissociation 
from actin leads to nuclear accumulation and SRF activation. Concomitantly, 
MRTF-A is phosphorylated on multiple residues. The aim of this thesis was to 
determine the role of phosphorylation in MRTF-A function. 
 
An MRTF-A derivative lacking all 26 identified phosphorylation sites was generated. 
Evidence is presented that phosphorylation of MRTF-A is required for its full 
capacity to activate SRF. One phosphorylation site, S98, is located within the RPEL 
domain. Phosphorylation of S98 attenuates actin binding to the RPEL domain and 
promotes nuclear accumulation of MRTF-A. I found that S98 is phosphorylated by 
ERK, which relies on an ERK binding motif just N-terminal of S98. Thus S98 
represents a means by which MAP kinase signalling can impinge on MRTF-A 
regulation. In contrast, S33 phosphorylation promotes export of MRTF-A conferred 
by a Crm1 NES that was identified within its N-terminus. I have shown that this 
NES can act as an autonomous NES, but cooperates with the RPEL domain to 
confer actin dependent Crm1 mediated export. MRTF-A phosphorylation, can 
therefore fine-tune MRTF-A regulation by affecting both localisation and activity. 
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Chapter 1. Introduction 
 
 
1.1 Signal transduction 
 
All aspects of cell behaviour, including growth, proliferation, survival or death, 
are dynamically regulated in response to internal and external cues. Cells 
continuously receive information regarding their surrounding environment, using 
receptors to sense concentrations of hormones, growth factors or extracellular 
matrix composition. Cells also sense changes in the intracellular milieu, such as 
changes in concentration of metabolites, structure proteins such as actin, or 
stresses such as DNA damage or unfolded proteins. Information regarding all these 
parameters must be transformed or transduced into signals that are capable of 
eliciting a set of molecular responses that together develop an appropriate cellular 
response. These signals are often in the form of post-translational modifications 
(PTMs) of proteins, orchestrated by groups of proteins that constitute signalling 
pathways. A major target for such pathways is gene expression machinery, which 
forms the focus of this introduction. 
 
1.1.1 Post translational modification 
Post translational modification (PTM) is any process that changes a protein, 
after it has been translated, leading to changes in its structure and/or function. 
Modification can be permanent, as is the case with cleavage and removal of part of 
the protein, or reversible as in the case of covalent attachment of chemical moieties. 
Enzymes that introduce or remove PTMs are major targets for signal transduction 
pathways. 
 Since PTMs are biochemical reactions catalysed by enzymes, a single 
enzyme can modify multiple targets leading to signal amplification. Antagonising 
enzymes, which reverse the modification, allow cells to dynamically regulate the 
Chapter 1 Introduction 
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target protein ensuring fast and controlled execution of cellular processes. A single 
protein can be the recipient of multiple and different PTMs allowing integration of 
signals at a single target. Signals from parallel signalling pathways can be 
integrated by converging onto a common component protein whose function will be 
defined by the combination of PTMs it has received. For example the 
transcriptional activity, cellular localisation and stability of p53 can be independently 
regulated by different forms of PTM (Lavin and Gueven, 2006; Kruse and Gu, 
2008). 
 There are several different types of PTM including phosphorylation, 
ubiquitination, SUMOylation, oxidation, neddylation, acetylation and methylation. 
Some are historically associated with specific processes, for example poly-
ubiquitination was initially best known as a degradation signal and phosphorylation 
was thought of as distinctive of glycogen metabolism (Johnson, 2009). As the field 
of signalling advanced it became evident that the different PTMs were widespread 
phenomena, not confined to specific cellular processes. In most cases, reversible 
PTMs are in essence a means to create or impair an interaction surface, either 
directly or allosterically. The new conformational state has context specific 
functional consequences; for example, in some cases PTMs can alter the 
enzymatic activity of a protein. In the next section I will focus on phosphorylation, 
one of the most common and well-studied PTMs. 
 
1.1.2 Phosphorylation 
Phosphorylation is the transfer of the terminal or γ-phosphate of ATP to a 
functional group of a target substrate. Substrates can be lipids, such as the 
membrane resident phosphoinositides, or proteins. In higher eukaryotes protein 
phosphorylation occurs on three residues; serine (Ser), threonine (Thr) and 
tyrosine (Tyr). Global phosphoproteomics studies showed that in resting cells, the 
relative abundance of phospho-serine, -threonine or -tyrosine was 86.4%, 4.8% 
and 1.8% respectively (Olsen et al., 2006). Histidine (His) phosphorylation has also 
been reported but is a rare event (Wagner and Vu, 1995; Attwood, 2013). 
 Phosphorylation can have strong effects on the conformation and hence 
function of a protein. Serine, threonine and tyrosine residues have a hydroxyl group 
Chapter 1 Introduction 
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on their side chains, to which the relatively bulky phosphate group is covalently 
attached.  At physiological pH the phosphate group exists as a dianion, adding a 
double negative charge to the previously neutral location (Johnson and Lewis, 
2001). The phosphorylated side chain can now form new intra- or inter-molecular 
interactions through hydrogen bonds or salt bridges. The resulting conformational 
changes can affect enzymatic activity of an active site or interactions with binding 
partners that can potentially affect any aspect of the proteins’ function (activity, 
localisation, half-life etc). 
 Each phosphorylatable residue can be attached to only one phosphate 
providing a form of binary code that might appear inflexible. However, a single 
protein can possess multiple phosphorylation sites, which can affect each other’s 
function and allow tunable thresholds and diverse functional outcomes (Kõivomägi 
et al., 2013). For Src kinases, C-terminal phosphorylation maintains the protein in a 
latent state, while phosphorylation of the activation loop is required for activation 
(Boggon and Eck, 2004).  
 Phosphorylation is catalysed by protein kinases. Over 500 kinases have 
been identified making up a 1.7% of the total number of human genes. Several 
kinases can sequentially phosphorylate each other, forming a signalling cascade. 
One of the most intensively studied signalling cascades is the Raf-MEK-ERK 
mitogen-activated protein kinase cascade. 
 
1.1.3 Mitogen-activated protein kinases (MAPKs) 
1.1.3.1 MAPK signalling cascade 
The mitogen-activated protein kinase pathway is highly conserved in 
eukaryotes and it responds to a multitude of intra- and extracellular signals to 
regulate a wide range of cell processes including proliferation, survival and 
differentiation, reviewed in (Yang et al., 2003; Kyriakis and Avruch, 2012). The 
pathway features a three-tiered architecture (Figure 1.1), at the end of which three 
families/groups of MAPKs are found: the extracellular signal-regulated kinase 
(ERK) family, the p38 family and the c-Jun N-terminal kinase (JNK) family. Stress 
or ligand activated cell surface receptors lead to the activation of the first tier, the 
Chapter 1 Introduction 
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MAP kinase kinase kinase (MAPKKK), MAPKKKs in turn activate the tier 2 kinases, 
the MAPKKs, through phosphorylation. MAPKKs in turn phosphorylate and activate 
the third tier, the MAPKs, downstream of which are a multitude of substrates; 
including further kinases such as the ribosomal S6 kinases (Rsks) (Raman et al., 
2007). Often substrates are transcription factors, whose DNA binding or activity is 
affected. One extensively studied case is that of Elk1/serum response factor (SRF). 
ERK phosphorylates the transcription activation domain of Elk1 at multiple 
positions, causing transcriptional activation, by facilitating recruitment of the 
Mediator complex through Med23 (Cruzalegui et al., 1999; G. Wang et al., 2005). 
 
1.1.3.2 The ERK1/2 module 
 Extracellular regulated kinase-1 (ERK1) and ERK2 were first noticed as two 
proteins which became tyrosine phosphorylated after growth factor stimulation 
(Cooper et al., 1982). A decade later their complementary DNAs (cDNAs) were 
cloned and were found to be highly related, sharing 83% sequence identity 
(Johnson, 2009; Boulton et al., 1990; 1991). Both are ubiquitously expressed, are 
activated in response to a variety of stimuli (Olsen et al., 2006; Boulton et al., 1990; 
Cooper et al., 1982) and share many but not all functions (Wagner and Vu, 1995; 
Lloyd, 2006).  
 Despite being co-expressed in the majority of tissues, the relative amounts 
of each isoform can be different between tissues (Johnson and Lewis, 2001; 
Boulton et al., 1991). The phenotypes of knockout mice are also different. ERK2 -/- 
mice die during development (Kõivomägi et al., 2013; Hatano et al., 2003; Yao et 
al., 2003), while ERK1-/- mice are born but have a defect in thymocyte maturation 
(Raman et al., 2007; Pagès et al., 1999). From these studies it was not clear 
whether there was a gene dosage effect. Lefloch et al. ablated ERK1 or ERK2 in 
cell based assays and investigated their relative contribution to immediate early 
gene expression and proliferation (Lefloch et al., 2008). The authors showed that a 
depletion of either ERK1 or ERK2 lowered immediate early gene expression but 
only ERK2 depletion would block proliferation. They next demonstrated that very 
low levels of ERK activity are sufficient for proliferation and the contribution of 
ERK1 was only uncovered upon sufficient depletion of ERK2. The authors 
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proposed that differences in ERK1 and ERK2 expression are responsible for the 
apparent differences seen between ERK1 and ERK2 knockout mice. 
 
 
 
Figure 1.1 Overview of the mitogen-activated protein kinase (MAPK) 
signalling pathways.  
MAPKs can be divided into three categories: ERK, JNK and p38, and each 
category is comprised of a 3-tier architecture: MAPKKKs phosphorylate MAKKs, 
which in turn phosphorylate and activate MAPKs. Some examples of transcription 
factors and kinases targeted by MAPKs are indicated. 
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1.1.3.3 Activation 
In mammalian cells ERK1/2 are activated in response to stimulation with 
growth factors such as epidermal growth factor (EGF), platelet derived growth 
factor (PDGF) and insulin, which activate receptor tyrosine kinases. Ligand binding 
induces dimerisation and activation of the receptors, seeding the assembly of 
signalling complexes that activate the membrane localised small GTPase Ras 
(Cooper et al., 1982; Lemmon and Schlessinger, 2010). Ras is also activated by 
lysophosphatidic acid (LPA), thrombin and other agonists of G-protein coupled 
receptors (GPCRs), although the mechanisms involved are less clear (Downward, 
2003; van Corven et al., 1993). Active Ras, RasGTP, in turn activates Raf, the 
apical kinase or MAPKKK of the ERK1/2 signalling cascade. 
 Raf is a family of three proteins (A-Raf, B-Raf and C-Raf or Raf1) of which 
Raf1 is ubiquitously expressed and most intensively studied (Storm et al., 1990). 
Raf1 activation is a complex set of molecular events that involves membrane 
recruitment, protein-protein interactions, dimerisation and phosphorylation. Raf1 is 
recruited to the membrane by binding to RasGTP via its Ras binding domain (RBD) 
(Wittinghofer and Nassar, 1996). This recruitment step is not sufficient for activation 
and is itself subject to multiple modes of regulation. Binding of 14-3-3 to the C-
terminus of Raf1 then stimulates the phosphorylation of multiple residues essential 
for activation, reviewed in (Wellbrock et al., 2004). Multiple kinases and the 
respective signalling pathways have been suggested to feed into Raf signalling 
through these phosphorylation sites, either positively or negatively affecting Raf1 
activation. Examples include protein kinase A (PKA), p21-activated kinase (PAK) 
and protein kinase C (PKC) (Dumaz et al., 2002; Kolch et al., 1993; Schönwasser 
et al., 1998; Chaudhary et al., 2000). Direct activation of Raf1 by PKCs, can be 
induced using tetradecanoyl phorbol acetate (TPA). TPA is an analog of diacyl 
glycerol, which binds and activates PKC and is frequently used experimentally to 
activate the MAPK pathway (Marquardt et al., 1994; Schönwasser et al., 1998). 
 The only widely accepted substrates of Raf1 are MAPK/ERK kinases 1/2 
(MEK1/2), the second tier kinases of the ERK1/2 cascade. MEK1/2 are activated 
after a double serine phosphorylation within their activation domain (S217 and 
S221 for MEK1) by Raf1 (Zheng and Guan, 1994). Substitution of these two 
residues to acidic residues and deletion of a small N-terminal sequence (aa32-51) 
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results in a constitutively active kinase (Mansour et al., 1994). Amounts of cellular 
MEK in most cell types tested are higher than those of Raf, allowing for signal 
amplification (Fujioka et al., 2006). Activated MEK1/2, being dual specificity kinases, 
phosphorylate the regulatory Thr and Tyr residues in the activation loop of ERK1/2 
(Ahn et al., 1992).  
A small molecule commonly used to inhibit ERK activation by MEK1/2, is 
U0126. U0126 is not an ATP competitor, instead it allosterically affects the activity 
of MEK, meaning that it binds MEK in a unique site (or at least less conserved than 
the ATP pocket) and is also able to inhibit constitutively active MEK mutants 
(Duncia et al., 1998). Evidence that U0126 inhibits MEK activation rather than MEK 
activity were later explained by the lower affinity of U0126 for activated rather than 
inactive MEK (Sheth et al., 2011; Davies et al., 2000) 
 Signal propagation down the cascade is organised by scaffold proteins, 
ensuring efficiency, spatial regulation and specificity. Several scaffolds have been 
identified in mammals, including kinase suppressor of Ras (KSR), MEK partner 1 
(MP-1) and β-arrestin (Therrien et al., 1996; Luttrell et al., 2001). KSR coordinates 
membrane assembly of Raf-MEK-ERK. Upon activation of Ras, KSR translocates 
to the membrane, bringing the pathway components in close proximity and greatly 
enhancing activation efficiency (Brennan et al., 2011). Upon angiotensin stimulation, 
β-arrestin-2 facilitates assembly of the Raf-MEK-ERK complex in endosomal 
vesicles and enhances Raf-MEK dependent activation of ERK (Luttrell et al., 2001). 
 Scaffolds can also have an impact on the kinetics of ERK signalling. 
Depletion of p14, an adaptor protein for the scaffold MP-1, results in its 
mislocalisation and a consequent shortening in the duration of ERK signalling (Teis 
et al., 2002). 
 
1.1.3.4 Docking of ERK to substrates 
ERK is a proline (Pro) directed Ser/Thr kinase, which means that it 
phosphorylates Ser/Thr residues followed by a proline. The optimal primary 
sequence is Pro-X-Ser/Thr-Pro but Ser/Thr-Pro is sufficient and represents the 
minimal consensus (Gonzalez et al., 1991; Clark-Lewis et al., 1991). There is 
therefore a specificity overlap with other proline directed kinases such as the cyclin-
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dependent kinases (CDKs) (Northwood et al., 1991; Hall and Vulliet, 1991). The 
presence of this minimal consensus in a protein does not necessarily make it an in-
vivo target. An important determinant of ERK substrate specificity is the presence 
of docking sites through which they can recruit ERK and in some cases other 
MAPKs as well. The docking sites can increase local concentration of the kinase 
and promote substrate phosphorylation. 
 The best characterised ERK binding motif is the D-domain, which is 
composed of a cluster of basic residues followed shortly by Leu-X-Leu (Yang et al., 
1998; Sharrocks et al., 2000). The D-domain can be recognised by all MAPKs but 
subtle differences in the sequence can discriminate between them (Garai et al., 
2012). The location of the D-domain can be either N- or C-terminal to the target site 
and is recognised by the common docking (CD) domain of ERK (Tanoue and 
Nishida, 2003). The D-domain is present in the ternary complex factor (TCF) family 
of SRF cofactors, and I will demonstrate a similar motif in myocardin related 
transcription factor A (MRTF-A) (see chapter 4). 
 Another ERK docking motif is the DEF domain or FxFP motif. This domain is 
recognised only by ERK and p38ɑ and is most often found downstream of the 
phospho-acceptor site (Tanoue and Nishida, 2003; Whitmarsh, 2007). However, 
ERK binding cannot be predicted based on the presence of the aforementioned 
docking sequences, as ERK docking sites that do not bear any resemblance to 
either motif have also been reported (Molina et al., 2005). 
 
1.1.3.5 Subcellular localisation of ERK 
 ERK phosphorylates many nuclear proteins, and to do so it must translocate 
to the nucleus. In fact inactivation of Crm1 mediated export using Leptomycin B 
(LMB), results in ERK nuclear accumulation, indicating that ERK continuously 
shuttles via the nucleus (Volmat et al., 2001). In resting 3T3 cells ERK is inactive 
and predominantly cytoplasmic, although recent studies have demonstrated 
periodical nuclear activity. In HeLa cells it is evenly distributed. In both cases, 
activation leads to rapid and sustained nuclear accumulation, which is the net effect 
of an unequal acceleration in import and export rates (Volmat et al., 2001; Chen et 
al., 1992; Ando et al., 2004).  
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 Cytoplasmic retention of ERK in resting cells is brought about by association 
with various anchor proteins, including MEK and the tubulin cytoskeleton 
(Chuderland and Seger, 2005; Reszka et al., 1995). Stimulation leads to an 
activation loop conformational change and detachment of ERK from cytoplasmic 
anchors (Wolf et al., 2001). In the latter studies it was shown that GFP-ERK lacking 
the regulatory phosphorylation sites (183-TEY-185) was unable to accumulate in 
the nucleus under non-saturating conditions (of MEK). This was in agreement with 
the observation that inhibition of MEK activity greatly reduced ERK nuclear 
accumulation (Lenormand et al., 1998). Wolf et al. show that residues 176-DHT-
178 are important for dissociation from MEK and propose that they serve as a lever 
that causes dissociation (Wolf et al., 2001). Inactive ERK derivatives have been 
reported to be nuclear in other studies, however, they involved microinjection or 
overexpression which can saturate cytoplasmic anchors (Khokhlatchev et al., 1998; 
Fukuda et al., 1997; Rubinfeld et al., 1999). Volmat et al. have reported continued 
nuclear accumulation of endogenous ERK 3h after stimulation (Volmat et al., 2001), 
by which time ERK is inactive. It is possible that the initial phosphorylation is only 
required for initial detachment from anchor proteins and not for nuclear 
translocation. 
 Translocation of ERK has been shown to occur both passively (by diffusion) 
and actively (Zehorai et al., 2010). It was recently discovered that a three-residue 
motif, 244-Ser-Pro-Ser-246, is responsible for signal induced nuclear accumulation 
of ERK as well as passive translocation (Chuderland et al., 2008). The motif 
appears to be a general nuclear translocation signal. Fusion of a 19-residue 
sequence containing the SPS motif led to nuclear translocation of non-diffusible 
proteins. 
 Phosphorylation of the SPS motif in ERK was shown to be required for both 
passive and active nuclear translocation, warranting a search for the responsible 
kinase or kinases. Plotnikov et al. showed that inhibition or depletion of casein 
kinase II (CKII) blocked phosphorylation of the SPS motif and prevented ERK 
nuclear translocation. In addition, they were able to phosphorylate the motif in vitro 
using recombinant CKII and were able to co-immunoprecipitate the complex from 
cell lysates. They also demonstrated that phosphorylation of the SPS motif is a 
distinct step that follows release from anchor proteins that prevent its 
phosphorylation (Plotnikov et al., 2011). 
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1.1.3.6 Inactivation by phosphatases 
The amplitude and duration of the ERK signal is also regulated by 
phosphatases that dephosphorylate and inactivate ERK (Owens and Keyse, 2007). 
Removal of either of the phosphates from the TEY motif in the ERK activation loop 
renders it inactive (Anderson et al., 1990). MAPK phosphatases (MKPs) are 
divided into three categories according to their specificity. These are the Ser/Thr 
phosphatases, the Tyrosine phosphatases and the dual specificity phosphatases 
(Keyse, 2000; Farooq and Zhou, 2004). There are ten dual specificity MKPs 
expressed in human, and they can be divided into Class I, II and III. Class I 
phosphatases are inducible. ERK activity promotes their de-novo synthesis after 
which they translocate to the nucleus to provide negative feedback. Class II is 
composed of cytoplasmic phosphatases. Class III phosphatases are found in either 
cellular compartment and preferentially target JNK and p38. Between them, the 
different classes of phosphatases form a complex network enabling negative 
regulation of ERK signalling (Roskoski, 2012; Owens and Keyse, 2007). 
 
1.1.3.7 Variations in ERK signalling dynamics produce different responses 
Signalling dynamics of ERK can be defined as the shape of the curve that 
describes the concentration, localisation and activity of ERK over time. As 
described above these parameters are affected by the stimulating extracellular 
ligand, the scaffolds and the phosphatases, which will all impinge on the efficiency 
and duration of ERK phosphorylation and activation in a given location.  
 Quantitative differences in the signalling dynamics of a signalling pathway 
can produce qualitatively different responses. An early report of such a case 
involved stimulation of PC12 neuronal precursor cells with two different growth 
factors, neuronal growth factor (NGF) and EGF. NGF led to differentiation and EGF 
led to proliferation. It was shown that the difference in cell fate was not due to 
activation of different signalling pathways, but instead that the two ligands 
produced distinctly different ERK activation profiles. EGF produced transient ERK 
activation, while NGF produced sustained ERK activation, which could presumably 
be sensed by downstream effectors such as transcription factors (Marshall, 1995). 
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 In further work, Grammer and Blenis showed it was possible to alter the 
ERK signal elicited by EGF and NGF, thereby swapping the expected outcomes. 
Using TPA, the normally transient ERK activation elicited by EGF, was converted to 
a sustained response, leading to differentiation. Conversely the PKC inhibitor 
Gö7874, made the NGF induced ERK activation a transient one, leading to 
proliferation (Grammer and Blenis, 1997). 
 At least one mechanism by which the different ERK signalling profiles were 
decoded is demonstrated with the example of the c-Fos protein. In Swiss 3T3 
fibroblasts, the transient ERK activity achieved by EGF stimulation led to a small 
induction of the immediate early gene Fos. PDGF produced sustained ERK activity, 
significant Fos induction and cell proliferation (Murphy et al., 2002). The c-Fos 
protein is unstable and rapidly degraded, unless phosphorylated by ERK. Upon 
sustained ERK activity c-Fos is synthesised, phosphorylated, stabilised and able to 
promote proliferation (Murphy et al., 2002). 
 The recent development of sensitive FRET biosensors for ERK activation 
has enabled live monitoring of ERK activity, on a single cell basis, in asynchronous 
cell populations (Aoki et al., 2012). It was shown that cell density affected the 
frequency of stochastic ERK activity pulses and that their frequency, but not the 
amplitude, correlated with cell proliferation. In addition, using a light activatable Raf 
protein the authors were able to control ERK activity frequency to accelerate cell 
proliferation. RNA sequencing analysis suggested the involvement of SRF in the 
expression of genes which responded to pulsatile rather than sustained ERK 
activity (Aoki et al., 2013).  
 
1.1.4 Regulation of transcription factors by phosphorylation 
Phosphorylation is a common mechanism employed to regulate 
transcription factor activity, allowing control over transcription of proteins necessary 
for appropriate cellular responses to stimuli. Phosphorylation or dephosphorylation 
can directly affect transcription factor behaviour including localisation, stability, 
interactions with other proteins and DNA binding. Examples are shown in Figure 
1.2. In essence, what is important is the concentration of the transcription factor at 
Chapter 1 Introduction 
 25 
the target gene location and the potency with which it can promote transcription of 
the target. 
 Wilms’ tumour 1 (WT1) is a transcription factor that differentially affects 
genes; it can either activate or suppress their transcription. WT1 binds DNA target 
sequences using its positively charged zinc finger domain. Phosphorylation of two 
serine residues within the zinc finger domain inhibits DNA binding (Fig 1.2 A) 
(Toska and Roberts, 2014; Sakamoto et al., 1997). 
 Nuclear factor of activated T cells (NF-AT) localisation is phosphorylation 
dependent. An increase in calcium levels activates the phosphatase calcineurin, 
which dephosphorylates NF-AT.  A subsequent conformational change leads to 
exposure of at least one nuclear localisation signal allowing nuclear accumulation 
and access to DNA target sequences (Fig 1.2 B)(Rao et al., 1997). 
 The transcription cofactor Elk1, a member of the TCF family, associates with 
DNA via the serum response factor (SRF). Upon ERK activation, phosphorylation 
of the Elk1 C-terminal transactivation domain leads to robust activation of the Fos 
gene. Multiple phosphorylations within the transactivation domain lead to 
recruitment of the Mediator complex and transcriptional activation (Fig 1.2 C) 
(Cruzalegui et al., 1999; Marais:1993uf Galbraith et al., 2013; G. Wang et al., 2005). 
 In unstressed cells the transcription factor p53 is bound by Mdm2. This 
interaction leads to the continuous ubiquitination and degradation of p53. DNA 
damage activates ATM/ATR signalling, which leads to p53 phosphorylation, 
interruption of the Mdm2 association and stabilisation of p53 levels, and 
transcriptional activity (Fig 1.2 D) (Prives, 1998; Moll and Petrenko, 2003; Lavin 
and Gueven, 2006). 
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Figure 1.2 Regulation of transcription factors by phosphorylation. 
Protein phosphorylation has context specific consequences. A. Phosphorylation of 
Wilms’ tumour 1 (WT1) by PKA and PKC on S365 and S393 respectively blocks its 
ability to bind DNA. B. In the phosphorylated form, NF-AT adopts a conformation in 
which the NLS is masked. Dephosphorylation allows nuclear translocation and 
activation of target genes. C. Activation of MAPK signalling leads to 
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phosphorylation of Elk1 on multiple sites within its C-terminal transactivation 
domain. Once phosphorylated Elk1 facilitates transcriptional activation by recruiting 
the Mediator complex through direct interaction with Med23. D. p53 is continuously 
poly-ubiquitinylated by Mdm2 and sent for proteasomal degradation. Stress 
activated protein kinases such as ATM, ATR and p38 phosphorylate and stabilise 
p53 by inhibiting the interaction with Mdm2. 
 
 
1.2 Nucleocytoplasmic shuttling 
 
The nucleus and cytoplasm are hosts to very different processes vital for cell 
function. The two compartments therefore contain very different sets of proteins. 
Some proteins are found exclusively in one compartment, however, in the case of 
nuclear proteins, they must first be synthesised and then sent to the nucleus. 
Conversely, the mRNA required for protein synthesis in the first place, originates 
from the nucleus. The two compartments must therefore cooperate and exchange 
both information and protein components.  
Many proteins possess signal peptides, which define the location of the protein 
once it is translated. Histones, which are required for chromatin assembly, are 
synthesised in the cytoplasm and subsequently imported into the nucleus where 
they can carry out their function. This implies that once translated a histone must 
either make its way to the nucleus by diffusion, or that it is recognised and actively 
imported into the nucleus. In addition it must “qualify” for nuclear localisation since 
not all proteins can be found in the nucleus. 
 The first evidence suggesting selective nuclear entry came from 
microinjection experiments by Bonner in 1975. By microinjecting radiolabelled 
proteins into the cytoplasm of oocytes they showed that small proteins were able to 
equilibrate between the nucleus and cytoplasm, whereas larger proteins were 
excluded from the nucleus. Interestingly, if the large protein was destined for the 
nucleus it would be granted nuclear access. In the case of histones nuclear 
accumulation would occur at equal or faster rates than other smaller proteins 
suggesting the presence of active import (Bonner, 1975a; 1975b).  
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 Not all proteins have a static subcellular localisation like histones. As 
described in section 1.1.3.5 some proteins like ERK, accumulate in the nucleus in a 
signal dependent manner. The case of ERK is a complicated one, but it 
demonstrates a variety of ways by which nuclear accumulation can be achieved. In 
resting cells ERK appears cytoplasmic despite its slow rate of shuttling through the 
nucleus. This can be achieved either by cytoplasmic anchoring, or a nuclear export 
rate which is faster that the import rate. Upon stimulation ERK accumulates in the 
nucleus by addressing both mechanisms that render it cytoplasmic. 
Phosphorylation leads to detachment from cytoplasmic anchors, and an increase in 
the rate of import. ERK localisation is therefore defined by the net effect of import, 
export and the stoichiometric capacity of anchors.  
 
1.2.1 The nuclear pore complex 
 For a protein to enter or exit the nucleus, it must translocate via a nuclear 
pore, a large protein complex spanning the nuclear envelope. The nuclear pore 
complex (NPC) is a ∼50MDa complex comprised of multiple copies of 
approximately 30 different nucleoporins (Nups) (Hetzer, 2010). Nups can be 
grouped into three categories (See Figure 1.3): (i) The transmembrane Nups, 
which line the “wall” of the hole in the nuclear envelope, form the interface with 
membrane lipids and anchor the NPC. (ii) FG-Nups contain phenylalanine-glycine 
(FG) repeats and constitute 30% of all Nups that make up the pore. (iii) Structural 
Nups (50% of all Nups) form a scaffold or framework that interacts both with the FG 
and transmembrane Nups (Wälde and Kehlenbach, 2010). 
The framework stabilises the sharply bent nuclear envelope and forms the 
central channel through which transport of macromolecules occurs (Devos et al., 
2004). Transport of these macromolecules is regulated by the FG-Nup filaments 
that fill the central channel and also extend from the NPC into the cytoplasm and 
nucleoplasm (Strambio-De-Castillia et al., 2010). On the nucleoplasmic side the 
filaments are attached to a distal ring, forming the nuclear basket (Alber et al., 
2007). Simply put, one can imagine the NPC as a stent holding open a channel in 
the nuclear envelope, and this channel is filled with a meshwork of flexible 
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filaments that obstruct the passage of molecules larger than ∼40 kDa (Terry and 
Wente, 2009; N. P. C. Allen et al., 2002; Bayliss et al., 2000; Denning et al., 2002). 
 
 
 
Figure 1.3 Schematic representation of the nuclear pore complex 
The nuclear pore complex (NPC) is an assembly of multiple copies of 30 different 
proteins known as nucleoporins (Nups), which can be split into three categories: (i) 
The transmembrane Nups shown in pink anchor the NPC in the nuclear 
membrane, (ii) Structural Nups shown in purple form the scaffold and (iii) FG Nups 
shown in green form the hydrophobic environment of the nuclear pore. 
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1.2.2 The NPC selectivity barrier 
 NPCs are semi permeable pores; small proteins, metabolites or ions can 
freely diffuse between the nucleus and cytoplasm, but macromolecule translocation 
is regulated. Since the NPC is not a motor and possesses no enzymatic activity, its 
ability to behave as a selective barrier is brought about by its components and their 
specific architecture (Wente and Rout, 2010).  
 In the case of passively diffusing small particles, their size strongly 
correlates with their translocation rate. It is thought that a 9nm diameter is available 
for passive diffusion through the NPC (Paine et al., 1975; Alber et al., 2007). With 
increasing size, translocation becomes increasingly inefficient. Diffusion of 
ovalbumin, which has a 6nm diameter and 46kDa mass, is negligible (Görlich and 
Kutay, 1999).  
 Despite the physical restrictions of the nuclear pore, molecules much larger 
than 9nm or 40 kDa can traverse the NPC, at high efficiencies, often against a 
concentration gradient, in an energy dependent manner (Breeuwer and Goldfarb, 
1990). Active transport across the NPC requires the binding of soluble nuclear 
transport receptors (NTRs) to a protein via a specific transport sequence. NTRs 
then guide their cargo through the FG-Nup mesh of the NPC (Dingwall et al., 1982; 
Wälde and Kehlenbach, 2010). The mechanism by which transport complexes 
traverse the NPC is not entirely understood, although several models have been 
proposed (Wälde and Kehlenbach, 2010). 
 According to the hydrogel model (Figure 1.4 A) (Frey and Görlich, 2007; 
Frey et al., 2006) the FG-Nups form a sieve that allows small molecules through, 
but not large ones. The sieve is formed through interaction between the FG-repeats 
within and between the filament-shaped FG-Nups. The resulting meshwork and 
entrapped cytoplasm form a hydrogel. Such a hydrogel was reconstituted 
successfully in-vitro using FG-Nups, and this hydrogel demonstrated some of the 
selective properties of the NPC. For example movement through the hydrogel was 
restricted for inert molecules, whereas facilitated diffusion was observed for NTRs 
(Frey and Görlich, 2009). NTRs are able to interact with FG repeats and in doing so 
disrupt the mesh as they pass through carrying their cargo with them. More 
recently direct evidence for this model was provided in a physiological context, 
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using NPCs reconstituted from frog Xenopus laevis extracts (Hülsmann et al., 
2012).  
 The polymer brush model (Rout et al., 2003) (Figure 1.4 B), is based on 
thermodynamic factors. Movement of a molecule into the restricted volume of an 
NPC would lead to a loss of entropy, which is energetically unfavourable. This 
effect is exacerbated by the presence of a barrier formed by the FG-Nups. In this 
model the FG-Nups do not form an adhesive meshwork, but rather wave back and 
forth in the channel space. Inert molecules are therefore excluded. Because of their 
ability to bind FG-Nups, NTRs release binding energy, which compensates for the 
loss of entropy and drives translocation through the pore. 
 The forest model is based on evidence that not all FG-domains are cohesive 
(Patel et al., 2007), meaning that FG-Nups can adopt a globular collapsed coil 
conformation, or a more extended coil conformation; by analogy the “shrubs” and 
“trees” of a forest (Figure 1.4 C). While the shrubs line the area close to the 
structural Nups of the pore wall, the trees point towards the center forming a tunnel. 
Together they form a meshwork much like in the hydrogel model, but with a tunnel 
running down the core. Cargo is then channelled down the tunnel, which is flexible 
to dilate if the cargo is bulky. It is further postulated that an alternative, more 
peripheral route is available for smaller cargo. Smaller cargo could translocate via 
the zone where the extended coils, or tree stalks are. This fits with observations of 
cargo found traversing via a more peripheral route (Yamada et al., 2010).  
 The reduction in dimensionality model (Figure 1.4 D) was hypothesised in 
part due to observations of a high number of apparently immobile NTRs, saturating 
the FG-domains in NPCs (Paradise et al., 2007; Peters, 2005; 2009). In this case a 
channel lined with NTRs is formed, through which small particles can traverse, 
whereas larger ones cannot due to size. NTR-cargo complexes however can 
interact with FG-Nups at the entrance of the pore and randomly move in either of 
the two available directions along the central channel wall. The NTR-cargo complex 
displaces the cargo-free NTRs it encounters by competing for FG-domain binding. 
 At present, there is evidence supporting each of the models and each model 
is able to explain some but not all observations. Further studies into the biophysical 
properties of FG-Nups and their interactions with NTRs, in conditions which are as 
physiological as possible, are required. 
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Figure 1.4 Models that describe passage through the NPC 
Several models have been proposed to describe the mechanisms that define 
passage through the NPC. Small molecules that can passively diffuse through the 
pore are shown as blue circles. Large molecules that traverse the pore by active 
transport are shown as green triangles. A. The hydrogel model B. The polymer 
brush model C. The forest model D. Reduction in dimensionality model. Detailed 
descriptions in text. Adapted from (Wälde and Kehlenbach, 2010). 
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1.2.3 Nuclear transport receptors: The karyopherin family  
The majority of macromolecules that translocate between the nucleus and 
cytoplasm require soluble NTRs to escort them across the NPC. Most NTRs belong 
to the β karyopherin family of proteins (or importin β-like proteins) which includes 
14 and 20 members in yeast and humans respectively (Mosammaparast and 
Pemberton, 2004). Even though sequence similarity between them is low (∼20%), 
they are all predicted to be composed of multiple tandem HEAT repeats 
(Mosammaparast and Pemberton, 2004). The HEAT motif consensus is a 
degenerate ∼40 residue sequence that forms a helix loop helix structure. Multiple 
HEAT motifs in sequence, stack up in parallel and give rise to a superhelical arch 
structure which is flexible and able to bind a variety of cargoes (Conti et al., 2006; 
Andrade et al., 2001). 
Karyopherins can function to move cargo into or out of the nucleus and 
accordingly they are classified as importins or exportins. Their function is 
determined by their ability to recognise either nuclear import sequences (NLSs) or 
nuclear export sequences (NESs) present on the cargo. Some karyopherins bind to 
their cargo after it has been recognised by an adaptor protein (Macara, 2001; 
Mosammaparast and Pemberton, 2004). In some cases a karyopherin can carry 
out both import and export. For example, Exportin 4, known to be responsible for 
the export of SMAD3, has been shown to facilitate import of the transcription 
factors Sox-2 and SRY (Gontan et al., 2009).  
Since karyopherins themselves translocate in and out the nucleus with their 
cargoes, a mechanism is required to define cargo binding, cargo release and their 
timely recycling so that they can repeat the cycle.  
  
1.2.4 Ran and the Ran GTPase system 
Ran is a member of the Ras superfamily of small GTPases. As such, it can 
be found in the GTP or GDP bound state. Nucleotide binding occurs through the G-
domain, in which the switch I and switch II loops are present (Milburn et al., 1990). 
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Depending on the nucleotide bound the switch regions adopt distinctly different 
conformations (Vetter and Wittinghofer, 2001). 
 RanGTP is present at high concentrations in the nucleus, where it triggers 
release of newly imported cargo from importins and promotes formation of export 
complexes (Weis, 2003). GTP hydrolysis and the resulting conformational switch in 
Ran drive dissociation from Impβ and Crm1 release of cargo in the cytoplasm. 
Therefore the processes of active import and export create a flux of RanGTP out of 
the nucleus, followed by GTP hydrolysis and an accumulation of RanGDP in the 
cytoplasm. In the absence of a replenishing system, nuclear RanGTP depletion 
would bring shuttling to a halt.  
In order to replete the nuclear RanGTP pool RanGDP is transported back to 
the nucleus and the GDP nucleotide is exchanged for a GTP. Nuclear transport 
factor 2 (NTF2), a transport factor with no similarity to the karyopherins, specifically 
recognises and binds RanGDP. NTF2 transports RanGDP to the nucleus by virtue 
of its ability to bind FG-Nups and traverse the NPC (Moore and Blobel, 1994). 
Once in the nucleus the nucleotide is exchanged.  
Ran binds guanine nucleotides with high affinity. After hydrolysis of GTP to 
GDP, in order to re-load Ran with GTP, guanine exchange factors (GEFs) are 
required (Vetter and Wittinghofer, 2001). The GEF for Ran is regulator of 
chromosome condensation 1 (RCC1) (Bischoff and Ponstingl, 1991a; 1991b). 
RCC1 is anchored in the nucleus by association with chromatin via the histones 
H2A and H2B (Nemergut et al., 2001). RCC1 binds Ran and forces the switch II 
region to adopt a conformation that displaces the so-called P-loop of Ran. P-loops 
are G-protein regions that are critical for nucleotide binding (Vetter and 
Wittinghofer, 2001). Thus the Ran/GDP interaction is destabilised allowing for 
nucleotide exchange and the replenishment of nuclear RanGTP.  
 Ran and the Ran GTPase system therefore orchestrate nucleocytoplasmic 
transport by providing the energy and directionality for nuclear import and export 
cycles (summarised in Figure 1.5).  
 
 
 
 
 
Chapter 1 Introduction 
 35 
 
 
 
 
Figure 1.5 Overview of nucleocytoplasmic transport. 
An overview showing the Impα/β import (right) and Crm1 export (left) cycles and 
the Ran/RanGTPase system that maintains and drives them. 
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1.2.5 Nuclear import 
 Proteins with an exposed or physically accessible NLS are recognised in the 
cytoplasm by importins, which enable translocation through the NPC. An NLS and 
the appropriate importin are the minimum requirements for facilitated translocation 
(Palacios et al., 1997). This can be demonstrated by the fusion of an NLS to a non 
nuclear protein, which consequently accumulates in the nucleus (Goldfarb et al., 
1986) .  
  The classical NLS sequence is a simple stretch of five basic amino acids 
KKKRK (Goldfarb et al., 1986). Alternatively, some proteins possess a bipartite 
NLS, which is comprised of two basic clusters separated by a spacer usually 10 
residues long (Dingwall and Laskey, 1998). Other sequences also exist, such as 
the SPS motif of ERK, which is recognised by importin 7 (Chuderland et al., 2008). 
In the case of the classical monopartite and bipartite NLSs, the importin 
responsible for their recognition is importin β (Impβ). Impβ was initially identified 
because of its ability to bind these basic sequences. Binding however, is not direct, 
but rather occurs through the adaptor importin α (Impα) (Görlich et al., 1995; Chi et 
al., 1995). Impα directly recognises NLSs through an NLS-binding domain adjacent 
to its Impβ binding domain (Görlich et al., 1995). The NLS binding domain consists 
of 10 armadillo (ARM) repeats which much like the HEAT repeats of Impβ, form a 
flexible superhelical structure, with a concave surface through which it can 
accommodate different cargoes (Andrade et al., 2001). An array of binding pockets 
available within the ARM repeats is differentially used to bind different NLSs. 
Monopartite and bipartite NLSs bind to a different number of pockets and even 
within common pockets form different interactions. Therefore it does not 
necessarily mean a bipartite NLS is bound with higher affinity (Conti and Kuriyan, 
2000; Kosugi et al., 2009).  
 Impβ, like most karyopherins do, can also directly recognise cargo using its 
19 HEAT repeats in distinctly different ways. Parathyroid hormone related protein 
(PTHrP) is bound directly, using the N-terminal HEAT repeats, as opposed to the 
C-terminal repeats used to bind Impα (Cingolani et al., 2002). In contrast, to bind 
sterol regulatory element binding protein 2 (SREBP-2), Impβ adopts a relatively 
more open conformation forming a greater number of interactions compared to 
PTHrP and Impα (Lee et al., 2003). 
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 Because importins are able to directly interact with the FG-Nups, 
importin/cargo complexes dock onto the NPC. As explained in section 1.2.2, 
translocation occurs through sequential interactions between importins and the FG-
Nups occupying the NPC channel. Once the importin/cargo complex arrives on the 
nucleoplasmic face of the NPC, the cargo is released, which is triggered by binding 
of RanGTP. 
The structure of the Impβ/RanGTP complex shows that Ran forms 
extensive interactions with the concave surface of the HEAT repeat arch (Vetter, 
Arndt, et al., 1999). Out of the 19 HEAT repeats of Impβ, the G-domain of Ran 
binds the first three N-terminal HEAT repeats, as well as HEAT repeat 8 and HEAT 
repeats 12-14.  Thus, RanGTP binding is mutually exclusive with that of known 
cargo because of an overlap in binding sites. Moreover Ran binding induces a 
more extended conformation of the Impβ arch which may be less compatible with 
cargo binding (Cook et al., 2007).  
 In the situations where cargo is bound via Impα, it is proposed that RanGTP 
induced dissociation of Impβ leads to a destabilisation of the Impα/cargo interaction. 
This occurs because in the absence of Impβ, the Impβ binding sequence binds the 
NLS binding domain of Impα thereby displacing and releasing the cargo (Goldfarb 
et al., 2004; Kobe, 1999; Harreman et al., 2003). Interactions between Impα and 
nucleoporins that promote cargo release have also been shown to play a role 
(Gilchrist et al., 2002; Matsuura and Stewart, 2005). Finally, it has been proposed 
that Cse1/CAS, the exportin for Impα also promotes cargo release from Impα 
(Gilchrist et al., 2002). It is possible that all three mechanisms may contribute to 
cargo release.  
 
1.2.6 Nuclear export 
 Upon RanGTP binding and consequent cargo release, importins directly 
translocate back to the cytoplasm in an energy and Ran independent manner 
(Kose et al., 1999; Görlich and Kutay, 1999). The adaptor Impα however, is 
exported by the exportin CAS (cellular apoptosis susceptibility, or Cse in yeast), yet 
another protein composed of multiple tandem HEAT repeats (Solsbacher et al., 
1998). The only export cargo known for CAS is Impα, to which it binds with high 
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affinity. CAS, Impα and RanGTP form a ternary complex, in which Impα is seen in 
the autoinhibited state, suggesting it can only be bound and exported after cargo 
release (Kobe, 1999). 
 One of the most intensely studied and versatile exportins is chromosome 
maintenance 1 (Crm1 or Xpo1) (Güttler et al., 2010). Crm1 shuttles between the 
nucleus and the cytoplasm mediating export of a broad range of structurally and 
functionally unrelated proteins (Ho et al., 2000; Fornerod et al., 1997; Xu et al., 
2012; Fu et al., 2013). Like CAS, Crm1 forms a ternary complex with RanGTP and 
its cargo. Crm1 binds either cargo or RanGTP weakly, but binds both cooperatively, 
to form a ternary complex (Paraskeva et al., 1999; Petosa et al., 2004). The ternary 
complex translocates to the cytoplasm and after hydrolysis of the Ran bound GTP 
the cargo is released from Crm1 (Kutay et al., 1997; Fornerod et al., 1997). 
  
1.2.7 Crm1 
Crm1 is a 120 kDa protein made up of 21 HEAT repeats, which are thought 
to adopt a horseshoe-like conformation (Figure 1.6 A) (Monecke et al., 2009). 
When Crm1 is not bound by Ran, the NES-binding hydrophobic cleft, which is 
formed by HEAT repeats 11 and 12, is inaccessible (Güttler et al., 2010; Dong et 
al., 2009). Interestingly, unlike the other karyopherins mentioned, cargo is not 
bound via the inner arched surface, but on the outer, which is where the NES 
binding cleft is located.  
 In addition to a closed cleft two additional structural features characterise 
the inactive conformation of Crm1 (Figure 1.6 B). The highly conserved loop 
connecting the helices of HEAT repeat 9 (H9 loop) interacts with the back of the 
NES binding cleft promoting a closed conformation (Saito and Matsuura, 2013; 
Monecke et al., 2013). Finally, the second helix of HEAT repeat 21 (H21B), instead 
of being packed against adjacent helices, crosses the horseshoe shape and 
interacts with HEAT repeat 9 and 10 on the inner concave surface. In doing so the 
H9 loop inhibitory conformation is stabilised (Dong et al., 2009; Saito and 
Matsuura, 2013; Fox et al., 2011). 
 For Crm1 to adopt the active state helix H21B must pack in the same plane 
as the rest of the helices forming the horseshoe, and the H9 loop must be 
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displaced from behind the NES binding cleft (Fox et al., 2011; Saito and Matsuura, 
2013). These conformational changes have been employed in both proposed 
models attempting to explain binding cooperativity in ternary complex formation 
(Crm1/RanGTP/cargo). 
 Saito and Matsuura proposed that first, RanGTP binds to the inner concave 
surface and displaces helix H21B. This rearrangement would facilitate closure of 
the horseshoe, which in turn would displace the H9 loop and allow opening of the 
NES cleft. The conformation can then be stabilised by NES binding, explaining 
positive cooperativity (Saito and Matsuura, 2013). 
 Monecke et al. propose that unliganded Crm1 exists in equilibrium between 
closed and open conformations, defined by the states of the H9 loop and H21B 
helix. Interaction with either RanGTP or cargo stabilises the compact horseshoe 
state, which corresponds to an open NES cleft. This initial event makes binding of 
the second component energetically more favourable (Monecke et al., 2013). 
 One model is based on induced fit mechanism while the other on a 
conformational selection, but both models rely on the same key features: 
rearrangement of the H21B helix, displacement of the H9 loop and opening of the 
NES groove driven by a compaction of the horseshoe shape resulting in an open 
NES binding cleft. 
 
1.2.7.1 Leptomycin B 
Leptomycin B (LMB) is a frequently used small molecule inhibitor of Crm1. It 
is a 540Da polyketide, which is able to covalently modify Cys528 within the NES 
binding cleft of Crm1 (Kudo et al., 1999). It has recently been shown that after LMB 
forms a covalent bond to the reactive cysteine Cys528, a subsequent reaction 
driven by the NES binding site itself, leads to hydrolysis of the LMB molecule (Q. 
Sun et al., 2013). Although LMB binding is sufficient to inhibit recognition of NES 
targets, based on a Crm1/LMB crystal structure, the authors suggest the hydrolysis 
reaction optimises the LMB-Crm1 interaction, forming a basis for the potency and 
longevity of the inhibition. 
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Figure 1.6 Structure of Crm1. 
A. Crm1 (grey) bound by RanGTP (blue). When bound by RanGTP Crm1 adopts 
the active state. In this state, the NES binding cleft, which is formed by helices of 
HEAT repeats 11 and 12 (green), is open and can bind an NES. The H9 loop is 
shown in red. From Monecke et al. Crystal Structure of the Nuclear Export 
Receptor CRM1 in Complex with Snurportin1 and RanGTP (2009) Science 
324(5930): 1087-1091. Reprinted with permission from AAAS B. Schematic 
representation of the inactive and active states of Crm1. Left: In the inactive state, 
when Crm1 is not bound by RanGTP, the NES binding cleft is closed and 
inaccessible to NESs. The closed conformation is stabilised by interactions with the 
H9 loop, which itself is stabilised in the inhibitory conformation by helix H21B. 
Right: Upon Ran binding helix H21B and the H9 loop are displaced, allowing 
opening of the NES binding cleft.  
 
Chapter 1 Introduction 
 42 
1.2.7.2 Cargo recognition by Crm1 
 Multiple mutagenesis and computational studies have led to the 
determination of the following leucine rich NES consensus sequence recognised by 
Crm1: Φ1- X(2-3)-Φ2-X(2-3)-Φ3-X-Φ4 (in which Φ is any hydrophobic residue, x is 
any amino acid). However the consensus is so broad that it frequently appears in 
proteins without necessarily acting as a functional NES (Henderson and 
Eleftheriou, 2000; la Cour et al., 2004; Kutay and Güttinger, 2005; Engelsma et al., 
2004).  
More recent structural studies have revealed how Crm1 is able to recognise 
such a broad set of NESs. Guttler et al. showed that the NES binding cleft does not 
adapt to accommodate for the varying positions of the hydrophobic residues. 
Instead different NES ligands bind to the same set of hydrophobic residues in the 
rigid NES binding cleft, docking to the NES cleft with strikingly different 
conformations. For example, the spinophilin NES binds the cleft as a helix, while 
the Rev NES binds in an extended conformation (Güttler et al., 2010). In fact the 
authors propose that there is a Rev-like NES consensus: Φ0Φ1Pro- X(2-3)-Φ2-X(2-
3)-Φ3-X-Φ4. 
 The affinity of leucine rich NESs for Crm1 is relatively weak. Other exportins, 
including CAS, bind their cargo in the low-nanomolar range, whereas in most cases 
Crm1 substrates exhibit a 100-500 fold lower affinity for Crm1 binding (Kutay et al., 
1997; Askjaer et al., 1999; Paraskeva et al., 1999; Kutay et al., 1998). The low 
affinity appears to be required for normal function of the export cycle, since 
synthetic high affinity NESs, which bind Crm1 with high affinity, lead to entrapment 
of the ternary complex at the NPC. This suggests that weak NES-Crm1 affinity has 
been selected to allow for efficient release of cargo and NPC dissociation 
(Engelsma et al., 2004).  
1.2.7.3 Crm1 cargo release 
 Dissociation of export ternary complexes is triggered by hydrolysis of the 
Ran bound GTP to GDP. The same hydrolysis reaction is what dissociates 
importin/Ran complexes that are recycled back to the cytoplasm. As mentioned 
above, the switch regions of Ran adopt different conformations depending on 
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whether GTP or GDP is bound. In addition, a second major conformational change 
is the rearrangement of the C-terminal extension. In the GDP form the C-terminal 
extension packs against the G-domain and sterically hinders interaction with 
karyopherins (Vetter, Nowak, et al., 1999). The C-terminus rearrangement is 
perhaps the most important change, as a truncated mutant is able to bind Crm1 
while bound to GDP (Nilsson et al., 2002). Hydrolysis of GTP and the consequent 
conformational changes, change the affinity of Ran to bind karyopherins from 
subnanomolar for the GTP-bound state, to 10µM for the GDP bound state (Vetter, 
Arndt, et al., 1999; Görlich et al., 1996). 
 Ran itself, like all GTPases, features low intrinsic activity that can be 
enhanced several-fold by regulatory proteins (Klebe et al., 1995). The timing of 
GTP hydrolysis is controlled by cytoplasmic proteins. When RanGTP arrives to the 
cytoplasm as part of the export complex, Ran binding protein 1 (RanBP1) and 
RanBP2 can bind it (Bischoff and Görlich, 1997; Bischoff et al., 1995). RanBP1 is a 
23kDa soluble protein that can bind to RanGTP via its Ran binding domain 
(RanBD) (Coutavas et al., 1993). RanBP2 is a nucleoporin component of the NPC 
fibrils that extend into the cytoplasm and possesses four RanBDs (Delphin et al., 
1997). Both RanBPs promote dissociation of RanGTP and stimulate Ran GTPase 
activating protein (RanGAP) mediated hydrolysis (Bischoff et al., 1995; Bischoff 
and Görlich, 1997). 
 RanGAP features a conserved N-terminal GAP domain and a C-terminus 
with which it binds to RanBP2 at the cytoplasmic face of the NPC (Mahajan et al., 
1997; Matunis et al., 1996; Haberland and Gerke, 1995). RanGAP forms extensive 
interactions with RanGTP, thereby correctly orienting and stabilising the 
catalytically active conformation of Ran that enables GTP hydrolysis (Seewald et 
al., 2002).  
 
1.2.8 Measuring nucleocytoplasmic transport 
Being able to measure protein mobility is crucial for understanding protein 
regulation (Haché et al., 1999; Meyer et al., 2002; Johnson et al., 1999). Signal 
induced nuclear accumulation of a transcription factor or the shuttling of proteins 
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involved in mRNA transport can be highly dynamic and therefore methods are 
needed to assess kinetics. 
 Immunostaining involves fixation of samples and this only reveals bulk 
protein concentrations but does not address the dynamics of shuttling. For example, 
for a protein continuously shuttling between the nucleus and cytoplasm, if the 
export rate is significantly faster that the import rate the majority of the protein will 
be localised at the cytoplasm at steady state. Immunostaining will show the 
cytoplasmic location of the protein, but will not reveal the fact that the protein is 
continuously shuttling, unless the kinetics of movement can be manipulated. In this 
regard inhibition of Crm1 by LMB has proved useful in many cases, to demonstrate 
shuttling of apparently cytoplasmic proteins, including MRTFs (Vartiainen et al., 
2007). 
 The classical heterokaryon assay is one way to assess shuttling properties 
of predominantly nuclear proteins (Flach et al., 1994). It involves the use of two 
nuclei from different species. Co-incubation of the nuclei allows a shuttling protein 
to exchange between the two nuclei, which can then be detected using species-
specific antibodies in immunofluorescence.  
 Fluorescence recovery after photobleaching (FRAP) and fluorescence loss 
in photobleaching (FLIP) are two techniques which enable direct measurement of 
protein movement. They allow direct measurement of import and export rates of a 
protein. Both techniques were made possible by the discovery of green fluorescent 
protein (GFP) (Tsien, 1998). Expression of GFP tagged proteins enabled live cell 
imaging. Further discovery of GFP-like proteins allowed simultaneous observation 
of multiple events (Miyawaki, 2005; Day and Davidson, 2009). Further development 
led to more stable versions of these fluorophores, as well as photoactivatable GFP 
(Patterson and Lippincott-Schwartz, 2002). These developments paved the way to 
major advances in our ability to measure protein movement. 
 In FRAP, a region where the GFP-protein of interest is present is bleached 
using a high-intensity laser, and recovery of the signal by unbleached protein is 
measured. For example the whole nucleus can be bleached and the kinetics of 
movement of the non-bleached GFP-protein from the cytoplasm to the nucleus can 
be accurately measured (Snapp et al., 2003).  
 In FLIP the high-intensity laser is used repeatedly to constantly bleach a 
certain area and the effect on fluorescence in non bleached regions is monitored. 
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For example, if a protein appears to be equally distributed between the nucleus and 
cytoplasm, the high-intensity laser can be used to repeatedly bleach a specific spot 
in the cytoplasm. By measuring fluorescence intensity of the nucleus one can 
determine the speed at which the protein shuttles between the two compartments. 
If the protein does not shuttle, nuclear fluorescence should remain constant as the 
cytoplasm gradually bleaches. If however the protein does shuttle, as the nuclear 
and cytoplasmic compartments equilibrate nuclear fluorescence will decrease as 
well(Köster et al., 2005; Snapp et al., 2003).  
There are many applications to these techniques but they fall beyond the 
scope of this thesis (reviewed in (Miyawaki, 2011; Köster et al., 2005; J. N. 
Henderson, 2006; Belaya, 2006). Whether they are used in combination with 
pharmacological inhibitors, stimulus induced changes in steady state or even 
heterokaryon assays, FRAP and FLIP enable direct measurements of the kinetics 
of protein movement, and allow accurate investigation of protein regulation. 
 Shuttling is a function of import, export and possible interactions of a protein 
that may anchor it in a particular compartment. Since import and export are 
conferred by NLS and NES sequences respectively, then identification of these 
elements is crucial to characterising the shuttling behaviour of a protein. Although 
there are exceptions, a sequence suspected to be an export signal could be fused 
onto another protein and tested for its ability to confer export. This is the basis of 
the Rev export assay. 
 The Rev assay uses the HIV-1 Rev protein as a reporter for export activity. 
Rev is an RNA binding protein, which localises to nucleoli. Rev continuously 
shuttles between the nucleus and cytoplasm by virtue of identified and 
characterised NLS and NES sequences. Inactivation of the NES renders the 
protein localised to nucleoli. Shuttling can be restored upon fusion to its own NES 
sequence or any other functional NES sequence. Henderson and Eleftheriou 
employed this strategy to identify NESs and compare their relative strengths 
(Henderson and Eleftheriou, 2000). It should be noted that the assay relies on the 
ability of the NES to relocalise the Rev GFP fusion to the cytoplasm and so a NES 
must be sufficiently effective to compete with the Rev NLS, complicating the 
interpretation. There are cases where a known NES was too weak to score in the 
assay (B. R. Henderson and Eleftheriou, 2000). 
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1.2.9 Regulation of transcription factor activity through controlled 
localisation 
 Many signalling pathways culminate in the activation of transcription factors. 
Often transcription factors have restricted access to their targets due to cytoplasmic 
retention. Once activated, through masking or unmasking of NES or NLS elements, 
they can accumulate in the nucleus and activate their target genes. In most cases 
multiple levels of control exist and localisation is one step of the activation process 
(Whitmarsh and Davis, 2000; Ziegler and Ghosh, 2005).  
 The transcription factor NF-AT is cytoplasmic in resting cells (Rao et al., 
1997; Crabtree, 1999). A rise in intracellular calcium concentration activates the 
phosphatase calcineurin, which dephosphorylates multiple residues on NF-AT. An 
intramolecular rearrangement unmasks at least one NLS which drives nuclear 
translocation (J. Zhu et al., 1998). 
 Nuclear factor κB (NF-κB) is also cytoplasmic in the absence of stimulation. 
Binding to inhibitor of NF-κB (IκB) retains NF-κB in the cytoplasm by two 
mechanisms. First, association with IκB masks the NLS of NF-κB, and secondly IκB 
contains an NES, which ensures cytoplasmic localisation (Ghosh et al., 1998; 
Ghosh and Karin, 2002; Hayden and Ghosh, 2004). Contrary to what was assumed 
for a long time, NF-κB in fact continuously shuttles through the nucleus. LMB 
treatment is sufficient to cause nuclear accumulation, indicating that it is 
continuously imported and then also exported (Ghosh and Karin, 2002). In 
response to signals, IκB is phosphorylated and marked for proteasomal 
degradation. IκB is therefore rapidly degraded. As a consequence the NLS of NF-
κB is exposed allowing for nuclear accumulation (Ghosh et al., 1998).  
 The Forkhead transcription factor FKHR1 localisation is controlled by the 
kinase Akt (Brunet et al., 1999; Biggs et al., 1999). Phosphorylation by Akt results 
in association with 14-3-3 proteins, which possess an NES which drives nuclear 
export (Brunet et al., 1999; Rittinger et al., 1999).  
 Protein subcellular relocalisation can occur because of a simple change, for 
example detachment from anchorage and exposure of a localisation signal. In other 
cases multiple parameters can change, some for different durations. The net effect 
may be brought about by an imbalance of import/export rates, de-novo synthesis of 
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anchors and signalling kinetics. Tools such as photoactivatable and even 
switchable fluorophores and techniques such as FRAP and FLIP are powerful tools 
in the investigation of such mechanisms. 
 
1.3 Actin 
 Actin is a highly conserved, abundant protein in eukaryotic cells. It is found 
primarily in two forms, the monomeric or globular form (G-actin) and the 
polymerised or filamentous form (F-actin). Interconversion between the two forms 
is a highly dynamic process, important for a vast range of cell functions including 
cell shape, motility, adhesion and division (Remedios et al., 2003). In order to be 
involved in such a variety of processes, actin is regulated by a multitude of proteins 
that can bind and control its polymerisation on a pancellular or very localised 
subcellular level (Remedios et al., 2003). Actin is also a target of post translational 
modifications such as methylation and oxidation (Raghavan et al., 1989). 
 Mammals possess six actin genes. The γsmooth-actin and three α-actin 
proteins are expressed mainly in skeletal, cardiac and smooth muscle, whereas β-
actin and γcyto-actin are expressed ubiquitously. All actins share at least 93% and 
up to 99% sequence similarity with one another and most variations are found in 
the N-terminus (Perrin and Ervasti, 2010; Herman, 1993). There is some evidence 
supporting isoform specific functions, reviewed in (Perrin and Ervasti, 2010). This 
thesis concerns a novel family of G-actin binding proteins, the MRTFs, whose 
activity is controlled by signal-induced fluctuations in G-actin concentration. 
 
1.3.1 Monomeric actin 
 Monomeric actin (G-actin) is a 375 amino acid polypeptide chain that folds 
into two major domains, the α and β major domains. Each of these major domains 
is composed of two subdomains (see Figure 1.7). The α and β domains share 
relatively few contacts and are separated by a flexible hinge region, resulting in the 
formation of two clefts that can move relative to each other. The upper cleft, 
between subdomains 2 and 4, binds ATP and an associated Mg2+, which bridge 
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and stabilise the α and β domains (Kabsch et al., 1990; Dominguez and Holmes, 
2011). The bottom cleft, between subdomains 1 and 3, is lined predominantly by 
hydrophobic residues (Oda et al., 2009). This cleft forms important contacts 
between actin units within a filament, and is the major binding site for the majority 
of G-actin-binding proteins (ABPs) (Dominguez, 2004). Nucleotide binding in the 
upper cleft causes conformational changes in the lower cleft. This provides the 
basis of how nucleotide binding affects interactions between actin molecules in 
filaments or with ABPs (Kudryashov et al., 2010; Pfaendtner et al., 2009). Due to its 
structural flexibility and different nucleotide states actin can interact with many 
different proteins. This enables actin to be involved in many different processes 
and also for many proteins to regulate actin polymerisation (see table 1.1). 
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Figure 1.7 Structure of monomeric actin.  
Ribbon representation of G-actin structure indicating the four subdomains in 
different colours. Subdomain 1 (residues 1-32, 70-144 and 338-372) is blue; 
subdomain 2 (residues 33-69) is red; subdomain 3 (residues 145-180 and 270-337) 
is orange; subdomain 4 (residues 181-269) is green. PDB2v52, rabbit Acta1, 
P68135. 
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Table 1: Actin binding proteins and their function 
 
Protein Function 
Dia Promotes nucleation and elongation of filaments. 
Associates with barbed ends. Recruits Profilin/actin complexes. 
Highly processive  
Arp2/3 complex Promotes  branching. Binds to existing filaments and nucleates a 
branch that grows out at a 70° angle. 
Profilin Promotes polymerisation. Binds G-actin and prevents spontaneous 
nucleation. Also promotes nucleotide release, promoting actin-ATP 
availability. Recruited with actin to the + end of filaments and then 
dissociates. 
ADF/Cofilin Promotes actin filament disassembly. Binds actin filaments at minus 
end and promotes actin-GDP dissociation. Promotes G-actin recycling, 
as liberated monomers become available for plus end incorporation. 
Gelsolin Caps and severs actin filaments. Binds and caps plus end of 
filament. Capped filaments are readily disassembled by the action of 
cofilin, but Gelsonin itself possesses weak sesering activity. 
Tropomodulin Capping. Binds and caps minus ends of filaments. 
CapG Capping. Binds and caps + ends and inhibits elongation. 
Fascin Bundles actin filaments. Binds and crosslinks filaments together. 
WAVE Nucleation promoting factor. Activates Arp2/3 complex in response 
to Rac signaling.  
WASP Nucleation promoting factor. Activates Arp2/3 complex in response 
to Cdc42 signaling. 
IRSp53 Coordinates plasma membrane curvature to actin dynamics. 
Directly interacts with WASP and membrane. 
MRTF Links actin dynamics to transcription. Directly binds G-actin via its 
RPEL domain. Regulates transcription of multiple ABPs, actin 
regulators and actin itself. 
Phactr1 Nucleocytoplasmic shuttling and interaction with protein phosphatase 1 
(PP1) are regulated by actin. Actin competes with PP1 and Impɑ/β for 
binding. 
RhoGAP12 Contains a single RPEL motif, through which actin regulates its ability 
to inactivate Rac. 
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1.3.2 Filamentous actin 
G-actin possesses weak ATPase activity and since it preferentially binds 
ATP, ATP most often occupies the upper cleft. The conformational differences 
between ATP or ADP actin primarily involve two loops: the Ser14-loop and the 
sensor loop. These two loops embrace the phosphates of ATP, with Ser14 
hydrogen bonding to the γ-phosphate. After hydrolysis and γ-phosphate release, 
Ser14 loses contact with the γ-phosphate and contacts the β-phosphate instead. In 
doing so the Ser14 loop moves the sensor loop into the space vacated by the γ-
phosphate, thereby sensing nucleotide status. These conformational changes 
appear to be transmitted to subdomain 2 (Graceffa and Dominguez, 2003). The 
changes in subdomain 2 involve the D-loop which forms critical interactions with 
the next actin in a filament (Wawro et al., 2005). Since ATP stabilises the α and β 
major domains, γ-phosphate release also compromises the rigidity of the structure 
and allows the domains to move relative to each other (Galkin et al., 2002; Oda et 
al., 2009; Tirion et al., 1995). 
 Assembly of G-actin into filaments, is accompanied by an increase in 
ATPase activity, yielding ADP + Pi. Actin-ATP and actin-ADP-Pi are functionally 
indistinguishable, probably because the presence of Pi prevents the rearrangement 
of Ser14 and sensor loops. Release of Pi yields actin-ADP, which leads to 
increased dissociation of the actin molecule from the filament and depolymerisation.  
 F-actin is a helical arrangement of two strands where interaction between 
actins within the same strand are stronger than those between strands (Hanson 
and Lowy, 1963; Holmes et al., 1990). Actin-ATP which has been incorporated into 
a filament is conformationally different to non-polymerised actin, consistent with the 
fact that once polymerised ATPase activity is enhanced (Tirion et al., 1995; Lorenz 
et al., 1993; Oda et al., 2009). The change has been described as a “flattening” of 
the molecule. 
 As seen for many biological polymers, F-actin does not form crystals 
suitable for analysis by X-ray crystallography (Tirion et al., 1995). Hence several 
models exist to describe F-actin, assembled from the available G-actin structures 
(Holmes et al., 1990; Lorenz et al., 1993; Tirion et al., 1995). No single model is 
able to describe F-actin, as differences in the twist of the helix and the tilt between 
units within the same filament can be seen (Egelman et al., 1982; Galkin et al., 
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2002; Schmid et al., 2004). F-actin is therefore structurally polymorphic and should 
probably be viewed as a collection of different states (Galkin et al., 2010).  
  
1.3.3 Dynamics of actin polymerisation 
Actin polymerisation can be simulated in vitro using purified actin. In low salt 
conditions actin maintains its monomeric form. Increasing salt concentration 
(particularly Mg2+), leads to the rapid formation of F-actin (Carlier, 1991a; 1991b; 
Korn, 1982). The filaments possess a barbed end (plus end) and a pointed end 
(minus end). At the plus end, actin monomers assemble at a faster rate than at the 
minus end (Pollard, 1986).  
 When polymerisation is initiated in vitro G-actin is depleted as the filaments 
are formed. Eventually a balance between G-actin and F-actin is achieved, at 
which point filament length remains constant, but is a result of constant association 
and dissociation of G-actin; an effect known as treadmilling. The concentration of 
actin required to maintain this steady state, the critical concentration (Cc), is a 
function of the rate of association and dissociation of G-actin. In addition the Cc is 
different for each end of the filament, 0.1µM for the plus end and 0.7µM for the 
minus end (Pollard and Borisy, 2003). This difference essentially means that as G-
actin concentration drops during a polymerisation reaction, the minus end stops 
growing while the plus end continues. Moreover as ATP is hydrolysed by 
incorporated actin, actin-ADP is formed. When addition of actin-ATP to the minus 
end slows down enough, the minus end is occupied by actin-ADP and has a higher 
dissociation rate. The minus end therefore begins to depolymerise. Actin 
monomers are hence continuously fluxed through the filament, added as actin-ATP 
to the continuously growing plus end, converting to actin-ADP and dissociating 
once reaching the receding minus end “front” (Pollard and Borisy, 2003).  
 Cellular concentrations of actin can be up to 400 fold higher than its critical 
concentration (65-300µM), yet a G-actin pool is able to be maintained and F-actin 
formation is controlled, dynamic and can occur at incredibly fast rates (Remedios et 
al., 2003). This is achievable through the actions of a multitude (over 160) of actin 
binding proteins, each acting in a way that promotes or inhibits F-actin formation 
(Remedios et al., 2003) (See table 1.1). Some ABPs can nucleate, stabilise or 
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sever filaments. In addition some ABPs sequester G-actin or promote nucleotide 
exchange and replenish G-actin-ATP. Together these regulators of actin 
polymerisation cooperate to bring about events such as the classical example of 
protrusion of the leading edge of a motile cell (Pollard and Borisy, 2003) (See 
Figure 1.8). 
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Figure 1.8 Regulation of actin filament dynamics by actin binding proteins. 
A variety of actin binding proteins with different functions, cooperate to regulate 
assembly and disassembly of F-actin filaments. Formins catalyse de novo filament 
nucleation and elongation; Gelsolin caps and severs filaments; Nucleation 
promoting factors such as WAVE and WASP activate arp2/3 causing branching of 
filaments; Profilin and Cofilin promote polymerisation and depolymerisation 
respectively. Adapted from (Pollard and John A Cooper, 2009). 
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1.3.4 Control of actin cytoskeleton by Rho GTPases 
 Actin dynamics are directly controlled by the above mentioned regulators. 
The regulators themselves are subject to incoming signalling, which affects their 
own function, enabling control over F-actin formation. 
 The Rho family of GTPases plays a central role in spatial and temporal 
control of actin dynamics. This family consists of 20 members, of which RhoA, Rac 
and Cdc42 are the best studied (Heasman and Ridley, 2008). Like other members 
of the Ras superfamily, Rho GTPases are GTP binding proteins that have weak 
intrinsic GTPase activity. Signal induced association with GAPs and GEFs, 
regulates their GTPase activity or nucleotide loading, defining whether they are in 
the GTP bound active state, or the GDP bound inactive state. Nucleotide binding 
defines conformational state and therefore binding to proteins which they can 
activate.   
  Cdc42 is important for cell polarity and filopodia formation. Filopodia are 
finger-like projections thought to be important for a cell to sense its environment 
(Gupton and Gertler, 2007). Filopodia contain F-actin bundles, which are formed 
due to the combined activities of multiple ABPs orchestrated by Cdc42 (Fig 1.9) 
(Ridley, 2011).  
 Out of the three Rac isoforms (Rac1, Rac2 and Rac3) Rac1 is the best 
studied and unlike the other isoforms, it is ubiquitously expressed (Didsbury et al., 
1989). Rac proteins affect activity of multiple ABPs, to stimulate formation of 
lamellipodia and membrane ruffles (Wittmann and Waterman-Storer, 2001). These 
structures are thin cytoplasmic sheets formed at the front of a migrating cell. The 
force required for the protrusions is generated by branched actin polymerisation, 
accomplished by ABP activity organised by activated Rac (Fig1.9) (Lauffenburger 
and Horwitz, 1996; Ridley, 2011; Ballestrem et al., 2000). 
 RhoA, RhoB and RhoC, share high homology and when overexpressed in 
fibroblasts they all induce stress fibre formation (Wheeler and Ridley, 2004). RhoA 
is the prototypical member of the Rho family. Because it can associate with many 
different proteins RhoA is involved in multiple signalling pathways. Two of the main 
effectors of RhoA are the Rho associated coiled coil forming kinase (ROCK) and 
diaphanous related formin 1 (Dia1) (Campellone and Welch, 2010). Activated 
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ROCK phosphorylates the kinase LIMK1. LIMK1 in turn phosphorylates and 
inactivates cofilin, thereby stabilising actin filaments. Dia1 nucleates and 
assembles actin filaments using its FH2 domain (Campellone and Welch, 2010; 
Wallar et al., 2006). Thus ROCK and Dia1 cooperate to promote actin 
polymerisation and stress fibre formation (Figure 1.9). 
 The clostridial enzyme C3-transferase has been widely used in the 
investigation of Rho function. C3 transferase is able to irreversibly ADP ribosylate 
and inactivate RhoA, Rho B and RhoC (Wilde and Aktories, 2001). 
 Rho GTPases are also targets of regulatory phosphorylation and ubiquitin 
mediated proteasomal degradation (P Lang, 1996; H.-R. Wang et al., 2003). An 
additional layer of regulation is post translational modification and scaffold 
mediated recruitment of the regulatory GAPs and GEFs that affect RhoGTPase 
activity (Marinissen and Gutkind, 2005). 
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Figure 1.9 Rho GTPases orchestrate the functions of ABPs to regulate actin 
dynamics. 
The Rho GTPases Rac, RhoA and Cdc42 utilise different sets of actin binding 
proteins to regulate F-actin assembly. Rac stimulates lamellipodia formation in 
migrating cells. RhoA stimulates formation of stress fibres facilitating cell motility 
and contractility. Cdc42 stimulates formation of filopodia, which play a role in 
sensing the extracellular environment. 
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1.3.5 RPEL motif containing proteins 
The RPEL motif is a G-actin-binding element (Guettler et al., 2008) present 
in some proteins which have been shown to be regulated by actin. Three families of 
RPEL proteins have been described.  
Two RhoGAP subfamilies have been shown to possess single RPEL motifs, 
of which the Rac-specific GAP RhoGAP12 is currently under investigation in the 
laboratory (Dr J. Diring, unpublished data). Actin inhibits RhoGAP12 activity by 
competing with Rac binding.  
 The transcription cofactor MRTF-A senses G-actin concentrations by direct 
binding through its RPEL domain. The RPEL domain, contains three RPEL repeats 
that cooperatively bind actin to regulate MRTF-A nucleocytoplasmic shuttling and 
activity (Vartiainen et al., 2007; Miralles et al., 2003). MRTF-A will be described in 
more detail in the next section. 
 The phosphatase and actin regulator (Phactr) family of proteins is also 
regulated by actin by virtue of RPEL motifs. The family contains four members, 
Phactr1, Phactr2, Phactr3 and Phactr4. The founding member, Phactr1, was first 
identified in a yeast-two-hybrid screen designed for the detection of protein 
phosphatase 1 (PP1) interacting proteins (P. B. Allen et al., 2004). It was found to 
interact with PP1, but also with G-actin via sequences containing RPEL motifs, 
which are highly conserved between family members. 
 Using the GST fused RPEL motifs of Phactr3, Sagara and colleagues 
showed that actin binding was direct and was important for the full length protein to 
regulate PP1 activity and cell motility (Sagara et al., 2009). Phactrs possess four 
RPEL motifs. One N-terminal and three clustered in the C-terminus, adjacent and 
partly overlapping with the extreme terminal PP1 binding site (Wiezlak et al., 2012). 
The C-terminal RPELs are separated by short spacers and are referred to as the 
Phactr RPEL domain. It has been shown that PP1 and actin competed for binding 
to the RPEL domain of Phactr1 (Wiezlak et al., 2012; Huet et al., 2013). Structural 
analysis revealed that each RPEL motif, including the N-terminal RPEL interacts 
with one actin molecule (Mouilleron et al., 2012). 
 In their analysis, Huet and colleagues showed that in NIH-3T3 cells, all 
Phactr family members exhibit pancellular localisation at steady state. Using FRAP, 
they demonstrated that Phactr4 is continuously imported. Upon bleaching of the 
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nucleus, the authors observed recovery of fluorescence, meaning that unbleached 
Phactr4-GFP was imported from the cytoplasm. This observation suggests Phactr4 
may shuttle between the nucleus and cytoplasm (Huet et al., 2013). 
 A separate analysis of Phactr localisation in NIH-3T3 cells showed that 
Phactr1 and 2 were predominantly cytoplasmic while Phactr 3 and 4 were 
pancellular (Wiezlak et al., 2012). Serum induced depletion of the G-actin pool led 
to nuclear accumulation of Phactr1, but not the other family members. Detailed 
molecular analysis showed that actin competes with importins for binding to nuclear 
localisation signals associated with the RPEL elements and the integrity of the 
RPEL motifs is required for cytoplasmic localisation. 
 LMB treatment did not lead to Phactr1 nuclear accumulation suggesting that 
Phactr1 is anchored in the cytoplasm and blockage of export alone is not sufficient 
for nuclear accumulation (Wiezlak et al., 2012). Alternatively Phactr1 is exported by 
a factor other than Crm1. This notion is supported by the observation that LMB 
does not potentiate the duration of serum induced Phactr1 nuclear accumulation 
(Magdalena Kratochívlova, unpublished). 
 RhoGAP12, MRTFs and Phactrs demonstrate how the status of actin in 
cells can be directly sensed by RPEL domain containing proteins, which coordinate 
actin dynamics to their respective function; Rac GAP activity in the case of 
RhoGAP12, transcription in the case of MRTF and PP1 regulation in the case of 
Phactr. Investigations of RhoGAP, MRTF and Phactr regulation required 
manipulation of actin binding and polymerisation properties. For this reason actin 
binding toxins played a crucial role and were extensively used. 
 
1.3.6 Actin binding drugs 
Actin conformation is crucial for defining the interactions it can make and 
therefore its function. Toxins that are able to bind actin can directly or indirectly 
obscure actin interaction surfaces. Small molecules that directly bind actin can be 
divided into two main categories, those that disrupt filament assembly and those 
that promote it (reviewed in (Fenteany and S. Zhu, 2003)). 
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1.3.6.1 Cytochalasins 
 Cytochalasins are a group of membrane permeant fungal metabolites best 
known for their ability to destabilise actin filaments. The mode of action is possibly 
the sum of different effects on actin function. Cytochalasins have been reported to 
bind the barbed end (plus end) of filaments and inhibit both association and 
dissociation of monomers. They have also been shown to promote ATP hydrolysis 
by stabilising dimer formation leading to increased actin-ADP concentration. 
Cytochalasin B (CB) and cytochalasin D (CD) are the most frequently used, with 
preference for CD as it is more selective. CB was shown to also inhibit 
monosaccharide transport (Cooper, 1987; Peterson and Mitchison, 2002). 
 
1.3.6.2 Latrunculins 
 Latrunculins are generally more potent than cytochalasins at inhibiting actin 
polymerisation. Latrunculin A, the most potent family member binds actin in a 1:1 
stoichiometry and in addition prevents nucleotide exchange (Coué et al., 1987). 
Insights from a high resolution structure suggest binding of Latrunculin A to actin 
causes conformational changes that lock the nucleotide in place and disfavour 
polymerisation. Latrunculin B binds actin in a very similar way but is less potent 
(Morton et al., 2000). Both drugs bind G-actin reversibly (Spector et al., 1983). 
 
1.3.6.3 Phalloidin 
 Phalloidin is a heptapeptide that binds and stabilises F-actin. On doing so 
phalloidin lowers the critical concentration ten-fold and promotes filament 
polymerisation (J A Cooper, 1987). Since Phalloidin is not membrane permeant it is 
mostly used in a fluorophore conjugated form, to label F-actin in permeabilised 
fixed cells (Wulf et al., 1979). 
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1.3.7 Role of nuclear actin 
 Evidence suggesting the presence of actin in the nucleus was first obtained 
40 years ago (Lane, 1969). Given its size, 42kDa, actin is at the limit of being 
capable of passive diffusion through the nuclear pore complex and it is possible it 
could freely move between the nucleus and cytoplasm (Bohnsack et al., 2006). G-
actin rapidly shuttles between the nucleus and cytoplasm. Nuclear import is 
mediated by importin 9 and export by exportin 6 (Dopie et al., 2012; Stüven et al., 
2003).  
 Using FRAP and FLIP Dopie and colleagues, showed that actin exchange 
between the two compartments occurs rapidly suggesting equilibration between the 
two can be fast (Dopie et al., 2012). In cells expressing actin-GFP, nuclear 
fluorescence recovered in 3 phases after bleaching. Fast recovery is probably by 
rapid import of G-actin in the nucleus. The second phase is likely to be due to actin 
exchange with the bleached short actin filaments, and the short phase is probably 
the exchange of actin with stable actin-containing complexes. Importantly, 
fluorescence recovery of cells expressing the non-polymerising derivative actin 
R62D GFP occurred in two phases, supporting the idea that the second recovery 
phase is filament associated. 
 Analogous to the example with transient or sustained ERK signalling, the 
same concept can apply with nuclear actin. A transient change in the G- to F-actin 
ratio in the nucleus would differentially affect nuclear actin binding proteins 
according to the stability of their association with actin.  
 G-actin has long been shown to have a role in the nucleus, namely, in gene 
expression. It has been shown to regulate activity of the transcription co-factor 
MRTF, as well as play a role in promoting transcription by all three polymerases 
(Vartiainen, 2008; Percipalle, 2013). It has also been shown to be a component of 
chromatin remodelling complexes, such as INO80 and the histone 
acetyltransferase NuA4 (Shen et al., 2000; Galarneau et al., 2000). The existence 
of actin filaments in the nucleus, however, has been elusive and controversial. 
 Nuclear actin concentration is generally low and detection of nuclear 
filaments proved difficult, while G-actin or oligomers are readily detectable 
(Schoenenberger et al., 2005; Jockusch et al., 2006). A significant amount of 
evidence indirectly pointed towards the possibility of nuclear actin filaments, 
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including the nuclear localisation of F-actin assembly proteins such as arp2/3 and 
WASP (Wu et al., 2006; Yoo et al., 2007).  
Recently, Baarlink and colleagues showed that serum stimulation of 
fibroblasts leads to nuclear actin filament formation (Baarlink et al., 2013). 
Visualisation of the filaments was accomplished using “Lifeact”, a 17 amino acid 
peptide able to bind actin monomers and filaments (Riedl et al., 2008). Lifeact was 
fused to an NLS, yielding the nuclear restricted Lifeact-NLS-GFP. Upon serum 
stimulation rapid and transient formation of actin filaments was observed, and this 
was dependent on the presence of Dia1. In addition, by using a photoactivatable 
tool, nuclear Dia1 was specifically activated, showing that nuclear actin 
polymerisation could be signal-inducible. Importantly this was accomplished without 
overexpressing actin, which was a common caveat of previous studies.  
 With the presence of actin filaments in the nucleus confirmed, many 
questions arise. Does the signal get from the cell membrane to nuclear actin 
regulators directly or do they translocate to the nucleus? Also, with respect to 
depletion of nuclear G-actin it is important to know the speed of equilibration 
between the two compartments. The functional significance of nuclear Dia activity 
and F-actin formation was demonstrated by assessing activity of the G-actin 
binding protein MRTF-A. At low G-actin concentrations MRTF-A dissociates from 
actin and activates target genes. Specific inhibition of nuclear Dia activity inhibited 
serum induced MRTF-A activation despite normal F-actin formation in the 
cytoplasm, suggesting that MRTF-A activity can be regulated by changes in 
nuclear actin dynamics. 
 A recent report on MICAL2 (molecule interacting with CasL) demonstrates 
another mode of G-/F-actin regulation in the nucleus (Lundquist et al., 2014). 
MICAL2 is a nuclear, mono-oxygenase-domain containing protein. MICAL1 has 
been shown to directly bind F-actin and oxidise methionine 44 leading to filament 
disassembly (Hung et al., 2011). Lundquist and colleagues show that nuclear 
MICAL2 catalyses nuclear F-actin disassembly (Lundquist et al., 2014). 
Interestingly instead of increasing nuclear G-actin concentration, the action of 
MICAL2 decreased G-actin, which in turn allowed MRTF-A activation. Actin 
derivatives mimicking the non-oxidisable (M44L) and oxidised (M44Q) forms, were 
more and less nuclear relative to wild type actin GFP, respectively (Lundquist et al., 
2014).  
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1.4 MRTFs 
 The Myocardin related transcription factors are a family of 3 members: 
Myocardin, MRTF-A and MRTF-B. The MRTFs are transcription co-activators, first 
identified as co-factors of the transcription factor SRF (serum response factor) (D.-
Z. Wang et al., 2002). 
 Along with the discovery of immediate early genes (Cochran et al., 1984; 
Greenberg and Ziff, 1984), SRF for years served as the paradigm for converting 
extracellular signals to changes in gene expression (Hill and Treisman, 1995; 
Treisman, 1996; Posern and Treisman, 2006). By associating with TCFs, a 
subfamily of Ets domain proteins, SRF allows regulation of c-fos by the MAP 
kinases (Shaw et al., 1989; Treisman, 1995). It was later discovered that SRF 
could respond to serum induced signals independently of TCFs, suggesting that 
other co-factors could associate with SRF (Hill et al., 1994). Soon after it was 
shown that the TCF-independent pathway required Rho activity (Hill et al., 1995). 
Sotiropoulos and colleagues showed that it was in fact changes in actin dynamics 
that activated SRF. Using actin-binding drugs and other cytoskeletal manipulations, 
they demonstrated that G-actin levels control SRF activity (Sotiropoulos et al., 
1999; Posern et al., 2002). 
 The discovery of Myocardin, the founding member of the MRTF family, 
provided the first evidence that other co-factors could bind SRF. Being expressed 
only in cardiac and smooth muscle, Myocardin could not be the transducer of the 
effects of G-actin levels on SRF (D. Wang et al., 2001). MRTF-A functional and 
biochemical properties indicated that MRTF-A and probably MRTF-B were the 
elusive link between Rho signalling, actin dynamics and SRF activation (Ma et al., 
2001; Mercher et al., 2001; D.-Z. Wang et al., 2002). MRTF-A was shown to 
associate with G-actin via its N-terminal RPEL domain, which was required for its 
subcellular localisation and ability to activate SRF in response to Rho-actin 
signalling (Miralles et al., 2003). 
A recent report has shown that in fibroblasts MRTF controls genes important 
for cell growth, cytoskeletal dynamics, cell adhesion, mechanosensing and 
circadian rhythm (Esnault et al., 2014). Indeed MRTF depletion has been shown to 
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reduce adhesion, spreading and motility of the metastatic cell lines B16F2 and 
MDA-MB-231, and to be required for experimental metastasis (Medjkane et al., 
2009). Also, Gerber et al. have shown that circadian signals cause rhythmic 
activation of MRTF, but also that the core circadian clock component Per2 is itself 
regulated by MRTF (Gerber et al., 2013). 
While MRTF-A knockout mice are viable, females are unable to nurse their 
offspring (S. Li et al., 2006; Y. Sun et al., 2006). The defect is caused by 
dedifferentiation and apoptosis of mammary gland myoepithelial cells required for 
milk ejection. The surprisingly restricted defect, despite ubiquitous MRTF-A 
expression, suggests redundancy amongst MRTF-A family members. The 
mammary gland phenotype may arise due to non-redundant functions between 
MRTFs or due to a dose dependent defect (Y. Sun et al., 2006; S. Li et al., 2006). 
MRTF-B inactivation leads to embryonic lethality (between E13.5 and 
E14.5) (Oh et al., 2005) or between E17.5 and postnatal day 1 (J. Li et al., 2005). 
The mice die from a spectrum of cardiovascular abnormalities and failure of smooth 
muscle cell differentiation in brachial arch arteries.   
 
1.4.1 Domain organization of MRTFs 
MRTF family members share a common organisation of functional domains, 
which have a high sequence similarity (see Figure 1.10) (D.-Z. Wang et al., 2002). 
  
1.4.1.1 B1 and Q regions 
 MRTFs share over 80% homology in the B1 region, which is rich in basic 
residues (Wang et al., 2002), and over 60% in the glutamine rich (Q) region. B1 
and Q regions are important for SRF binding. Deletion of B1 abolished MRTF-SRF 
complex formation and deletion of Q reduced it (Miralles et al., 2003).  
 The B1 region was shown to be important for efficient nuclear import of 
MRTF-A after serum stimulation (Miralles et al., 2003). Being a stretch of basic 
residues, B1 could constitute a classical NLS. However, since B1 also mediates 
SRF binding, it was hypothesised that SRF binding could provide nuclear 
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anchorage and contribute to nuclear accumulation by retention. Alternatively SRF 
binding could cause occlusion of an export sequence. These possibilities were 
excluded by alanine substitutions of key basic residues which completely blocked 
complex formation and had no effect on localisation (Zaromytidou, 2007).  
 Within the Q-region (QQQQLFLQLQILNQQQQQQQQQQ) the leucine 
residues have been shown to function as an export signal (Muehlich et al., 2008), 
explaining why deletion of the Q-region promotes nuclear localization (Miralles et 
al., 2003). Mutational analysis showed that there was no correlation between SRF 
binding and nuclear retention, in agreement with the observations for B1 
(Zaromytidou, 2007).  
 
1.4.1.2 The SAP domain 
 The SAF-A /B, Acinous and PIAS (SAP) domain, which is found in many 
different nuclear proteins involved in chromatin remodelling, is predicted to form 
two amphipathic helices competent of DNA binding (Aravind and Koonin, 2000). 
NMR determination of the yeast SAP domain of SUMO E3 ligases, revealed they 
are four-helix bundles, capable of binding A/T rich DNA (Suzuki et al., 2009).  
 SAP domain deletion in Myocardin resulted in impaired activation of a 
subset of target genes (Wang et al., 2001). Deletion in the context of MRTF-A had 
no significant effect on localisation or in-vitro SRF binding (Miralles et al., 2003).  
 
1.4.1.3 The Leucine Zipper and transactivation domains 
 MRTFs feature a leucine zipper domain (LZ) that enables formation of 
homo- and heterodimers between MRTF-A and B. Deletion of the LZ resulted in a 
reduction of ternary complex (MRTF, SRF, DNA) formation in bandshift assays, 
suggesting MRTF-A preferentially binds SRF as a dimer. Myocardin appears to 
bind SRF as a monomer (Miralles et al., 2003). 
 Fusion of the C-terminus of MRTFs to the LexA DNA binding domain shows 
they can act as autonomous transcription units in a LexA reporter system. Inclusion 
of the LZ in the LexA fusion doubled the activation efficiency. Stimulation did not 
affect activity of this moiety with or without the LZ present (Miralles et al., 2003). 
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Figure 1.10 Domain organisation of MRTF family members. 
MRTF family members share a common organisation of homologous functional 
domains. The RPEL domain mediates direct actin binding. In the case of Myocardin 
actin is only weakly bound; the B1 and Q regions mediate SRF binding; family 
members also possess a SAP domain, which is involved in chromatin remodelling; 
the leucine zipper mediates homo- and hetero dimerisation, except in the case of 
Myocardin which binds SRF as a monomer. All family members contain a 
transactivation domain within their C-terminus, through which SRF activity is 
stimulated. A detailed description of the domains can be found in the text. 
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1.4.1.4 The RPEL domain 
 The RPEL domain is located at the N-terminus of the MRTF proteins (Figure 
1.10). It contains three RPEL motifs (PFAM 02755), separated by two spacer 
regions. The name of the motif is derived from the near invariant RPxxxEL core. 
The RPEL domain enables MRTFs to sense cellular levels of G-actin, and is 
required for responsiveness to Rho-actin signalling (Miralles et al., 2003; Posern et 
al., 2004). Using their RPEL domains, MRTF-A and MRTF-B but not Myocardin, 
directly bind and are subjected to regulation by G-actin (Guettler et al., 2008; 
Posern et al., 2004).  
 Each RPEL motif constitutes an actin binding element, able to bind actin at 
a 1:1 stoichiometry (Guettler et al., 2008). Actin binding by the intact domain 
however occurs cooperatively, as the apparent affinity is higher than that of any of 
the RPEL motifs alone (Mouilleron et al., 2008; 2012). When bound to actin single 
RPEL motifs adopt an L-shaped conformation comprised of two helices, the α1 and 
α2 helices connected by the R-loop. Helix α1 binds actin in the hydrophobic cleft 
formed between subdomains 1 and 3, explaining the ability of the RPEL domain to 
inhibit actin polymerisation (Posern et al., 2004; Mouilleron et al., 2008). Helix α2 
interacts with a hydrophobic ledge on subdomain 3. Cooperativity arises from the 
ability of actin bound RPEL motifs to form secondary contacts with subsequent 
actins bound in the RPEL domain, thereby contributing to the strength of the 
interaction (Mouilleron et al., 2011; 2012).  
 Solution of the structure of the RPEL domain with actin, revealed that the 
RPEL motifs are not the only actin binding elements within the RPEL domain 
(Mouilleron et al., 2011). The RPEL domain formed a pentavalent complex with 
actin, by binding actin to each of the RPEL motifs, but also one actin on each 
spacer, referred to as spacer 1 (S1) and spacer 2 (S2) (Figure 1.11 A).   
 The same study also identified a trivalent G-actin complex. In this complex, 
RPEL motif 1 (RPEL1), spacer1 and RPEL2 bound actin, whereas spacer2 and 
RPEL3 did not (Figure 1.11 B) (Mouilleron et al., 2011). Analysis by size exclusion 
chromatography (SEC) revealed that both the pentameric and the trimeric 
complexes can exist in solution, but the trimeric complex is more stable. SEC 
analysis of actin incubated with an excess of RPEL domain leads to the detection 
of the trimeric complex, demonstrating the cooperative manner in which the RPEL 
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domain binds actin. Inclusion of actin in the running buffer during separation, 
allowed detection of the pentameric complex, which was dependent on the integrity 
of key residues required for spacer 2 and RPEL3 to bind actin. The results indicate 
that a stable trimeric complex is readily formed via RPEL1-spacer1-RPEL2 and that 
the spacer2-RPEL3 actins associate relatively weakly. In addition, binding of actin 
by spacer2 was dependent on actin binding by RPEL3 (Mouilleron et al., 2011). 
 Formation of the pentameric complex provided an explanation as to why 
high G-actin concentrations block MRTF-A nuclear accumulation (Vartiainen et al., 
2007; Mouilleron et al., 2011). Embedded within the RPEL domain is a bipartite 
NLS comprised of two basic elements B2 and B3. B2 is embedded in spacer 2 and 
B3 in RPEL2 (see Figure 1.11). This bipartite NLS is recognised by the Imp α/β 
heterodimer which competes with actin for binding (Pawłowski et al., 2010). 
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Figure 1.11 Crystallography structures of MRTF-A RPEL domain and actin 
Crystallisation of the RPEL domain of MRTF-A (67-199) led to the solution of two 
distinct crystal forms. RPEL motifs are shown in red; spacers are in grey; the B2 
and B3 elements are dark grey. A. In the pentameric actin/RPEL complex each 
RPEL motif and spacer element binds actin via primary contacts. Each RPEL/actin 
unit also forms secondary contacts with the next actin in the complex. In this 
complex the B2 and B3 elements that form the bipartite NLS are masked. B. In the 
trimeric RPEL/actin complex actin is bound by RPEL1, Spacer1 and RPEL2. From 
Mouilleron et al. Structure of a Pentavalent G-Actin•MRTF-A Complex Reveals 
How G-Actin Controls Nucleocytoplasmic Shuttling of a Transcriptional Coactivator 
(2011) Sci. Signal., 4(177): ra40. Reprinted with permission from AAAS. 
 
1.4.2 Regulation of MRTF-A by actin 
 G-actin regulates MRTF-A nuclear transport and activity (Figure 1.12) 
(Miralles et al., 2003; Vartiainen et al., 2007). In NIH-3T3 cells, MRTF-A 
continuously shuttles between the nucleus and cytoplasm. In most resting cells 
MRTF-A is predominantly cytoplasmic because the rate of export is higher than the 
rate of import. Export is mediated by Crm1 and is actin dependent. Serum induced 
Rho activation and consequent G-actin depletion leads to a reduction in export and 
concomitant MRTF-A nuclear accumulation. Reduction in G-actin binding to MRTF-
A was confirmed by a decrease in Forster resonance energy transfer (FRET) 
efficiency between mCherry-actin and MRTF-A-GFP. CD, which binds to actin 
competitively with the RPEL domain, almost completely eliminated FRET efficiency 
and blocked export (Vartiainen et al., 2007). 
LMB treatment traps MRTF-A in the nucleus without disrupting the 
interaction between MRTF-A and actin. Comparison of LMB and serum induced 
nuclear accumulation revealed that import rate was almost identical, showing that 
nuclear accumulation was regulated at the level of export (Vartiainen et al., 2007). 
Artificially increasing G-actin levels, for example by LatB treatment or C3-
transferase transfection, led to import inhibition (Vartiainen et al., 2007).  
 Regulation of MRTF-A by actin is conferred by the RPEL domain. Removal 
of the RPEL domain or mutation of the RPEL motifs relieves MRTF-A from 
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regulation by G-actin (Miralles et al., 2003). In fact, the N-terminus and RPEL 
domain are sufficient to confer actin regulated MRTF-A-like shuttling characteristics. 
A reciprocal swap between the MRTF-A RPEL domain and that of Myocardin, 
which binds actin very weakly, renders MRTF-A constitutively nuclear and 
independent of actin regulation. Conversely, Myocardin becomes regulated by actin 
(Guettler et al., 2008). In addition, fusion of the MRTF-A RPEL domain to the 
normally cytoplasmic pyruvate kinase confers MRTF-A like shuttling characteristics 
(Guettler et al., 2008). 
 Mutation of each actin-binding element in the RPEL domain (RPEL1, 
spacer1, RPEL2, spacer2, RPEL3) revealed that integrity of the whole RPEL 
domain is required for correct MRTF-A regulation by actin (Mouilleron et al., 2008; 
2011). Mutation of RPEL3 results in strong MRTF-A deregulation despite the fact 
that it is a weak actin binder and does not appear involved in the stable trimeric 
complex seen in-vitro. This observation shows RPEL3 can bind actin in cells and 
contributes to MRTF-A regulation. However, the functional significance of RPEL3 is 
determined by the engagement of actin with the preceding actin binding elements 
(Guettler et al., 2008). It is possible the trimeric complex readily forms in-vivo and is 
refractory to small changes in G-actin levels, but enables spacer2-RPEL3 to sense 
more subtle fluctuations. 
 In addition to regulating MRTF-A localisation, actin independently regulates 
MRTF-A activity. This was demonstrated either by fusion of an SV40 NLS 
sequence to MRTF-A, or by LMB treatment, both of which lead to MRTF-A nuclear 
entrapment while preserving actin binding. In both cases, actin dissociation was 
required for activation of target gene transcription (Vartiainen et al., 2007).  
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Figure 1.12 MRTF-A nucleocytoplasmic shuttling. 
Actin regulates nucleocytoplasmic shuttling of MRTF-A. In the absence of growth 
factors MRTF-A continuously shuttles between the nucleus and cytoplasm. Under 
these conditions MRTF-A is predominantly cytoplasmic due to a high rate of export, 
which is mediated by Crm1. Serum stimulation activates Rho, which leads to actin 
polymerisation, G-actin depletion and dissociation from MRTF-A. Because Crm1 
mediated export of MRTF-A is actin dependent, MRTF-A accumulates in the 
nucleus and activates SRF target genes. 
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1.4.3 Regulation of MRTF-A by post-translational modifications 
 MRTF-A has previously been shown to be regulated by PTM. Nagakawa 
and Kuzumaki showed that serum stimulation or active Rho expression, promote 
MRTF-A SUMOylation on three lysine residues close to the leucine zipper domain. 
Using GAL4-SUMO-1-MRTF fusions they show that SUMOylation represses 
MRTF-A activity without affecting localisation or SRF binding (Nakagawa and 
Kuzumaki, 2005). 
 Serum stimulation leads to MRTF-A phosphorylation on multiple sites, which 
can be seen as a reduction in electrophoretic mobility in SDS-PAGE (Miralles et al., 
2003; Olsen et al., 2006; Gnad et al., 2011). Inhibition of MEK1/2 using U0126 or 
inhibition of Rho using C3-transferase reduced phosphorylation of MRTF-A, while 
inhibition of both Rho and MEK-ERK signalling completely blocked it (Miralles et 
al., 2003). Serum induced phosphorylation of MRTF-A is therefore dependent on 
Rho and MEK-ERK signalling.   
 In neurons MRTF-A has been reported to be constitutively nuclear but still 
regulated. Brain derived neurotrophic factor (BDNF) treatment resulted in MRTF-A 
activation and phosphorylation, both of which were sensitive to inhibition of MEK-
ERK signalling (Kalita et al., 2006). At least in this system phosphorylation is not a 
prerequisite for nuclear accumulation and appears to correlate with transcriptional 
activation.  
In contrast, another study reported a negative role for MAPK signalling on 
MRTF-A. Muehlich and colleagues reported that ERK mediated phosphorylation of 
residues Ser449, Thr450 and Ser454 in human MRTF-A (Ser540, T541 and S545 
in mouse) promotes actin association resulting in nuclear export (Muehlich et al., 
2008).  
 The aim of this thesis is to investigate the role of MRTF-A phosphorylation 
and how MAPK signalling is involved in MRTF-A regulation. 
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Chapter 2. Materials & Methods 
 
 
2.1 Chemicals and reagents 
Chemical Supplier 
3MM paper Whatman plc 
4’,6’-diamidino-2-phenylindole (DAPI) Molecular Probes 
Agarose Life technologies 
Ampicillin Sigma-Aldrich 
Anti-Flag M2 agarose beads Sigma-Aldrich 
ATP (disodium salt) Sigma-Aldrich 
ATP, [γ -32P] 10mCi/mL Perkin Elmer 
Benzamidine Sigma-Aldrich 
Bromophenol Blue BioRad 
Bovine serum albumin (BSA) Sigma-Aldrich 
Chloramphenicol Boehringer Mannheim 
Complete protease inhibitor cocktail tablets Roche 
Coomassie Brilliant Blue BioRad 
Cytochalasin D Calbiochem 
Dimethyl sulfoxide (DMSO) Fisher Scientific 
Dithiothreitol (DTT) Calbiochem 
DMEM Life technologies 
Ethidium Bromide Boehringer Mannheim 
Fetal calf serum (FCS) Life technologies 
Glutathione sepharose 4B GE Healthcare 
Import Ligand, fluorescent Sigma-Aldrich 
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Isopropyl-β-D-thiogalactopyranoside (IPTG) MP Biomedicals 
Kanamycin Sigma-Aldrich 
Latrunculin B Calbiochem 
Lipofectamine2000 Life technologies 
Optimem Life technologies 
Orange G Sigma-Aldrich 
P-81 phosphocellulose squares Merck Millipore 
Phenylmethyl-sulphonyl fluoride (PMSF) Sigma-Aldrich 
Protease inhibitors Roche 
PROTRAN transfer membranes Whatman plc 
Slide-A-Lyzer dialysis cassettes Pierce Biotechnology Inc 
Tetracyclin Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
Tween 20 Sigma-Aldrich 
  
 
2.2 Buffers and solutions 
 
 Deionised Milli-Q water (Millipore purification systems) was used to prepare 
the buffers. The most commonly used buffers and solutions are listed below: 
 
Phosphate Buffered Saline 
(PBS) 
137 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 pH 7.4 
Tris-Buffered Saline (TBS) 50 mM Tris-HCl pH 7.5 
150 mM NaCl 
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Tris/Borate/EDTA (1x TBE) 80 mM Tris base 
89 mM Boric acid 
2 mM EDTA 
Luria broth (LB) medium 1% w/v Bacto-tryptone 
0.5% w/v Bacto-yeast extract 
1% w/v NaCl 
SOC medium 
 
2% w/v Bacto-tryptone 
0.5% w/v Bacto-yeast extract 
10 mM NaCl 
2.5 mM KCl 
10 mM MgCl2 
20 mM glucose 
Mowiol 6 ml glycerol 
mixed at 500C 
and filtered 
(0.45 µm) 
2.4 g Mowiol 4-88 (Calbiochem) 
12 ml Tris-HCl pH 8.5 
6 ml water 
2.5% w/v 1,2-diazabucyclo-[2.2.2]octane (Dabco, 
Sigma-Aldrich) 
Tris-EDTA (TE) 10mM Tris-HCl pH 8.0 
1mM EDTA pH 8.0 
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2.3 Molecular cloning 
 
2.3.1 Bacterial strains 
One Shot® TOP10 Chemically Competent E. coli (Life Technologies) were 
used for cloning and plasmid propagation. Genotype: F- mcrA Δ( mrr-hsdRMS-
mcrBC) Φ80lacZΔM15 Δ lacX74 recA1 araD139 Δ(araleu)7697 galU galK rpsL 
(StrR) endA1 nupG 
 
2.3.2 Transformation 
One vial (50µL) of chemically competent Top10 bacteria were thawed on ice 
and incubated with DNA for 30 minutes. The bacteria were then heat-shocked for 
40 seconds at 42°C on a thermoblock and immediately returned to ice for 2 
minutes. Pre-warmed SOC medium was next added and the vial was incubated for 
1 hour at 37°C on a shaker. The bacteria were plated on LB agar containing the 
appropriate antibiotic (30µg/mL kanamycin or 100µg/mL ampicillin) and incubated 
at 37°C for approximately 15 hours. 
 
2.3.3 Expression vectors 
All MRTF-A constructs used in this study were derivatives of pEF-Flag-
MRTF-A (Figure 2.1) (Miralles et al., 2003). The MRTF-A cDNA sequence was 
inserted between BamHI and XbaI sites. The pEF-Flag-MRTF-A plasmid used in 
this study was generated by Dr F. Miralles. The nucleotide sequence was modified 
from 5’-521AGCTGGTGGAGA532-3’ to 5’-521AACTAGTAGAAA532-3’ to make the 
plasmid resistant to the siRNA used in the lab; the amino acid sequence remained 
unchanged. The non-phosphorylatable derivative, E3, was generated by Dr F. 
Miralles. 
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 pEF-HA-DYRK1A-WT, pEF-HA-DYRK1A-K188R, pEF-HA-DYRK1B WT 
and pEF-HA-DYRK1B K140R were generated by Dr F. Miralles. cDNAs were 
inserted into the pEF-HA vector using the BamHI and XbaI  restriction sites. 
Products are N-terminally HA tagged. 
 pEF-Flag-Pyruvate kinase was obtained from Dr F. Miralles and encodes 
the first 1270 nucleotides corresponding to chicken pyruvate kinase, cloned into the 
pEF-Flag vector (Hill and Treisman, 1995), using the BamHI and EcoRI restriction 
sites. MRTF-A 2-204 was inserted between the Flag and pyruvate kinase coding 
sequences using the BamHI site (Figure 2.1), as previously described (Guettler et 
al., 2008). 
 pRev(1.4)-GFP and pRev(1.4)-NES-GFP were obtained from Dr B.R. 
Henderson (B. R. Henderson and Eleftheriou, 2000). Sequences were inserted 
between the Rev and GFP coding sequences using the BamHI and AgeI restriction 
sites (Figure 2.1). 
 The plasmid encoding the constitutively active form of mDia1 is described in 
(Copeland and Treisman, 2002). This plasmid encodes for the FH1 and FH2 
domains (amino acids 567-1181) of mDia, which are constitutively active in the 
absence of the regulatory region of the protein. 
 
2.3.3.1 Bacterial Expression vectors 
 pET-41a-3CΔ is a modified form of pET-41a (Novagen, Inc). The 
enterokinase site was replaced with a 3C-protease site and all restriction sites 5’ of 
the BamHI site were deleted (Figure 2.1).  
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Figure 2.1 Plasmids used in this thesis. 
Shown are the pEF-Flag-MRTF-A, pEF-Flag-MRTF-A (2-204)-PK, pRev1.4-GFP 
and pET-41a-3CΔ-MRTF-A plasmids with their corresponding antibiotic resistance 
indicated; Kanamycin (Kan) or Ampiciliin (Amp). Promoters are shown in blue 
(PEF1ɑ corresponds to the promoter/enhancer region of elongation factor 1ɑ  and 
PCMV corresponds to the Cytomegalovirus promoter). Coding sequences are shown 
in colour. Restriction endonuclease sites that were frequently used are also 
indicated.  
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2.3.4 Purification of plasmid DNA 
A single bacterial colony was used to inoculate LB medium (5mL for 
minipreps and 100mL for maxipreps) supplemented with the appropriate antibiotic. 
Cultures were incubated overnight at 37°C, 200rpm. For minipreps the bacteria 
were pelleted and submitted to the CRUK Equipment park miniprep service. For 
Maxipreps DNA was isolated using the QIAGEN plasmid maxi kit, according to the 
manufacturer's instructions. Isolated DNA was stored in TE buffer at 0.5µg/µL. 
 
2.3.5 Agarose gel electrophoresis 
Depending on the size of DNA fragments to be analysed, 0.5-1.5% w/v 
agarose gels were prepared using 1x TBE pH 8 and with a final concentration of 
0.5µg/mL ethidium bromide. Samples were mixed with 5x DNA loading buffer 
(0.01% w/v Orange G, 80% Glycerol, 50mM EDTA). Electrophoresis was 
performed in 1x TBE buffer at 100V. NEB 2-log ladder (New England Biolabs 
(NEB)) was used for estimation of fragment size. 
 
 
2.3.6 Recombinant DNA techniques 
2.3.6.1 Polymerase Chain Reaction 
 Polymerase chain reaction (PCR) was used for amplification of DNA for 
subcloning and site directed mutagenesis. Pfu Turbo DNA polymerase 
(Stratagene) was used because of its proofreading ability. PCR reactions were set 
up as follows: 
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PCR set-up (50µL) 
20ng DNA template 
1.5µL (10µM) Forward primer 
1.5µL (10µM) Reverse primer 
5µL (100mM) dNTP mix (25mM each) 
5µL 10x PCR buffer 
1µL (2.5U/µL) Pfu Turbo 
Up to 50µL with water 
Thermal cycling 
95°C 2 min  
 
 
20-30 
cycles 
95°C 30 sec 
50-60°C 1 min 
68°C 2 min/Kb 
72°C 2 min/Kb +2 min 
4°C hold 
 
 
2.3.6.2 Restriction Endonuclease digestion 
All restriction enzymes and buffers were from NEB and reactions were set 
up according to NEB recommendations. Generally 10 units of restriction enzyme 
were used for up to 5µg of plasmid DNA, for a 1-2 hour digestion.  
 
2.3.6.3 Dephosphorylation of 5’ phosphates of DNA ends 
To prevent vector re-circularisation without insert, 5’ phosphates were 
removed from digested vectors using Antarctic Phosphatase. 5.5µL of AP-reaction 
buffer and 1µL (5 units) of Antarctic phosphatase were added directly to the 
restriction enzyme reaction. The mixture was incubated for 15 min and enzymes 
were heat inactivated at 70°C for 5 min. 
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2.3.6.4 Purification of DNA fragments 
DNA fragments generated by PCR or after restriction digests were purified 
using the QIAquick PCR purification kit (Qiagen). When multiple fragments were 
generated, the reaction was resolved by agarose gel electrophoresis. The desired 
DNA fragment(s) was cut out of the gel and DNA was recovered using the 
QIAquick gel extraction kit (Qiagen), according to the manufacturer's instructions. 
 
2.3.6.5 DNA ligation 
Concentrations of vector and insert were quantified by measuring absorption 
at 260nm using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher 
Scientific). 150ng of digested and 5’ dephosphorylated vector and a 3-fold molar 
excess of digested insert were mixed with 1µL 10x T4 DNA ligase buffer and water 
up to 9µL. After a 5 min incubation at 50°C the mixture was placed on ice for 10 
minutes. 1µL (400 units) of T4 DNA ligase was mixed into the reaction. The ligation 
was carried out for 15 minutes at room temperature, or overnight at 16°C. 2-6µL of 
the reaction were next used for transformation of TOP10 bacteria (see section 
2.3.2). 
 
2.3.6.6 Site directed mutagenesis: Amino acid substitutions using QuikChange  
Amino acid substitutions were carried out using the QuikChange Site 
Directed Mutagenesis kit (Stratagene) according to the manufacturer's guidelines. 
A pair of complementary primers, 33-45 nucleotides in length, was designed with 
up to 3 codon changes in the centre of each primer. A PCR reaction was set up as 
described in section 2.3.6.1, but the number of cycles was restricted to 18. The 
entire template vector was amplified and then digested for 1.5 hours with DpnI. The 
remaining DNA was precipitated by the addition of 5.5 µL NaOAc (3M pH 5.2) and 
160µL 96% ethanol. Precipitated DNA was pelleted, washed three times in 70% 
ethanol and air dried. The DNA was resuspended in 10µL of water, half or all of 
which was used to transform TOP10 bacteria.  
 Constructs generated and primers used are shown in the table below. 
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Primers used for amino acid substitutions with the QuikChange method 
Plasmid Description. Primers (5’ to 3’) 
pEF-MRTF-A E3a 
Template: pEF-MRTF-A E3 
Change: AAA204/205/206SSS 
Forward Primer: 
ccaaaggtagcagacAGtTccTccttcgacgaggacgccg 
Reverse Primer: 
cggcgtcctcgtcgaaggAggAaCTgtctgctacctttgg 
pEF-MRTF-A E3b 
Template: pEF-MRTF-A E3a 
Change: AA211/212SS 
Forward Primer: tccttcgacgaggacAGcAGcgatgccctggctcct 
Reverse Primer: aggagccagggcatcgCTgCTgtcctcgtcgaagga 
pEF-MRTF-A E3c 
Template: pEF-MRTF-A E3b 
Change: S33A 
Forward Primer: tctgtctgcggcccccGCcccccagagcgaagctgt 
Reverse Primer: acagcttcgctctgggggGCgggggccgcagacaga 
pEF-MRTF-A E3d 
Template: pEF-MRTF-A E3c 
Change: A402T 
Forward Primer: 
tggaagcagtgcccctAccccatcacgcagcctctcca 
Reverse Primer: 
tggagaggctgcgtgatggggTaggggcactgcttcca 
pEF-MRTF-A E3f 
Template: pEF-MRTF-A E3d 
Change: T545A 
Forward Primer: ggcagcacaggctccGcaccccccgtggctccca 
Reverse Primer: tgggagccacggggggtgCggagcctgtgctgcc 
pEF-MRTF-A E3g 
Template: pEF-MRTF-A E3f 
Change: T551A 
Forward Primer: ccccccgtggctcccGccccttcagagcgctca 
Reverse Primer: tgagcgctctgaaggggCgggagccacgggggg 
pEF-MRTF-A E3h 
Template: pEF-MRTF-A E3g 
Change: S587A 
Forward Primer: agctcaccctgcaggccGccccactgcagatagtg 
Reverse Primer: cactatctgcagtggggCggcctgcagggtgagct 
pEF-MRTF-A E3i 
Template: pEF-MRTF-A E3h 
Change: S601A 
Forward Primer: ggtgcccgtgctgcgGcctgctgtctagcccct 
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Reverse Primer: aggggctagacagcaggCcgcagcacgggcacc 
pEF-MRTF-A E3j 
or 26ST/A 
Template: pEF-MRTF-A E3i 
Change: S775A 
Forward Primer: ggcttgcctgcagggGCcccccagcagcccttg 
Reverse Primer: caagggctgctgggggGCccctgcaggcaagcc 
pEF-MRTF-A 
LL74/76AA 
Template: pEF-MRTF-A 
Forward Primer: 
gagcggaagaatgtgGCgcagGCgaagctccagcagcgg 
Reverse Primer: 
ccgctgctggagcttcGCctgcGCcacattcttccgctc 
pEF-MRTF-A α1AA 
Template: pEF-MRTF-A 
Change: LL74/78AA 
Forward Primer:  
gagcggaagaatgtgGCgcagttgaagGCccagcagcggcggacc 
Reverse Primer: 
ggtccgccgctgctggGCcttcaactgcGCcacattcttccgctc 
pEF-26ST/A x23 
Template: pEF-26ST/A 
Change: R81A 
Forward Primer: ttgaagctccagcagGCgcggacccgggaggaa 
Reverse Primer: ttcctcccgggtccgcGCctgctggagcttcaa 
pEF-26ST/A xx3 
Template: pEF-26ST/A x23 
Change: R125A 
Forward Primer: cggaagatccgttccGCgcccgagagagcagagc 
Reverse Primer: gctctgctctctcgggcGCggaacggatcttccg 
pEF-26ST/A xxx 
Template: pEF-26ST/A xx3 
Change: R169A 
Forward Primer: gaaaagattgcacagGCgcctggccccatggaa 
Reverse Primer: ttccatggggccaggCGCctgtgcaatcttttc 
pEF-E3 x23 
Template: pEF-E3 
Change: R81A 
Forward Primer: ttgaagctccagcagGCgcggacccgggaggaa 
Reverse Primer: ttcctcccgggtccgcGCctgctggagcttcaa 
pEF-E3 xx3 
Template: pEF-E3 x23 
Change: R125A 
Forward Primer: cggaagatccgttccGCgcccgagagagcagagc 
Reverse Primer: gctctgctctctcgggcGCggaacggatcttccg 
pEF-E3 xxx Template: pEF-E3 xx3 
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Change: R169A 
Forward Primer: gaaaagattgcacagGCgcctggccccatggaa 
Reverse Primer: ttccatggggccaggCGCctgtgcaatcttttc 
pEF-MRTF-A Y330A 
Template: pEF-MRTF-A 
Change: Y330A 
Forward Primer: gtgaagaagctcaagGCccaccagtacatcccc 
Reverse Primer: ggggatgtactggtgcGCcttgagcttcttcac 
pEF-MRTF-A Y330A 
ΔLZ 
Template: pEF-MRTF-A ΔLZ 
Change: Y330A 
Forward Primer: gtgaagaagctcaagGCccaccagtacatcccc 
Reverse Primer: ggggatgtactggtgcGCcttgagcttcttcac 
pEF-MRTF-A 
RK70/71AA 
Template: pEF-MRTF-A  
Change: RK70/71AA 
Forward Primer: cctccacttagtgagGCgGCgaatgtgctgcagttg 
Reverse Primer: caactgcagcacattcGCcGCctcactaagtggagg 
pEF-MRTF-A 
RK70/71VQ 
Template: pEF-MRTF-A  
Change: RK70/71VQ 
Forward Primer: cctccacttagtgagGTgCAgaatgtgctgcagttg 
Reverse Primer: caactgcagcacattcTGcACctcactaagtggagg 
pEF-MRTF-A S33A 
Template: pEF-MRTF-A  
Change: S33A 
Forward Primer: ctgtctgcggcccccGCcccccagagcgaagc 
Reverse Primer: gcttcgctctgggggGCgggggccgcagacag 
pEF-MRTF-A S33D 
Template: pEF-MRTF-A  
Change: S33D 
Forward Primer: ctgtctgcggcccccGAcccccagagcgaagc 
Reverse Primer: gcttcgctctgggggTCgggggccgcagacag 
pEF-MRTF-A-B2A 
LSL46/47/48AAA 
Template: pEF-MRTF-A B2A 
Change: LSL46/47/48AAA 
Forward Primer: tgaactgcaggagGCgGccGCgcagcccgagctga 
Reverse Primer: tcagctcgggctgcGCggCcGCctcctgcagttca 
pEF-MRTF-A (2-204)-
PK S33A 
Template: pEF-MRTF-A (2-204)-PK 
Change: S33A 
Forward Primer: ctgtctgcggcccccGCcccccagagcgaagc 
Reverse Primer: gcttcgctctgggggGCgggggccgcagacag 
pEF-MRTF-A (2-204)-
PK S33A S98D 
Template: pEF-MRTF-A (2-204)-PK 98D 
Change: S33A 
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Forward Primer: ctgtctgcggcccccGCcccccagagcgaagc 
Reverse Primer: gcttcgctctgggggGCgggggccgcagacag 
MRTF-A (2-204)-PK 
S33D 
Template: pEF-MRTF-A (2-204)-PK 
Change: S33D 
Forward Primer: ctgtctgcggcccccGAcccccagagcgaagc 
Reverse Primer: gcttcgctctgggggTCgggggccgcagacag 
pEF-MRTF-A (2-204)-
PK S33D S98A 
Template: pEF-MRTF-A (2-204)-PK 98D 
Change: S33D 
Forward Primer: ctgtctgcggcccccGAcccccagagcgaagc 
Reverse Primer: gcttcgctctgggggTCgggggccgcagacag 
pRev(1.4) 2-115 P94A 
Template: pRev(1.4) 2-115 
Change: P94A 
Forward Primer: agccaagggatcatgGCgcctttgaaaagcccc 
Reverse Primer: ggggcttttcaaaggcGCcatgatcccttggct 
pRev(1.4) 2-115 P94S 
Template: pRev(1.4) 2-115 
Change: P94S 
Forward Primer: agccaagggatcatgTCgcctttgaaaagcccc 
Reverse Primer: ggggcttttcaaaggcGAcatgatcccttggct 
pRev(1.4) 2-115 P94A 
L96A 
Template: pRev(1.4) 2-115 
Change: P94A L96A 
Forward Primer: 
agccaagggatcatgGCgcctGCgaaaagccccgctgc 
Reverse Primer: 
gcagcggggcttttcGCaggcGCcatgatcccttggct 
pRev(1.4) 2-204 B2A 
xxx 
Template: pRev(1.4) 2-204 xxx 
Change: KK152/154AA (B2A) 
Forward Primer: aggccaagcagctgGCgctgGCgagagccaggctggc 
Reverse Primer: gccagcctggctctcGCcagcGCcagctgcttggcct 
pRev(1.4) 2-204 B3A 
xxx 
Template: pRev(1.4) 2-204 xxx 
Change: KRK119/120/121AAA 
Forward Primer: accgaggactatttgGCAGCGGCGatccgttccgctc 
Reverse Primer: gagcggaacggatCGCCGCTGCcaaatagtcctcggt 
pRev(1.4) 2-204 S98A 
Template: pRev(1.4) 2-204 B2A 
Change: S98A 
Forward Primer: atgccgcctttgaaaGCccccgctgcatttcat 
Reverse Primer: atgaaatgcagcggggGCtttcaaaggcggcat 
pRev(1.4) 2-204 S98D Template: pRev(1.4) 2-204 B2A 
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Change: S98D 
Forward Primer: 
TcatgccgcctttgaaaGAccccgctgcatttcatgag 
Reverse Primer: 
ctcatgaaatgcagcggggTCtttcaaaggcggcatgA 
pRev(1.4) 2-204 α1AA 
Template: pRev(1.4) 2-204 B2A 
Change: α1AA 
Forward Primer: 
gagcggaagaatgtgGCgcagttgaagGCccagcagcggcggacc 
Reverse Primer: 
ggtccgccgctgctggGCcttcaactgcGCcacattcttccgctc 
pRev(1.4) 2-204 S33A 
Template: pRev(1.4) 2-204 B2A 
Change: S33A 
Forward Primer: ctgtctgcggcccccGCcccccagagcgaagc 
Reverse Primer: gcttcgctctgggggGCgggggccgcagacag 
pRev(1.4) 2-204 S33D 
Template: pRev(1.4) 2-204 B2A 
Change: S33D 
Forward Primer: ctgtctgcggcccccGAcccccagagcgaagc 
Reverse Primer: gcttcgctctgggggTCgggggccgcagacag 
pET-41a-3CΔ 67-199 
α1AA 
Template: pET-41a-3CΔ 67-199 
Change: LL74/78AA 
Forward Primer:  
gagcggaagaatgtgGCgcagttgaagGCccagcagcggcggacc 
Reverse Primer: 
ggtccgccgctgctggGCcttcaactgcGCcacattcttccgctc 
pET-41a-3CΔ 67-199 
12x 
Template: pET-41a-3CΔ 67-199 
Change: R169A 
Forward Primer: gaaaagattgcacagGCgcctggccccatggaa 
Reverse Primer: ttccatggggccaggcGCctgtgcaatcttttc 
pET-41a-3CΔ 67-199 
S98A 
Template: pET-41a-3CΔ 67-199 
Change: S98A 
Forward Primer: atgccgcctttgaaaGCccccgctgcatttcat 
Reverse Primer: atgaaatgcagcggggGCtttcaaaggcggcat 
pET-41a-3CΔ 67-199 
12x S98D 
Template: pET-41a-3CΔ 67-199 S98D 
Change: R169A 
Forward Primer: gaaaagattgcacagGCgcctggccccatggaa 
Reverse Primer: ttccatggggccaggcGCctgtgcaatcttttc 
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pEF-Phactr1(MRTF) B1A 
Template: pEF-Phactr1(MRTF) 
Change: RRR108/109/110AAA (B1A) 
Forward Primer: caccccgcccatcGCgGCggcgagtaagtttgcc 
Reverse Primer: ggcaaacttactcgccGCcGCgatgggcggggtg 
pEF-Phactr1(MRTF) B2A 
Template: pEF-Phactr1(MRTF) 
Change: KK152/154AA (B2A) 
Forward Primer: aggccaagcagctgGCGctGGCGagagccaggctggc 
Reverse Primer: gccagcctggctctCGCCagCGCcagctgcttggcct 
pEF-Phactr1(MRTF) B3A 
Template: pEF-Phactr1(MRTF) 
Change: KRK119/120/121AAA 
Forward Primer: accgaggactatttgGCAGCGGCGatccgttcccggc 
Reverse Primer: gccgggaacggatCGCCGCTGCcaaatagtcctcggt 
pEF-Phactr1(MRTF) B1A 
B2A 
Template: pEF-Phactr1(MRTF) B1A 
Change: KK152/154AA (B2A) 
Forward Primer: aggccaagcagctgGCgctgGCgagagccaggctggc 
Reverse Primer: gccagcctggctctcGCcagcGCcagctgcttggcct 
pEF-Phactr1(MRTF) B1A 
B3A 
Template: pEF-Phactr1(MRTF) B1A 
Change: KRK119/120/121AAA 
Forward Primer: accgaggactatttgGCAGCGGCGatccgttcccggc 
Reverse Primer: gccgggaacggatCGCCGCTGCcaaatagtcctcgg 
pEF-Phactr1(MRTF) B1A 
xxx 
Template: pEF-Phactr1(MRTF) xxx 
Change: RRR108/109/110AAA (B1A) 
Forward Primer: caccccgcccatcGCgGCggcgagtaagtttgcc 
Reverse Primer: ggcaaacttactcgccGCcGCgatgggcggggtg 
pEF-Phactr1(MRTF) B2A 
xxx 
Template: pEF-Phactr1(MRTF) xxx 
Change: KK152/154AA (B2A) 
Forward Primer: aggccaagcagctgGCgctgGCgagagccaggctggc 
Reverse Primer: gccagcctggctctcGCcagcGCcagctgcttggcct 
pEF-Phactr1(MRTF) B3A 
xxx 
Template: pEF-Phactr1(MRTF) xxx 
Change: KRK119/120/121AAA 
Forward Primer: accgaggactatttgGCAGCGGCGatccgttccgctc 
Reverse Primer: gagcggaacggatCGCCGCTGCcaaatagtcctcggt 
pEF-Phactr1(MRTF) B1A 
B2A xxx 
Template: pEF-Phactr1(MRTF) B1A xxx 
Change: KK152/154AA (B2A) 
Forward Primer: aggccaagcagctgGCgctgGCgagagccaggctggc 
Reverse Primer: gccagcctggctctcGCcagcGCcagctgcttggcct 
pEF-Phactr1(MRTF) B1A Template: pEF-Phactr1(MRTF)  B1A xxx 
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B3A xxx  Change: KRK119/120/121AAA 
Forward Primer: accgaggactatttgGCAGCGGCGatccgttccgctc 
Reverse Primer: gagcggaacggatCGCCGCTGCcaaatagtcctcggt 
pEF-Phactr1(MRTF NT 
RPEL) B1A 
Template: pEF-Phactr1(MRTF NT RPEL) 
Change: RRR108/109/110AAA (B1A) 
Forward Primer: caccccgcccatcGCgGCggcgagtaagtttgcc 
Reverse Primer: ggcaaacttactcgccGCcGCgatgggcggggtg 
pEF-Phactr1(MRTF NT 
RPEL) B2A 
Template: pEF-Phactr1(MRTF NT RPEL) 
Change: KK152/154AA (B2A) 
Forward Primer: aggccaagcagctgGCGctGGCGagagccaggctggc 
Reverse Primer: gccagcctggctctCGCCagCGCcagctgcttggcct 
pEF-Phactr1(MRTF NT 
RPEL) B3A 
Template: pEF-Phactr1(MRTF NT RPEL) 
Change: KRK119/120/121AAA 
Forward Primer: accgaggactatttgGCAGCGGCGatccgttcccggc 
Reverse Primer: gccgggaacggatCGCCGCTGCcaaatagtcctcggt 
pEF-Phactr1(MRTF NT 
RPEL) B1A B2A 
Template: pEF-Phactr1(MRTF NT RPEL) B1A 
Change: KK152/154AA (B2A) 
Forward Primer: aggccaagcagctgGCgctgGCgagagccaggctggc 
Reverse Primer: gccagcctggctctcGCcagcGCcagctgcttggcct 
pEF-Phactr1(MRTF NT 
RPEL) B1A B3A 
Template: pEF-Phactr1(MRTF NT RPEL) B1A 
Change: KRK119/120/121AAA 
Forward Primer: accgaggactatttgGCAGCGGCGatccgttcccggc 
Reverse Primer: gccgggaacggatCGCCGCTGCcaaatagtcctcgg 
pEF-Phactr1(MRTF NT 
RPEL) B1A xxx 
Template: pEF-Phactr1(MRTF NT RPEL) xxx 
Change: RRR108/109/110AAA (B1A) 
Forward Primer: caccccgcccatcGCgGCggcgagtaagtttgcc 
Reverse Primer: ggcaaacttactcgccGCcGCgatgggcggggtg 
pEF-Phactr1(MRTF NT 
RPEL) B2A xxx 
Template: pEF-Phactr1(MRTF NT RPEL) xxx 
Change: KK152/154AA (B2A) 
Forward Primer: aggccaagcagctgGCgctgGCgagagccaggctggc 
Reverse Primer: gccagcctggctctcGCcagcGCcagctgcttggcct 
pEF-Phactr1(MRTF NT 
RPEL) B3A xxx 
Template: pEF-Phactr1(MRTF NT RPEL) xxx 
Change: KRK119/120/121AAA 
Forward Primer: accgaggactatttgGCAGCGGCGatccgttccgctc 
Reverse Primer: gagcggaacggatCGCCGCTGCcaaatagtcctcggt 
pEF-Phactr1(MRTF NT 
RPEL) B1A B2A xxx 
Template: pEF-Phactr1(MRTF NT RPEL) B1A xxx 
Change: KK152/154AA (B2A) 
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Forward Primer: aggccaagcagctgGCgctgGCgagagccaggctggc 
Reverse Primer: gccagcctggctctcGCcagcGCcagctgcttggcct 
pEF-Phactr1(MRTF NT 
RPEL) B1A B3A xxx  
Template: pEF-Phactr1(MRTF NT RPEL)  B1A xxx 
Change: KRK119/120/121AAA 
Forward Primer: accgaggactatttgGCAGCGGCGatccgttccgctc 
Reverse Primer: gagcggaacggatCGCCGCTGCcaaatagtcctcggt 
pRev(1.4) 2-115 
PPS2/3/4AAA  
Template: pRev(1.4) 2-115 
Change: PPS2/3/4AAA 
Forward Primer: 
ggaaccaaagaggatccaGccGctGccgtcattgctgtga 
Reverse Primer: 
tcacagcaatgacggCagCggCtggatcctctttggttcc 
pRev(1.4) 2-115 
VIA5/6/7AAA 
Template: pRev(1.4) 2-115 
Change: VIA5/6/7AAA 
Forward Primer: 
gatccacccccttccgCcGCtgctgtgaatgggctggacg 
Reverse Primer: 
cgtccagcccattcacagcaGCgGcggaagggggtggatc 
pRev(1.4) 2-115 
VNG8/9/10AAA 
Template: pRev(1.4) 2-115 
Change: VNG8/9/10AAA 
Forward Primer: 
ccttccgtcattgctgCgGCtgCgctggacggaggaggg 
Reverse Primer: 
ccctcctccgtccagcGcaGCcGcagcaatgacggaagg 
pRev(1.4) 2-115 
LDG11/12/13AAA 
Template: pRev(1.4) 2-115 
Change: LDG11/12/13AAA 
Forward Primer: 
attgctgtgaatgggGCggCcgCaggaggggctggcgaa 
Reverse Primer: 
ttcgccagcccctcctGcgGccGCcccattcacagcaat 
pRev(1.4) 2-115 
GGA14/15/16AAA 
Template: pRev(1.4) 2-115 
Change: GGA14/15/16AAA 
Forward Primer: 
aatgggctggacggagCagCggctggcgaaaatgacgacg 
Reverse Primer: 
cgtcgtcattttcgccagccGctGctccgtccagcccatt 
pRev(1.4) 2-115 
GEN17/18/19AAA  
Template: pRev(1.4) 2-115 
Change: GEN17/18/19AAA 
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Forward Primer: 
gacggaggaggggctgCcgCaGCtgacgacgagccagtgc 
Reverse Primer: 
gcactggctcgtcgtcaGCtGcgGcagcccctcctccgtc 
pRev(1.4) 2-115 
DDE20/21/22AAA  
Template: pRev(1.4) 2-115 
Change: DDE20/21/22AAA 
Forward Primer: 
ggggctggcgaaaatgCcgCcgCgccagtgctcctgtctc 
Reverse Primer: 
gagacaggagcactggcGcgGcgGcattttcgccagcccc 
pRev(1.4) 2-115 
PVL23/24/25AAA  
Template: pRev(1.4) 2-115 
Change: PVL23/24/25AAA 
Forward Primer: 
gaaaatgacgacgagGcagCgGCcctgtctctgtctgcg 
Reverse Primer: 
cgcagacagagacaggGCcGctgCctcgtcgtcattttc 
pRev(1.4) 2-115 
LSL26/27/28AAA 
Template: pRev(1.4) 2-115 
Change: LSL26/27/28AAA 
Forward Primer: 
gacgagccagtgctcGCgGctGCgtctgcggcccccagc 
Reverse Primer: 
gctgggggccgcagacGCagCcGCgagcactggctcgtc 
pRev(1.4) 2-115 
PSP32/33/34AAA 
Template: pRev(1.4) 2-115 
Change: PSP32/33/34AAA 
Forward Primer: 
tctctgtctgcggccGccGCcGcccagagcgaagctgtt 
Reverse Primer: 
aacagcttcgctctgggCgGCggCggccgcagacagaga 
pRev(1.4) 2-115 
QSE35/36/37AAA  
Template: pRev(1.4) 2-115 
Change: QSE35/36/37AAA 
Forward Primer: 
gcggcccccagccccGCgGCcgCagctgttgccaatgaa 
Reverse Primer: 
ttcattggcaacagctGcgGCcGCggggctgggggccgc 
pRev(1.4) 2-115 
NEL41/42/43AAA  
Template: pRev(1.4) 2-115 
Change: NEL41/42/43AAA 
Forward Primer: 
agcgaagctgttgccGCtgCaGCgcaggagctgtccctg 
Chapter 2 Materials and Methods 
 
 92 
Reverse Primer: 
cagggacagctcctgcGCtGcaGCggcaacagcttcgct 
pRev(1.4) 2-115 
QEL44/45/46AAA  
Template: pRev(1.4) 2-115 
Change: QEL44/45/46AAA 
Forward Primer: 
gttgccaatgaactgGCggCgGCgtccctgcagcccgag 
Reverse Primer: 
ctcgggctgcagggacGCcGccGCcagttcattggcaac 
pRev(1.4) 2-115 
SLQ47/48/49AAA  
Template: pRev(1.4) 2-115 
Change: SLQ47/48/49AAA 
Forward Primer: 
gaactgcaggagctgGccGCgGCgcccgagctgactctag 
Reverse Primer: 
ctagagtcagctcgggcGCcGCggCcagctcctgcagttc 
pRev(1.4) 2-115 
PEL50/51/52AAA  
Template: pRev(1.4) 2-115 
Change: PEL50/51/52AAA 
Forward Primer: 
gagctgtccctgcagGccgCgGCgactctaggcctccat 
Reverse Primer: 
atggaggcctagagtcGCcGcggCctgcagggacagctc 
pRev(1.4) 2-115 
TLG53/54/55AAA  
Template: pRev(1.4) 2-115 
Change: TLG53/54/55AAA 
Forward Primer: 
ctgcagcccgagctgGctGCagCcctccatcctgggagg 
Reverse Primer: 
cctcccaggatggaggGctGCagCcagctcgggctgcag 
pRev(1.4) 2-115 
LHP56/57/58AAA  
Template: pRev(1.4) 2-115 
Change: LHP56/57/58AAA 
Forward Primer: 
gagctgactctaggcGCcGCtGctgggaggaaccccaatt 
Reverse Primer: 
aattggggttcctcccagCaGCgGCgcctagagtcagctc 
pRev(1.4) 2-115 
GRN59/60/61AAA  
Template: pRev(1.4) 2-115 
Change: GRN59/60/61AAA 
Forward Primer: 
ctaggcctccatcctgCgGCgGCccccaatttacctccac 
Reverse Primer: 
gtggaggtaaattggggGCcGCcGcaggatggaggcctag 
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pRev(1.4) 2-115 
PNL62/63/64AAA  
Template: pRev(1.4) 2-115 
Change: PNL62/63/64AAA 
Forward Primer: 
catcctgggaggaacGccGCtGCacctccacttagtgagc 
Reverse Primer: 
gctcactaagtggaggtGCaGCggCgttcctcccaggatg 
pRev(1.4) 2-115 
PPL65/66/67AAA  
Template: pRev(1.4) 2-115 
Change: PPL65/66/67AAA 
Forward Primer: 
aggaaccccaatttaGctGcaGCtagtgagcggaagaatg 
Reverse Primer: 
cattcttccgctcactaGCtgCagCtaaattggggttcct 
Note: Substituted bases are shown in upper case 
 
2.3.6.7 Site Directed Mutagenesis: Amino acid substitution using conventional 
restriction cloning 
Two complementary primers were designed with the desired mutation in the 
centre and approximately 15 bases on either side. Fragments to be subcloned 
were generated in 3 PCR reactions. In the first PCR reaction, the forward 
mutagenesis primer and a reverse primer covering the closest restriction site (in the 
direction 3’ of the forward primer) were used. In the second PCR reaction the 
reverse mutagenesis primer and a forward primer covering the closest restriction 
site (in the direction 3’ of the forward primer) were used. In the third PCR reaction, 
the products from the previous reactions were purified and used in a PCR with the 
forward and reverse primers covering the restriction sites. The final product was 
purified and digested with the same restriction enzymes as the vector. Ligation was 
carried out as described in section 2.3.6.5.  
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Primers used for amino acid substitutions using conventional method 
Plasmid Primers (5’ to 3’) 
pEF-MRTF-A S98D Reaction1: gccatggccggatcccccccttcc (BamHI) and 
ctcatgaaatgcagcggggTCtttcaaaggcggcatga 
Reaction2:  
tcatgccgcctttgaaaGAccccgctgcatttcatgag and 
gtctctccaggatccggagcc (BamHI) 
Reaction3:  
gccatggccggatcccccccttcc (BamHI) and  
gtctctccaggatccggagcc (BamHI) and products from 
reactions 1 and 2. 
pET-41a-3CΔ 67-199 S98D Reaction1:  
cgaacgccagcacatggac (BamHI) and 
ctcatgaaatgcagcggggTCtttcaaaggcggcatga 
Reaction2: 
TcatgccgcctttgaaaGAccccgctgcatttcatgag and 
tgctagttattgctcagcggt (XhoI) 
Reaction3: cgaacgccagcacatggac (BamHI) and 
tgctagttattgctcagcggt (XhoI) and products from 
reactions 1 and 2. 
Note: Substituted bases are shown in upper case 
 
2.3.6.8 Site Directed Mutagenesis: Insertions 
Primers were designed to be homologous to approximately 15 nucleotides 
of the fragment to be amplified. 5’ to these nucleotides the appropriate restriction 
site was included, which itself was preceded by an extra 6 nucleotides to ensure 
efficient restriction enzyme digestion. Fragments were amplified by PCR, purified 
and digested as described in sections 2.3.6.1-2.3.6.4. Ligation was carried out as 
described in section 2.3.6.5, using a digested and 5’ dephosphorylated vector. 
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Plasmid Primers (5’ to 3’) 
pRev(1.4) 30-60 
Template: pEF-MRTF-A 
Forward Primer: TCTAGAGGATCCagcggcccccagcccc (BamHI) 
Reverse Primer: TCTAGAACCGGTttcctcccaggatggag	  	  (AgeI) 
pRev(1.4) 35-52 
Template: pEF-MRTF-A 
Forward Primer: TCTAGAGGATCCacagagcgaagctgttg (BamHI)	  
Reverse Primer: TCTAGAACCGGTgtcagctcgggctgcag (AgeI) 
pRev(1.4) 85-104 
Template: pEF-MRTF-A 
Forward Primer: TCTAGAGGATCCagaggaactggtgagcc (BamHI) 
Reverse Primer: TCTAGAACCGGTcgctccaggcttcttctc (AgeI) 
pRev(1.4) 89-110 
Template: pEF-MRTF-A 
Forward Primer: TCTAGAGGATCCaagccaagggatcatgc (BamHI) 
Reverse Primer: TCTAGAACCGGTtgctcatgaaatgcagcg (AgeI) 
pRev(1.4) 2-67 
Template: pEF-MRTF-A 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTctaagtggaggtaaa	  (AgeI)	  
pRev(1.4) 2-67 33A 
Template: pEF-MRTF-A S33A 
Forward Primer: TCTAGAGGATCCacccccttccgtc (BamHI) 
Reverse Primer: TCTAGAACCGGTctaagtggaggtaaa (AgeI) 
pRev(1.4) 2-67 
LSL46/47/48AAA 
Template: pEF-MRTF-A LSL46/47/48AAA 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTctaagtggaggtaaa	  (AgeI) 
pRev(1.4) 2-67 33D 
Template: pEF-MRTF-A S33D 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTctaagtggaggtaaa	  (AgeI) 
pRev(1.4) 2-115 
Template: pEF-MRTF-A 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTtcctcggtcctgg	  (AgeI) 
pRev(1.4) 2-115 33D 
Template: pEF-MRTF-A S33D 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTtcctcggtcctgg	  (AgeI) 
pRev(1.4) 2-115 α1AA 
Template: pEF-MRTF-A α1AA 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTtcctcggtcctgg	  (AgeI)	  
pRev(1.4) 2-115 α2AAA 
Template: pEF-MRTF-A α2AAA 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	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Reverse Primer: TCTAGAACCGGTtcctcggtcctgg	  (AgeI)	  
pRev(1.4) 2-115 S33A 
Template: pEF-MRTF-A S33A 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTtcctcggtcctgg	  (AgeI) 
pRev(1.4) 2-115 R81A 
Template: pEF-MRTF-A R81A 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTtcctcggtcctgg	  (AgeI) 
pRev(1.4) 2-115 S98A 
Template: pEF-MRTF-A S98A 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTtcctcggtcctgg	  (AgeI) 
pRev(1.4) 2-115 S98D 
Template: pEF-MRTF-A S98D 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTtcctcggtcctgg	  (AgeI) 
pRev(1.4) 2-115 S96A 
Template: pEF-MRTF-A S96A 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTtcctcggtcctgg	  (AgeI) 
pRev(1.4) 2-115 
LSL46/47/48AAA 
Template: pEF-MRTF-A LSL46/47/48AAA 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTtcctcggtcctgg	  (AgeI) 
pRev(1.4) 67-204 
Template: pEF-MRTF-A 
Forward Primer: TCTAGAGGATCCacttagtgagcggaag	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTgaactgtctgctacc	  (AgeI)	  
pRev(1.4) 67-204 B2A 
Template: pEF-MRTF-A B2A 
Forward Primer:	  TCTAGAGGATCCacttagtgagcggaag	  (BamHI)	  
Reverse Primer:	  TCTAGAACCGGTgaactgtctgctacc	  (AgeI) 
pRev(1.4) 2-204 
Template: pEF-MRTF-A 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTgaactgtctgctacc	  (AgeI) 
pRev(1.4) 2-204 xxx 
Template: pEF-MRTF-A xxx 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTgaactgtctgctacc	  (AgeI) 
pRev(1.4) 2-204 B2A 
LSL46/47/48AAA 
Template: pEF-MRTF-A-B2A LSL46/47/48AAA  
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	  
Reverse Primer: TCTAGAACCGGTgaactgtctgctacc	  (AgeI)	  
pRev(1.4) 2-204 153A 
Template: pEF-MRTF-A L153A 
Forward Primer: TCTAGAGGATCCacccccttccgtc	  (BamHI)	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Reverse Primer:	  TCTAGAACCGGTgaactgtctgctacc	  (AgeI) 
pRev(1.4) 2-204 153D 
Template: pEF-MRTF-A L153D 
Forward Primer:	  TCTAGAGGATCCacccccttccgtc	  (BamHI) 
Reverse Primer: TCTAGAACCGGTgaactgtctgctacc	  (AgeI)	  
pRev(1.4) 2-204 
151/3AA 
Template: pEF-MRTF-A LL151/153AA 
Forward Primer:	  TCTAGAGGATCCacccccttccgtc	  (BamHI) 
Reverse Primer:	  TCTAGAACCGGTgaactgtctgctacc	  (AgeI) 
Note: Restriction sites are shown in upper case italics, preceded by six bases to promote 
cleavage efficiency. 
 
2.3.7 Cloning using the In-Fusion HD Cloning Kit (Clontech Laboratories, 
Inc) 
Primers were designed according to the manufacturer's recommendations. 
The 15 nucleotides at the 5’ end of the primer were homologous to the DNA 
fragment to which it would be joined. The 3’ end of the primer contained 15 
nucleotides homologous to the target sequence to be amplified. The primers were 
used to amplify the desired fragment, which was then purified as described in 
section 2.3.6.4. The vector was linearised either by restriction digestion or by 
inverse PCR and purified. The recombinase based reaction was carried out 
according to the manufacturer's instructions, and a fraction of the reaction was 
used to transform TOP10 bacteria. 
 
Plasmid Primers (5’ to 3’) 
pEF-MRTF-A Δ92 Template: pEF-MRTF-A 
Forward Primer:  
gccatggccGGATCCccgcctttgaaaagccccgctgca (BamHI) 
Reverse Primer:	  
gggtgaattTCTAGActacaagcaggaatcccagtggag (XbaI)	  
	  
pEF-MRTF-A vector was digested with BamHI and XhoI 
pEF-MRTF-A Δ92 
STS544/545/549AAA 
Template: pEF-MRTF-A STS544/545/549AAA 
Forward Primer:  
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gccatggccGGATCCccgcctttgaaaagccccgctgca (BamHI) 
Reverse Primer:	  
gggtgaattTCTAGActacaagcaggaatcccagtggag (XbaI)	  
	  
pEF-MRTF-A vector was digested with BamHI and XhoI	  
pEF-Phactr1(MRTF) Template: pEF-MRTF-A 
Insert Forward Primer: 
ttgtacaccagctcacttagtgagcggaagaatgtgctg 
Insert Reverse Primer:	  
gtcttgggcatctgctgggtaatttacctggcccacaat 
	  
Inverse PCR to linearise pEF-Phactr1 plasmid and delete Phactr1 
RPEL: 
Forward Primer: gcagatgcccaagactatg 
Reverse Primer: tgagctggtgtacaaagag 
pEF-Phactr1(MRTF) xxx Template: pEF-MRTF-A xxx 
Insert Forward Primer: 
ttgtacaccagctcacttagtgagcggaagaatgtgctg 
Insert Reverse Primer:	  
gtcttgggcatctgctgggtaatttacctggcccacaat 
	  
Inverse PCR to linearise pEF-Phactr1 plasmid and delete Phactr1 
RPEL domain: 
Forward Primer: gcagatgcccaagactatg 
Reverse Primer: tgagctggtgtacaaagag	  
pEF-Phactr1(MRTF NT 
RPEL)  
Template: pEF-MRTF-A 
Insert Forward Primer:  
ttgtacaccagctcacccccttccgtcattgctgtgaa 
Insert Reverse Primer:	  
gtcttgggcatctgctgggtaatttacctggcccacaat 
	  
Inverse PCR to linearise pEF-Phactr1 plasmid and delete Phactr1 
RPEL domain: 
Forward Primer: gcagatgcccaagactatg 
Reverse Primer: tgagctggtgtacaaagag	  
pEF-Phactr1(MRTF NT 
RPEL) xxx 
Template: pEF-MRTF-A xxx 
Insert Forward Primer:  
ttgtacaccagctcacccccttccgtcattgctgtgaa 
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Insert Reverse Primer:	  
gtcttgggcatctgctgggtaatttacctggcccacaat 
	  
Inverse PCR to linearise pEF-Phactr1 plasmid and delete Phactr1 
RPEL domain: 
Forward Primer: gcagatgcccaagactatg 
Reverse Primer: tgagctggtgtacaaagag 
pET-41a-3CΔ 2-67 Template: pEF-MRTF-A 
Forward Primer: 
caggggcccGGATCCcccccttccgtcattgctgtgaat 
Reverse Primer: 
gtggtggtgCTCGAGTTAaagtggaggtaaattggggttcct 
 
pET-41a-3CΔ digested with BamHI and XhoI 
pET-41a-3CΔ 2-67 
LSL46/47/48AAA 
Template: pEF-MRTF-A LSL46/47/48AAA 
Forward Primer: 
caggggcccGGATCCcccccttccgtcattgctgtgaat 
Reverse Primer: 
gtggtggtgCTCGAGTTAaagtggaggtaaattggggttcct 
 
pET-41a-3CΔ digested with BamHI and XhoI 
pET-41a-3CΔ 2-115 Template: pEF-MRTF-A  
Forward Primer: 
caggggcccGGATCCcccccttccgtcattgctgtgaat 
Reverse Primer: 
gtggtggtgCTCGAGttactcggtcctggcccgctccaggct 
 
pET-41a-3CΔ digested with BamHI and XhoI 
pET-41a-3CΔ 2-115 
LSL46/47/48AAA 
Template: pEF-MRTF-A LSL46/47/48AAA 
Forward Primer: 
caggggcccGGATCCcccccttccgtcattgctgtgaat 
Reverse Primer: 
gtggtggtgCTCGAGttactcggtcctggcccgctccaggct 
 
pET-41a-3CΔ digested with BamHI and XhoI 
Note: Restriction sites are shown in upper case italics. 
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2.3.8 Sequencing 
All plasmids generated were confirmed by sequencing which was carried 
out by CRUK Equipment Park sequencing services. 
 
2.4 Oligonucleotides 
Primers were synthesised by Sigma-Aldrich. Lyophilised oligonucleotides 
were dissolved in TE buffer at 100µM for long-term storage and in water at 10µM 
for short storage (both stored at -20°C). 
siRNA was purchased from Thermo Scientific Dharmacon. Lyophilised 
siRNAs were dissolved in 1x siRNA buffer (Thermo Scientific Dharmacon) to a final 
concentration of 20µM, aliquoted and stored at -20°C. All oligos, except for the non-
targeting control and MRTF-A/B, were a pool of 4 siRNAs targeting different 
locations of the same target. 
 
 
siRNA 
siRNA name siRNA sequence 
Non-targeting control UUCUCCGAACGUGUCACGU 
MRTF-A/B UGGAGCUGGUGGAGAAGAA 
CDC2L5 
 
GAAGAAAGUCGCCCAUAUA 
UAACUAUGGUGGUAACUUA 
GCACGUAGUUUCAUUGGAA 
CUAACAAGGUCAUUACUUU 
CLK2 
 
GAUAACAAGUUGACACAUA 
GGAAGCAGCCCGACUAGAA 
GAACACGAGUUGCCCUGAA 
CAAGAGCGAUAUGAAAUUG 
CDK7 GGACAUAAGUCUAACAUUA 
GUACCGGGCUCCUGAGUUA 
UGUGUAGUCUUCCCGAUUA 
CAAGGAAUAUUGCCCAAGA 
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CDK8 GAUCCCAUAUCCCAAACGA 
CAUCAUGACCUCCGACUAU 
GACCCAAUAAAGCGAAUUA 
UAACAGAAGAAGAGCCUGA 
CDK9 GGCCAAACGUAGACAAGUA 
CUACUCACUUGACGUCUAU 
AGACGGAAUUUGAACGUGU 
GCAGAGAUGUGGACUCGUA 
CSNK1A1 
 
GAAUUUGCCAUGUACUUAA 
GUAUUGGGCGUCACUGUAA 
GCUCCAAGGCCGAAUUUAU 
CUAUGAAGACCGUACUUAU 
DYRK1A GAAAUCGACUCCUUAAUAG 
GAAAUGAAGUACUACAUAG 
GAACCUAACACGAAAGUUU 
GGAUGUAUCUUGGUUGAAA 
DYRK1B CUGAUGAACCAGCAUGAUA 
CAACAGAGCCUACCGAUAC 
GACCAGAUGAGCCGUAUUG 
GGACAAAGGAACUCAGGAA 
DYRK2 GGGACCAGCUGGCUUGUAU 
GGUCGAAGCAGUAUUAAAG 
GGACAAGGACAACACUAUG 
GUACAUCCAGUCACGCUUU 
DYRK3 CAGGGAAGCGGGUAGUUAA 
UAGCAAGUCUACACCCAAA 
GGGAUAGCCAGUAAGCUUA 
UCCAGAAGGCUAAAUAUUA 
DYRK4 CCAAGUCACUGUUAAAGUU 
CCUCAAGCAUGCCUGGAUU 
AGUCGGAGGUUGAGAGUAA 
GAAUCAACCUGUAUGAGUU 
HIPK1  UAACAGAGAUCCUAAUUUG 
UGACAUGGCUCAGGUAAAU 
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GCAACCAGCUCAACACAGU 
GCUAUGAAGUCCUGGAGUU 
HIPK2 GGACAAAGACAACUAGGUU 
UCAUUGACCUGUUAAAGAA 
GAAGCAAGAAAGUACAUUU 
GCACGGAGAGCGCUGAUGA 
HIPK3  GGAAGGAGGUGAUCUCUUG 
GAACAGGAGUAAUUCAUUG 
GGAAGGCGACUAUCAGUUA 
GAAAGAGGUUGAGGAAGUA 
MKNK2 GGAAUAUGCUGUCAAGAUC 
GAACAGCUGUGCCAAAGAC 
CAUAGAAGGCGCCACUUUA 
GUUCGAAGAUGUCUAUCAG 
NDR2 CAUGAAAGCUGGGAAGUUA 
ACAGAAACCUCACACAUAA 
GAAGGAGACUCUGGCAUUU 
GGACUUGAUUCUCAGAUUU 
OSR1 CAAGAUCCCUAUCAGUCUA 
GAAGGGAUUUAGUAAUAGU 
AAACCGAUCUGUCACUUUC 
AUCCUAACAUUGUGUCUUA 
PHKG2 
 
GAAGGCCAAUAUCAGUUUA 
CAGAUACGCCUUUCAGAUU 
GUUCAAACACCGUCAAAGA 
GUGCGGGACUCCAGGGUAU 
PIM3 
 
CACAGGACCUCUUCGACUU 
CAGAGUGGAUCCGAUAUCA 
CCAGAGUGCCAGCAGCUUA 
GAACUGUGACCUUCGGCUU 
SNARK GCAGCAAGAUUGUGAUUGU 
GCGUGAAUCUGGUUACUAC 
GCACAUACGGAGGGAGAUU 
CCGAAAGGCAUUCUCAAGA 
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TAK1 GGACAUUGCUUCUACAAAU 
AAACACACAUGACCAAUAA 
GAUGGCGCCUGAAGUAUUU 
AAAUACAUCUCGUCUGGUA 
TLK1 GAAAUCAAACCUCCUAUUA 
GCAAGAAACUACUUAUUGA 
GAAAGAAGCUCGGUCUAUU 
GAAAUUGGCAGCAUUAGAA 
TLK2 GAGGAAAUCUUCAAACUUA 
GAAGCCCGAUCCAUUAUUA 
CCAAAGAUCUCAAAUAAAG 
UAGUGAAGCUGUAUGAUUA 
ULK1 CCACUCAGGUGCACAAUUA 
UCACAAAGCCCUGCUAUUG 
GCAUGGACUUUGAUGAAUU 
UUACGGACCUGCUGCUUAA 
ULK3 UGACCUGUCUCGCUUCAUU 
CAAGAAGGAUACUCGGGAA 
GCACGUACGCCACGGUGUA 
YSK4 UAACAACUCUUGCCAAAUA 
GCCGAUGUGUCGUUAAUAA 
CAACGGACCAGGCAUCUAU 
GAUCCUAAGCUUUGUGAUU 
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2.5 Peptides 
Peptides used in this study were synthesised and purified by the Peptide 
synthesis laboratory (CRUK). Phospho-acceptor sites are shown in bold. 
 
Peptide name Peptide sequence 
KEMPtide LRRASLG 
DYRKtide RRRFRPASPLRGPPK 
Peptide S33 RRLSLSAAPSPQSEAVA 
Peptide S216 RREDSSDALSPEQPASH 
Peptide S231 RRESQGSVPSPLESRVS 
Peptide S248 RRLPSATSISPTQVLSQ 
Peptide T402 RRTPGSSAPTPSRSLST 
Peptide S412 RRRSLSTSSSPSSGTPG 
Peptide S414 RRLSTSSSPSSGTPGPS 
Peptide S549 RRTGSTPPVSPTPSERS 
Peptide T566 RRSTGDENSTPGDAFGE 
Peptide S587 RRTQLTLQASPLQIVKE 
Peptide S605 RRRAASCCLSPGARAEL 
Peptide S785 RRQPLSQPGSPAPGPPA 
Peptide S883 RRPPLTPQPSPLSELPQ 
Peptide S949 RRAILDHPPSPMDTSEL 
RPEL1 (67-98) 
5-FAM labelled 
LSERKNVLQLKLQQRRTREELVSQGIMPPLKS 
RPEL1 (62-104)  
5-FAM labelled 
PNLPPLSERKNVLQLKLQQRRTREELVSQGIMPPLKSPAAFHE 
S33 SAAPSPQSEC 
pS33 SAAP(pS)PQSEC 
S1-R2 PPLKSPAAFHEQRRSLERARTEDYLKRKIRSRPERAELVRMHILEETSA 
S1-R2 pS98 PPLK(pS)PAAFHEQRRSLERARTEDYLKRKIRSRPERAELVRMHILEETSA 
 
 
2.6 Mammalian cell culture 
Cell lines used in this thesis were the mouse embryonic fibroblasts NIH-3T3 
(Treisman Laboratory, Cancer Research UK), NIH-TR3 that express Flag-MRTF-A 
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upon tetracycline treatment (generated by Dr F. Miralles), 3T3.3DA.18 stably 
transfected with the 3DA MRTF-A activity reporter and the TK-luciferase plasmid 
(generated by Dr R. Pawlowski), and the human cervical adenocarcinoma cell line 
HeLa. 
 All the cell lines were cultured in DMEM supplemented with 10% FCS and 
1% Penicillin/Streptomycin (CRUK media production) and incubated at 37°C and 
10% CO2. To detach cells from dishes, two PBS washes were followed by 
incubation in trypsin/versene (CRUK media production) for approximately 5 
minutes. Trypsin was inactivated by addition of 10% FCS DMEM and cells were 
seeded into new dishes. 
 
2.7 siRNA transfection 
siRNA was transfected using Lipofectamine RNAiMax transfection reagent 
(Life technologies) according to the manufacturer's instructions. siRNA 
transfections were carried out in a 24-well-plate format as follows: 
 
1. Preparation of DNA and LipofectamineRNAiMax solutions (per well) 
DNA mix: 50µL Opti-mem + siRNA (for final concentration of 25nM) 
Lipofectamine mix: 50µL Opti-mem + 0.6µL Lipofectamine RNAiMax 
2. Incubation of transfection mixture 
The DNA mixture and Lipofectamine mixture were combined, vortexed and 
incubated at room temperature for 20 minutes. The combined 
DNA/Lipofectamine mixture (100µL) was transferred to a well of a 24-well-plate. 
3. Transfection 
Cells were detached as described in section 2.6, counted and diluted to 35 000 
cells per 400µL of 10% FCS DMEM. 400µL of the cell suspension were added to 
a well containing the transfection mixture, to give a final volume of 500µL. Cells 
were then incubated overnight.  
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2.8 Luciferase reporter assays 
For luciferase assays cells were seeded in 24-well-plates. Cells were 
typically transfected with siRNA the previous day, as described in the previous 
section. The following day cells were transfected with the MRTF-A reporter plasmid, 
TK-Renilla plasmid and other plasmids according to the experiments, using 
Lipofectamine 2000 reagent. Transfection was carried out as follows: 
 
 
1. Preparation of DNA and Lipofectamine2000 solutions (per well) 
DNA mix: 50µL Opti-mem + 200ng DNA (8ng p3D.A-luc, 20ng ptkRL, 40ng SRF-
VP16, different amounts of other plasmids according to experiment, up to 200ng 
with “empty” vector) (Typically a titration of 0.5 to 40ng per well was used; 5ng of 
plasmid lead to expression of MRTF-A at endogenous levels, as assessed by 
western blot). 
 
Lipofectamine mix: 50µL Opti-mem + 0.6µL Lipofectamine 2000 
2. Incubation of transfection mixture 
The DNA mixture and Lipofectamine mixture were combined, vortexed and 
incubated at room temperature for 20 minutes.  
3. Transfection 
Cells were washed twice in PBS and 100µL of Opti-mem was added. The 
combined DNA/Lipofectamine mixture was then added to the cells, for a final 
volume of 200µL. Cells were incubated at culture conditions for 2 hours. The 
transfection mixture was then replaced by 0.3% FCS DMEM and cells were 
starved overnight. 
 
The following day cells were treated and stimulated for 6 hours. Cells were 
lysed in 100µL 1x passive lysis buffer (Promega) and placed on a shaker for 10 
minutes. 20µL of lysate were transferred to a flat-bottom 96-well plate (Matrix 
Technology). 50µL of luciferase assay reagent II (Promega) were added to the 
lysate and luminescence was measured using an EnVision Multilabel Reader 
(Perkin Elmer). Next, 50µL of Stop&Glo reagent was added, which quenches firefly 
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luciferase activity and elicits renilla luciferase activity. Luminescence generated by 
Renilla luciferase activity was measured as before.  
 Firefly luciferase values were normalised using renilla luciferase values. 
Where stated, normalised values were expressed as a percentage of activity of 
SRF-VP16. 
 
Mammalian reporter plasmids 
p3D.A-luc A 3D.ACAT SRF reporter derivative (Mohun et al., 1987), in 
which the CAT sequence was replaced by that of firefly 
luciferase. The promoter is composed of 3 copies of the Fos 
serum response element (SRE) with a Xenopus type 5 actin 
TATA box and transcription start site (Geneste et al., 2002). The 
SRE was modified, making the reporter unresponsive to TCF 
signalling. Firefly luciferase expression is therefore dependent 
on MRTF-A/SRF (Hill et al., 1995). 
ptkRL Renilla luciferase preceded by the thymidine kinase promoter 
(Geneste et al., 2002). The plasmid was used as an internal 
reference to control for transfection efficiency and non-specific 
activation of the p3D.A-luc reporter. 
 
  
2.9 Quantitative real-time PCR 
 
Cells were seeded at 30 000 cells per well in 24-well-plates unless they were 
transfected with siRNA the previous day (see section 2.7). After appropriate 
treatments, RNA was isolated using the GenElute Mammalian total RNA miniprep 
kit (Sigma-Aldrich) according to the manufacturer's protocol (250µL lysis buffer; 
40µL elution buffer). Isolated RNA was treated with DNAseI to remove 
contaminating DNA. 0.5µg of RNA was reverse transcribed using the Superscript III 
First Strand synthesis system (Life Technologies). The reactions were set up as 
follows: 
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DNAseI treatment 
1µg RNA 
1µL DNAseI (2 units) 
1µL 10x DNAseI buffer 
Top up to 7µL with water 
10 min incubation at room temperature  
1µL EDTA (25mM) and incubation at 65°C for 10 min to inactivate DNAseI 
 
Priming reaction 
0.5µg RNA 
1µL random hexamers 
1µL dNTPs (10mM) 
Top up to 10µL with water 
5 min incubation at 65°C followed by 5 min incubation on ice 
1µL of EDTA (25mM) and incubation at 65°C for 10 min to inactivate DNAseI 
 
cDNA synthesis 
10µL Priming reaction 
2µL 10x RT buffer 
4µL MgCl2 (25mM) 
2µL DTT (0.1M) 
1µL RNaseOUT (40U/µL) 
1µL Superscript III reverse transcriptase 
Incubation: 25°C 10 min, 50°C 50 min, 85°C 5 min, 4°C hold. 
1µL RNase H, incubation at 37°C for 20 min. 
cDNA was next used for qRT-PCR as follows: 
qRT-PCR 
Reaction set-up 
1µL cDNA 
1µL forward primer (10mM) 
1µL reverse primer (10mM) 
10µL SYBR Green reaction mix (Life Technologies) 
7µL water 
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Thermal cycling 
95°C 10 min  
40 cycles 95°C 10 sec 
60°C 30 sec 
 
qRT-PCR primers 
Target Primer sequence (5’ to 3’) Notes 
Itgb1 FW: GAGTGGAAGCCCTGAAGACATT 
RV: TTGCCTTTTCCTTATGACTGACAA 
 
Intronic 
Myh9 FW: CATTTCCACATCGTGCTTCCTA 
RV: AGGGTTTTGGCACGTGTGA 
 
Intronic 
Vcl FW: GATCCTGGTGTCTGTCGCTTCT 
RV: TGAGCAAAATGCCCCGAA 
 
Intronic 
Srf FW: GTCAGGAATGGAGGATGGACAT 
RV: CCTTTCTCGGACTAGCACAGGTA 
 
Intronic 
Dyrk1a FW: GCTTGCACCGTCGTTCTCAT 
RV: GCATCTGTGCAGCCATCTGA 
 
Exonic 
Dyrk1b FW: GTGTTTGAGCTGCTGTCCTACAA 
RV: GACACCCCGAAAGTGTGTGTT 
 
Exonic 
Dyrk2 FW: CACTGCCATGCACGTTCCT 
RV: GGCCGAAGGTTTCCTGGTTA 
 
Exonic 
Dyrk3 FW: GCCCGGGTCTATGATCACAA 
RV: TCATTGCGCACCATTTTCA 
 
Exonic 
Dyrk4 FW: CCGATCCCCAGAGGTGATT 
RV: CCCAGGCTCCACATGTCAAT 
 
Exonic 
Egr1 FW: GACCCAAACGTCCAGTCCTTTC 
RV: CAAGACCCTGGAGCTGTGTGAA 
 
Intronic 
Mkl1 (MRTF-A) FW: TCCGTCATTGCTGTGAATGG 
RV: TGGCTCGTCGTCATTTTCG 
 
Exonic 
Mkl2 (MRTF-B) FW: CCAAGAATCCAAACGACAAACA 
RV: CTCGCGGTTTCGGATCTTT 
 
Exonic 
Gapdh FW: TCTTGTGCAGTGCCAGCCT 
RV: CCATATGGCCAAATCCGTTCA 
 
Exonic 
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Target abundance was quantitated using absolute quantification and a 
standard curve ranging from 0.1pg/µL to 10ng/µL. 
 
2.10  Immunofluorescence microscopy 
 150 000 cells per well were seeded into 6-well-plates containing coverslips 
and transfected as follows: 
 
1. Preparation of DNA and Lipofectamine2000 solutions (per well) 
DNA mix: 100µL Opti-mem + 1µg DNA (50ng of pEF-MRTF-A derivatives, 20ng 
of pEF-PK derivatives,100ng for pEF-chimera derivatives, 200ng of pRev 
derivatives, topped up to 1µg with “empty” vector) 
 
Lipofectamine mix: 100µL Opti-mem + 3µL Lipofectamine 2000 
2. Incubation of transfection mixture 
The DNA mixture and Lipofectamine mixture were combined, vortexed and 
incubated at room temperature for 20 minutes.  
3. Transfection 
Cells were washed twice in PBS and 1mL of Opti-mem was added. The 
combined DNA/Lipofectamine mixture was then added to the cells, for a final 
volume of 1.2mL. Cells were incubated at culture conditions for 2 hours. The 
transfection mixture was then replaced by DMEM 0.3% FCS and cells were 
starved overnight. 
 
The next day cells were treated accordingly and fixed with 4% 
parafolmaldehyde (PFA) for 10 min at room temperature. After a PBS wash cells 
were permeabilised with 0.2% Triton-X in PBS for 10 min and blocked in blocking 
solution (10% FCS, 1% fish skin gelatin, 0.05% Triton-X in PBS) for 1 hour. 
Coverslips were then placed cell-side down on 50µL drops of blocking solution 
containing primary antibody and incubated for 1 hour. Coverslips were washed in 
PBS and transferred to 50µL drops of blocking solution containing secondary 
antibodies, as well as phalloidin and DAPI. After an hour incubation coverslips were 
washed twice in PBS, once in water and mounted on microscopy slides using 5µL 
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Mowiol. Imaging was carried out using a Zeiss Axiovert microscope. Cells were 
scored as predominantly nuclear, pancellular or predominantly cytoplasmic; 200 
cells were counted per condition. 
 
Antibodies used in immunofluorescence microscopy 
Antibody Species Dilution 
Flag (F7425, Sigma-Aldrich) rabbit 1:1000 
AlexaFluor 488 IgG (H+L)  
(Molecular probes) 
Donkey anti-rabbit 1:250 
 
Other staining reagents 
DAPI 300nM Stains DNA. 
Used to mark 
nucleus 
Phalloidin Texas-Red-X  
(Molecular Probes) 
1:200 Stains F-actin. 
Used to mark 
cytoplasm 
 
2.10.1  Rev NES detection assay 
80 000 cells per well were seeded in 6-well plates containing coverslips. 
Transfection was carried out as described in the section above, however at the end 
of the transfection 10% FCS DMEM was used to replace the transfection reaction. 
Cells were starved the next day as opposed to immediately after transfection. 
After treatment and stimulation, cells were fixed with 4% PFA for 10 minutes, 
washed twice in PBS and incubated for 10 minutes in 300nM DAPI in PBS. After 
two PBS washes and one wash in water coverslips were mounted on microscope 
slides using 5µL Mowiol. Imaging and scoring was carried out as described above. 
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2.11  Protein Expression and Purification 
 
 
2.11.1 Expression and purification of recombinant MRTF-A fragments 
E. Coli Rosetta (DE3) pLysS (Novagen) (Genotype: F- ompT hsdSB(rB- mB-) 
gal dcm (DE3) pLysSRARE (CamR)) were transformed with the expression 
plasmid and plated on agar supplemented with the appropriate antibiotics. A single 
colony was then used to inoculate 100mL of LB media containing the appropriate 
antibiotics. The culture was incubated on a shaker at 37°C, 180rpm overnight. Next 
day, 5mL were used to inoculate 1L of LB media containing antibiotics. The culture 
was incubated as before, until it reached an OD600 of 0.6, at which time expression 
was induced by adding 0.5mM IPTG. Induced cultures were incubated at 30°C for 
5h or at 20°C for 18h. Bacteria were pelleted by centrifugation at 4000 xg for 15 
minutes. Pellets were either frozen on dry ice for storage at -80°C or processed 
immediately. 
 
 
GST fusion protein purification 
Bacterial lysis buffer 50mM Tris-HCl pH 7.5 
300mM NaCl 
1% TX-100 
5mM DTT 
10mM EDTA pH 8 
1mM PMSF 
15µg/mL Benzamidine 
Wash buffer 1  50mM Tris-HCl pH 7.5 
300mM NaCl 
1mM DTT 
Wash buffer 2  50mM Tris-HCl pH 7.5 
500mM NaCl 
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1mM DTT 
Wash buffer 3  50mM Tris-HCl pH 7.5 
50mM KCl 
20mM MgCl2 
5mM ATP 
1mM DTT 
Equilibration buffer 50mM Tris-HCl pH 7.5 
100mM NaCl 
1mM DTT 
 
Pellets were resuspended in lysis buffer (100mL/10g of pellet) and 
homogenised using a Dounce homogeniser on ice, before being passed through a 
French press until clear. Lysates were pelleted by centrifugation at 100 000 xg for 
30 min, 4°C. Supernatants were then transferred to a new vessel containing 1.5mL 
of Glutathione Sepharose 4B (GE Healthcare) per 10g of pellet, and incubated for 2 
hours at 4°C with gentle agitation. 
 The resin was then transferred to a column and washed with 150mL wash 
buffer 1, 300mL wash buffer 2, 150mL wash buffer 3 and equilibrated in 
equilibration buffer. The GST moiety was cleaved off by overnight incubation with 
100µg GST-3C protease per mL of resin (purified by S. Guettler). The cleaved 
protein was eluted with 1mL per mL of resin, quantified and stored at -80°C. 
 
2.11.2  Purification of Crm1 
E. Coli BLR bacteria were transformed with the pH10zz-[TEV]-MmCrm1 
plasmid (a gift from Thomas Guttler, Dirk Gorlich lab, Max Planck Institute for 
Biophysical Chemistry, Germany). A single colony was used to inoculate a pre-
culture and was incubated overnight in the presence of 100µg/mL ampicillin. The 
following day, 5mL of pre-culture were used to inoculate 1L 2YT medium (2% w/v 
glycerol, 30mM K2PO4) supplemented with 100µg/mL ampicillin. The culture was 
incubated at 37°C until it reached OD600= 0.5, then cooled to 18°C and induced 
with 150µM IPTG for 20 hours. 
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Bacteria were pelleted by centrifugation at 4000 xg for 15 minutes and pellet 
were either frozen on dry ice for storage at -80°C or processed immediately. Pellets 
were resuspended in lysis buffer (100mL/10g of pellet) and homogenised using a 
Dounce homogeniser on ice, before being passed through a French press until 
clear. Lysates were pelleted by centrifugation at 100 000 xg for 30 min, 4°C. 
Supernatants were then transferred to a new vessel containing 3mL of 
Complete His-Tag purification Resin (Roche) per 10g of pellet, and incubated for 2 
hours at 4°C with gentle agitation. The resin was then transferred to a column and 
washed with 200mL wash buffer. Elution was carried out by incubating in 5mL 
elution buffer for 5 minutes. This was repeated 3-4 times, and eluates were pooled 
for a final volume of approximately 20mL. The eluate was concentrated to 5mL 
using a Vivaspin 20 concentrator (50kDa MWCO, Sartorius). 
Using a HiPrep 26/10 Desalting column (GE Healthcare) mounted on an 
AKTA FPLC system, buffer was exchanged for desalting buffer. After concentrating 
to 5mL again, 100 units of Ac-TEV protease (His tagged, Life Technologies) were 
added to cleave off the His10-zz tag, and incubated overnight at 4°C on rollers. The 
eluate was collected and gel filtered in SEC buffer using a Superdex 200 16/60 
column (GE Healthcare).  Appropriate fractions (between 65-80mL elution volume) 
were pooled and concentrated to 10mg/mL. Purified Crm1 was aliquoted and 
stored at -80°C. 
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Crm1 purification buffers 
Lysis buffer 50mM Tris-HCl pH 7.5 
500mM NaCl 
1mM EDTA  
2mM Imidazole  
1mM PMSF  
5mM DTT 
Wash buffer 50mM Tris-HCl pH 7.5 
500mM NaCl 
1mM EDTA 
2mM Imidazole  
1mM PMSF  
5mM DTT 
100mM KCl 
10mM Mg(OAc)2 
2mM ATP 
Elution buffer 50mM Tris-HCl pH 7.5 
500mM NaCl 
1mM EDTA  
300mM Imidazole  
1mM PMSF  
5mM DTT 
Desalting buffer 50mM Tris-HCl pH 7.5 
200mM NaCl 
1mM EDTA 
1mM DTT 
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2.11.3 Purification of Ran Q69L 
E. Coli BLR bacteria were transformed with the pH10zz-[TEV]-HsRan(1-
180) Q69L plasmid (a gift from Thomas Guttler, Dirk Gorlich lab). The expression 
and lysis procedure was identical to that of Crm1 (see above). 
 The clarified bacterial lysate was incubated with 3mL of Complete His-Tag 
purification Resin (Roche) per 10g of pellet, and incubated for 2 hours at 4°C with 
gentle agitation. The resin was then transferred to a column and washed with 
200mL lysis buffer. Elution was carried out by incubating in 5mL elution buffer for 5 
minutes. This was repeated 3-4 times, and eluates were pooled for a final volume 
of approximately 20mL. The eluate was concentrated to 2mL using a Vivaspin 6 
concentrator (30kDa MWCO, Sartorius) and dialysed against 1L dialysis buffer 
overnight, in the presence of 100 units Ac-TEV. The next day the solution was 
incubated with 3mL of fresh Complete His-Tag purification Resin, which was 
previously equilibrated in dialysis buffer, for 1 hour. The eluate was concentrated to 
3.5mL and subjected to gel filtration in dialysis buffer, on a Superdex 75 16/60 
column (GE Healthcare). Appropriate fractions were pooled and concentrated to 
1.8 mg/mL (90µM). 
 Ran concentration was measured using an extinction coefficient ε280=34 820 
M-1cm-1 to correct for the presence of GTP, whose absorption spectrum overlaps 
with that of proteins. 
 
 
 
RanQ69L purification buffers 
Lysis buffer 50mM K-Phosphate pH 7 
500mM NaCl 
5mM Mg(OAc)2 
1mM EDTA pH 8 
2mM Imidazole  
1mM PMSF  
5mM DTT 
30µM GTP 
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Elution buffer 50mM K-Phosphate pH 7 
500mM NaCl 
1mM EDTA pH 8 
300mM Immidazole  
1mM PMSF  
5mM DTT 
30µM GTP 
Dialysis buffer 50mM K-Phosphate pH 7 
200mM NaCl 
1mM EDTA 
1mM DTT 
20µM GTP 
 
 
2.11.4 Purification of rabbit skeletal muscle actin 
Actin was purified from rabbit skeletal muscle as previously described 
(Spudich and Watt, 1971). The following procedure was carried out at 4°C unless 
stated otherwise. Approximately 500g of rabbit leg tissue was minced until 
homogenous and mixed vigorously in 4L of the following solutions. Between 
washing steps muscle tissue was drained using gauze.  
 
10mM KCl 10 min 
50mM NaHCO3 10 min 
1mM EDTA 10 min 
The following steps are per 250g of initial rabbit muscle 
Deionised water 5 min 
Deionised water 5 min, then bring to room temperature 
Cold acetone As briefly as possible 
500mL Acetone 10 min room temperature 
500mL Acetone 10 min room temperature 
500mL Acetone 10 min room temperature 
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After a final draining through gauze the homogenate was spread over 3MM 
Whatman paper in a fume hood to dry overnight. The following day the acetone 
powder was stored as 10g aliquots at -80°C, and used for actin extraction and 
purification. 
The following quantities are for 10-12g of acetone powder. Acetone powder 
was rehydrated to 200mL with ice cold Ca2+ G-buffer supplemented with 0.15mM 
PMSF for 1h at 4°C, while stirring. The homogenate was drained and this step was 
repeated three times. The filtrates were pooled and centrifuged for 90 min at 27 
000 xg, 4°C.The clarified filtrate was transferred to a beaker and actin 
polymerisation was induced by adjusting final concentrations to 1mM ATP, 2mM 
MgCl2, 50mM KCl. Actin was polymerised under gentle stirring for 2 hours. 4.1g of 
solid KCl/100mL were then added directly to bring KCl to 600mM under fast stirring. 
Polymerised actin was next pelleted at 100 000 xg for 90 min and resuspended in 
30mL Ca2+ G-buffer supplemented with 0.5mM ATPand 1mM DTT, using a Dounce 
homogeniser on ice. Homogenisation was carried out carefully to avoid introduction 
of air. Actin was dialysed for 2 days in 4L of Ca2+ G-buffer with twice daily changes 
of buffer. ATP concentration of the dialysis buffer was gradually decreased from 
0.5mM to a final 0.2mM ATP. After dialysis, insoluble material was pelleted by 
centrifugation at 100 000 xg for 30 min, 4°C. 
A second round of polymerisation and dialysis was repeated to increase 
actin purity. After the final dialysis step, actin at 100µM (4.2 mg/mL) was aliquoted 
and stored at -80°C. For Latrunculin B-bound actin, which is rendered unable to 
polymerise, a 5-fold molar excess of Lat-B (50mM stock in DMSO, Calbiochem) 
was slowly added under continuous stirring. After overnight incubation, actin 
polymerisation was induced using 20x polymerisation buffer as before. Insoluble 
material was pelleted at 200 000 xg for 15 min, 4°C and the supernatant was 
dialysed in Mg2+ G-buffer. Lat-B G-actin was aliquoted and stored at -80°C. 
Actin concentration was measured at 290nM using a molar extinction 
coefficient of ε290=26 600 M-1cm-1, because measurement at A280 is affected by ATP 
present in the buffer. 
 
 
 
Chapter 2 Materials and Methods 
 
 119 
Actin extraction and purification buffers 
Ca2+ G-buffer 5mM Tris-HCl pH 8.0 
0.2mM CaCl2 
0.2mM ATP 
0.5mM DTT 
20x Polymerisation buffer 2M NaCl 
60mM MgCl2 
10mM ATP 
Mg2+ G-buffer 2mM Tris-HCl pH 8 
0.3 mM MgCl2 
0.2mM EGTA 
0.2mM ATP 
0.5mM DTT 
 
 
 
2.12  Protein analysis 
 
2.12.1 GST affinity pull-down assays 
The GST-MRTF-A fragments used as bait in the Crm1 and ERK pull-down 
assays were prepared as described in section 2.11.1, but were not cleaved off the 
resin. The resin was washed in pull-down buffer. The conditions for the reactions 
are shown below: 
 
 
Pull down buffer 
50mM Tris-HCl pH 7.5 
100mM NaCl 
10mM MgCl2 
0.05% NP-40 
Chapter 2 Materials and Methods 
 
 120 
Pull-down reactions 
Crm1 ERK2 
25µL resin 12.5µL resin 
2µL Crm1 (10 mg/mL) 3µL ERK2 (5.5mg/mL) 
2µL RanQ69L (1.8 mg/mL) - 
Final volume 200µL Final volume 200µL 
 
Reactions were incubated for 3 hours at 4°C on a shaker. The resin was 
then washed with 1mL pull-down buffer 5 times. The proteins were eluted with 
SDS-loading buffer, resolved by SDS-PAGE and analysed either by coomassie 
staining or Western blotting. 
 
2.12.2 RhoGTP pull-down assay 
RhoGTP pull-downs were performed using the Rho activation assay kit 
(Merck Millipore) with a modified protocol. Cells were grown in 15cm dishes and 
stimulated according to the experiment. After treatment cells were washed twice in 
ice-cold TBS placed slanted on ice. TBS was completely removed and cells were 
scraped in 400µL 2x lysis buffer (supplemented with 16% glycerol). Samples were 
snap-frozen as they were collected. 
 Samples were next thawed on ice, made up to 800µL using ice-cold water 
and insoluble material was pelleted at maximum speed on a refrigerated bench top 
centrifuge. 20µL of the supernatant were retained and mixed with SDS loading 
buffer; the rest was incubated with 20µL GST-Rhotekin resin for 45 min at 4°C. The 
resin was next washed 3 times with 1mL 1x Lysis buffer (supplied with the kit) and 
proteins were eluted by addition of SDS loading buffer. Active Rho levels were 
assessed by Western blotting using RhoA antibody (Cell Signalling, 67B9, 1:1000). 
 
2.12.3 SDS-PAGE 
Proteins were resolved according to their size by sodium dodecyl sulfate 
polyacrylamide electrophoresis (SDS-PAGE) on 4-12% gradient gels (Life 
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Technologies). Usually SDS-PAGE was carried out in MOPS buffer, unless better 
resolution was desired for the smaller molecular weights, in which case MES buffer 
was used. For assessment of changes in MRTF-A electrophoretic mobility 7% tris-
acetate gels (Life Technologies) were run with tris-acetate running buffer. 
Electrophoresis was performed at 150V. 
2.12.4  Protein detection 
2.12.4.1  Coomassie Staining 
Following SDS-PAGE gels were incubated in Coomassie staining solution 
for 30-60 minutes on a shaker. Gels were then destained after multiple washes with 
destaining solution. For rapid staining/destaining, incubations were preceded by 
microwaving for 1 min. 
 
Staining solution 0.1% Coomassie brilliant blue 
50% methanol 
10% acetic acid 
40% water 
Destaining solution 10% Methanol 
10% acetic acid 
80% water 
 
2.12.4.2  Western blotting 
After SDS-PAGE, proteins were transferred to nitrocellulose or PVDF 
membranes (Whatman). PVDF required activation by a 1-minute incubation in 
methanol. The gel and membrane were sandwiched between 3MM Whatman 
paper. Transfers were performed in Mini Trans-Blot Cell (Biorad) filled with transfer 
buffer, at 250mA for 75 minutes.  
Membranes were then blocked by incubation in blocking solution for 45 
minutes at room temperature on a shaker. Membranes were incubated with primary 
antibodies diluted in blocking solution overnight at 4°C or at room temperature for 1 
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hour. Next, the membranes were washed 3 times in PBS-Tween for 10 minutes, 
and incubated in HRP-conjugated secondary antibodies for 45 minutes. After three 
washes in PBS-Tween, HRP activity was detected using ECL Western blotting 
detection reagents (GE Healthcare) and ECL Hyperfilm (GE Healthcare). 
 
 
Western blotting buffers 
Transfer buffer 
192mM Glycine 
25mM Tris base 
10% Methanol 
PBS-Tween 
PBS 
0.1% Tween 20 (Sigma-Aldrich) 
Blocking buffer 
PBS-Tween 
4% dry milk powder 
 
Primary Antibodies 
Name Working dilution 
MRTF-A (C-19, Santa Cruz) 1:1000 
Flag (F7425, Sigma-Aldrich) 1:1000 
RhoA (67B9. Cell Signalling) 1:1000 
Phospho-ERK1/2 (Cell Signalling) 1:1000 
panERK (BD Biosciences) 1:10 000 
HA-12CA5 (Abcam plc) 1:1000 
MRTF-A phospho-specific antibodies 1-2µg/mL 
Secondary Antibodies 
Name Working dilution 
Rabbit IgG-HRP (DAKO) 1:2000 
Mouse IgG-HRP (DAKO) 1:2000 
Goat IgG-HRP (DAKO) 1:2000 
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2.13  Fluorescence polarisation assay 
 
Fluorescence polarisation (FP) assays were carried out as described in 
(Guettler et al., 2008), in 384-well-flat-bottom black polystyrene plates with a non-
binding surface (Corning Inc) and a final volume of 10µL. Peptides were dissolved 
in FP assay buffer to a concentration of 0.5µM. Lat-B actin was added at a 
concentration ranging from 1nM to 60µM. Reactions were incubated for at least 5 
hours at room temperature to allow attainment of binding equilibrium.  
Measurements were made using a Safire2 microplate reader (Tecan). Using 
the fluorescence polarisation mode the following settings were selected:  
 
FP-assay settings 
Excitation 470nm 
Emission  525nm 
Excitation bandwidth 20nm 
Emission bandwidth 20nm 
Time between move and flash 10ms 
Integration time 40µs 
Lag time 0 
Automatically determined z-position  
Optimal gain  
10 reads  
 
Anisotropies were calculated by the Magellan software. Dissociation 
constants were calculated using the GraphPad Prism6 software by non-linear 
regression and using the equation: Y=((Ab-Af)*(X/(KD+X))) +Af, where Y is total 
anisotropy; Ab is anisotropy from bound ligand; Af is anisotropy from free ligand; X 
is a protein concentration; KD is the dissociation constant (Heyduk and J. C. Lee, 
1990).  
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2.14  Analytical gel filtration 
 20µL of 100µM LatB-actin was mixed with a 3-fold molar excess of peptide 
or purified MRTF-A RPEL domain in a total volume of 110µL, using GF buffer to top 
up. The mixture was incubated for 5 minutes at room temperature and then 
subjected to size exclusion chromatography on an equilibrated S200 10/300 
column (GE Healthcare). The entire sample was injected into a 100µL loop. Elution 
of proteins was followed by absorption at 215nm and 280nm. The column was 
calibrated using a gel filtration standard (Biorad). 
 
 
 
GF-Buffer 2mM Tris-HCl pH 8 
100mM NaCl 
3mM MgCl2 
0.2mM EGTA 
0.3mM TCEP 
5% w/v glycerol 
 
 
2.15  IP/Kinase assay 
 Cells were seeded into 10cm dishes at 1x106 cells per dish and incubated 
overnight in 10% FCS DMEM. The next day, cells were transfected with either 
empty vector, DYRK1A or DYRK1B as follows: 
 
1. Preparation of DNA and Lipofectamine2000 solutions (per well) 
DNA mix: 500µL Opti-mem + 4µg DNA (pEF, DYRK1A or DYRK1B) 
 
Lipofectamine mix: 500µL Opti-mem + 12µL Lipofectamine 2000 
2. Incubation of transfection mixture 
The DNA mixture and Lipofectamine mixture were combined, vortexed and 
incubated at room temperature for 20 minutes.  
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3. Transfection 
Cells were washed twice in PBS and 4mL of Opti-mem was added. The 
combined DNA/Lipofectamine mixture was then added to the cells, for a final 
volume of 5mL. Cells were incubated at culture conditions for 2 hours. The 
transfection mixture was then replaced by 0.3% FCS DMEM and cells were 
starved overnight. 
 
After a 15 minute serum stimulation, cells were washed twice in PBS and 
then scraped in 500µl lysis buffer. Lysates were brought to 1mL using lysis buffer 
and incubated on ice for 20 minutes. The lysates were next sonicated (two 10 
second pulses) and insoluble material was pelleted by centrifugation at maximum 
speed in a refrigerated bench top centrifuge. 
Supernatants were then transferred to fresh tubes containing 20µL of HA-
agarose beads (Sigma-Aldrich) and incubated for 1.5 hours at 4°C on a rotating 
mixer. The beads were next washed three times in 1mL IP wash buffer and used 
for kinase assays. 
 
 
  
IP lysis buffer 50mM HEPES pH 7.4 
1% NP-40 
150mM NaCl 
2mM EDTA 
30mM Sodium pyrophosphate 
25mM NaF 
1mM Na3VO4 
1mM PMSF 
2µg/mL aprotinin 
2µg/mL leupeptinin 
1µg/mL pepstatin 
IP wash buffer 50mM HEPES (pH7.4) 
150mM NaCl 
2mM EDTA 
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Kinase Buffer 25mM HEPES pH 7.4 
5mM MgCl2 
5mM MnCl2 
0.5mM DTT 
200µM γ-32P ATP (100-150µCi/mL) 
200µM substrate peptide 
 
Kinase reactions were initiated by addition of 20µL kinase buffer to 10µL of 
beads with immobilised kinase. Reactions were incubated at 30°C for 20 minutes. 
8µL of the reaction were spotted onto P81 paper and allowed to dry. P81 paper 
was then washed extensively with 5% Phosphoric acid and activity was measured 
using a scintillation counter. 
 When full-length MRTF-A was used as a substrate the reaction was 
resolved by SDS-PAGE and transferred to nitrocellulose membrane. The 
membrane was then scanned using a Typhoon FLA 7000 Phosphorimager and 
subsequently immunoblotted. 
 
2.16  λ-phosphatase assay 
NIH-TR3 cells were seeded in 10cm dishes at 1x106 cells per dish in the 
presence of 1µg/mL tetracyclin, to induce Flag-MRTF-A expression. After treatment 
and stimulation, cells were scraped in 500µL RIPA buffer and incubated on ice for 
15 minutes. Lysate volume was brought to 1mL using RIPA buffer and insoluble 
material was pelleted by centrifugation at maximum speed in a refrigerated bench 
top centrifuge. The supernatant was transferred to a fresh tube containing 30µL 
Flag-beads (Sigma-Aldrich) and incubated for 1 hour at 4°C on a rotating shaker. 
The beads were next washed 3 times with 1mL RIPA buffer and 3 times with 
phosphatase buffer. The beads were then split in two and made up to 30µL with 
phosphatase buffer. 
1000 units of λ-phosphatase (NEB) were added to one of the tubes. The 
reaction was carried out at 30°C for 30 minutes. Beads were washed three times in 
phosphatase buffer and then 50µL of SDS-loading buffer was added to the beads. 
The samples were subsequently resolved by SDS-PAGE on a 7% Tris-Acetate gel. 
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RIPA buffer 50mM Tris-HCl 
150mM Nacl 
0.1% SDS 
0.5% Sodium Deoxycholate  
1% Triton X-100 
1mM PMSF 
Phosphatase buffer 50mM HEPES 
100mM NaCl 
2mM DTT 
0.01% Brij 35 
1mM MgCl2 
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Chapter 3. Characterisation of MRTF-A 
phosphorylation 
 
 
3.1 Aims 
 
Serum stimulation leads to MRTF-A nuclear accumulation and target gene 
activation. Simultaneously, MRTF-A is also multiply phosphorylated suggesting a 
positive regulatory role, especially since the C-terminal part containing the 
transactivation domain is phosphorylated. In this chapter I aim to gain further 
insight into the determinants of MRTF-A phosphorylation and how phosphorylation 
impinges on MRTF-A activity. 
 
3.2 MRTF-A phosphorylation correlates with the onset of 
activity 
 
The observation that activated MRTF-A is also phosphorylated is 
reminiscent of other transcription factors, such as Elk1, where phosphorylation of 
its transactivation domain switches it to the active state (Cruzalegui et al., 1999). If 
the case for MRTF-A phosphorylation is analogous, then phosphorylation should 
precede target gene activation, assuming that all phosphorylation positively 
regulates activity. I therefore sought to look at the kinetics of phosphorylation in 
more detail and compared these to the kinetics of target gene activation. 
 After FCS stimulation, transcription of representative MRTF/SRF targets 
sharply increased and peaked within 30 minutes, as assessed by qRT-PCR (Figure 
3.1A). Induction was transient and returned to baseline after 2 hours. FCS 
stimulation also led to a sharp decrease in electrophoretic mobility in SDS-PAGE, 
which reached a maximum within 10 minutes (Figure 3.1B). Maximum 
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phosphorylation persisted for an hour and began to decrease after 2 hours, by 
which time target gene transcription was already back to baseline. 
 As the initial kinetics of the events correlate, it is possible that 
phosphorylation could be required for target gene activation, like in the case of Elk1. 
However the lack of correlation between phosphorylation and transcription shut off 
suggests that other regulatory mechanisms must be involved. One explanation 
could be that MRTF-A dissociates from SRF within 2 hours and that 
dephosphorylation is not involved in the shut down of transcription. 
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Figure 3.1 MRTF-A phosphorylation correlates with the onset of 
transcriptional activity 
A. MRTF-A target gene transcription kinetics. NIH 3T3 cells maintained on 0.3% 
FCS overnight were stimulated with 15% FCS and RNA was extracted at indicated 
times. MRTF-A target genes expression was analysed by qPCR using intronic 
probes. Target gene abundance was normalised to GAPDH and data are 
expressed relative to starved conditions (fold change). Error bars represent 
standard error of the mean (SEM) from at least two independent experiments. B. 
Kinetics of gross MRTF-A phosphorylation. NIH 3T3 cells were starved in 0.3% 
serum overnight and stimulated with 15% FCS for indicated times. Cell lysates 
were resolved on a 7% polyacrylamide gel. Endogenous MRTF-A was detected by 
immunoblotting.  
 
 
3.3 Actin dissociation and ERK activation lead to MRTF-A 
phosphorylation 
 
 Serum induced phosphorylation is sensitive to inhibition of MEK and Rho 
activity, using U0126 and C3-transferase respectively (Fig 3.2A) and (Miralles et 
al., 2003)). Actin dissociation is required for MRTF-A activation, but it is unknown 
whether this is sufficient for MRTF-A phosphorylation. In addition the sensitivity to 
MEK1/2 inhibitor U0126 once again (Muehlich et al., 2008) suggests MRTF-A is an 
ERK target.  
To investigate the role of ERK in MRTF-A phosphorylation, tetradecanoyl 
phorbol acetate (TPA) was used as an alternative way to activate ERK.  TPA 
activates ERK in a PKC dependent manner (Marquardt et al., 1994). Treatment of 
cells with TPA resulted in partial phosphorylation and MEK1/2 inhibition using 
U0126 completely blocked this effect (Figure 3.2B). Since ERK is the only known 
MEK1/2 substrate, this result suggests that active ERK either directly 
phosphorylates MRTF-A or lies upstream of the kinases that could, for example 
Mnks or Rsk. The complete block of phosphorylation by U0126 precludes PKCs 
from being the kinases that directly phosphorylate MRTF-A after TPA stimulation. 
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CD disrupts F-actin, but its binding to actin is mutually exclusive with RPELs, 
and so CD activates MRTF-A (Sotiropoulos et al., 1999). Treatment of cells with 
CD also led to MRTF-A phosphorylation (Figure 3.2B). This phosphorylation was 
not U0126 sensitive excluding the possibility that basal ERK activity is sufficient 
once actin is dissociated. In addition this demonstrates that kinases other than ERK 
are able to phosphorylate MRTF-A. CD and TPA co-stimulation resulted in 
reduction of electrophoretic mobility equivalent to that with FCS stimulation, 
suggesting that disruption of the actin-MRTF interaction and simultaneous ERK 
activation are sufficient for full phosphorylation. 
The Rho component of MRTF-A phosphorylation could be due to depletion 
of G-actin, activation of downstream kinases or nuclear accumulation per se. G-
actin depletion using constitutively active mDia1*, was sufficient for MRTF-A 
phosphorylation (Figure  3.2C), however positive feedback from mDia to RhoA has 
been reported (Kitzing et al., 2007). CD treatment circumvents this issue by making 
actin incapable of binding to MRTF-A. However it is still possible that F-actin 
disruption by CD could activate kinases, such as LATS (Reddy et al., 2013) or PKD 
(Eiseler et al., 2009; 2007; Higuchi et al., 2009). 
 MRTF-A xxx, that does not bind actin, was constitutively nuclear and 
phosphorylated in starved cells (Figure 3.2C), suggesting that actin binding inhibits 
MRTF-A phosphorylation. Co-transfection of Dia1 did not further decrease 
electrophoretic mobility, confirming that actin dissociation per se is sufficient for 
partial phosphorylation. Serum stimulation was then able to further increase 
phosphorylation, presumably due to activation of the MAPK pathway. 
If phosphorylation positively regulates MRTF-A activity, then the relative 
levels of phosphorylation caused by TPA, CD and FCS stimulations could correlate 
with the relative MRTF-A activity. TPA and CD which induce partial phosphorylation 
induced the SRF/MRTF target genes Vcl and Srf less effectively than FCS, which 
leads to full phosphorylation, suggesting that phosphorylation correlates with initial 
transcriptional activation (Figure 3.2D). 
 Taken together these data show that actin dissociation per se is sufficient 
for MRTF-A phosphorylation, that this phosphorylation can be potentiated by MAPK 
pathway activity and that the extent of phosphorylation correlates with levels of 
target gene activation. 
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Figure 3.2 Serum induced MRTF-A phosphorylation depends on an intact 
RhoA and MAPK pathway 
A. NIH-3T3 cells transfected with empty vector or C3-transferase were starved 
overnight and stimulated with 15% FCS in the presence or absence of U0126. Cell 
lysates were resolved on a 7% polyacrylamide gel. Endogenous MRTF-A was 
detected by immunoblotting (experiment performed by F. Miralles). B. NIH-3T3 
cells were transfected with indicated MRTF-A derivatives and co-transfected with 
constitutively active Dia1 where indicated. After overnight starvation cells were 
stimulated with 15% FCS for 30 min. Cell lysates were resolved on a 7% 
polyacrylamide gel and MRTF-A derivatives were detected by immunoblotting. 
MRTFxxx does not bind actin. C. NIH 3T3 cells were starved overnight and 
stimulated for 45 min with either 15% FCS, 2µM CD, 100ng/mL TPA or CD and 
TPA simultaneously, in the presence of 10µM U0126 where indicated. Cell lysates 
were resolved on a 7% gel. Endogenous MRTF-A was detected by immunoblotting. 
D. NIH-3T3 cells were starved overnight and stimulated with 15% FCS, 2µM CD or 
100ng/mL TPA. RNA extracted at indicated times was analysed by qPCR using 
intronic probes against MRTF target genes. Target gene abundance was 
normalised to GAPDH and data are expressed relative to unstimulated conditions 
(fold change). Error bars represent standard error of the mean (SEM) from at least 
two independent experiments. 
 
3.4 Nuclear localisation is required but not sufficient for full 
MRTF-A phosphorylation 
 
 FCS induced target gene expression requires MRTF-A nuclear localisation. 
Both phosphorylation and nuclear localisation are coupled, as both are dependent 
on actin. Previous studies have shown that an NLS defective MRTF-A mutant that 
is unable to accumulate in the nucleus was also only partially phosphorylated after 
FCS treatment and this partial phosphorylation was U0126 sensitive (R. Pawlowski, 
unpublished). Furthermore CD treatment did not lead to any phosphorylation of this 
mutant. These observations indicate that ERK dependent phosphorylation does not 
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require nuclear accumulation, but the phosphorylation resulting from actin 
dissociation does.  
Since actin dissociation leads to simultaneous nuclear accumulation and 
phosphorylation, the question arises whether actin dissociation is really a 
requirement for phosphorylation or simply nuclear accumulation. LMB treatment 
blocks MRTF-A export and leads to rapid nuclear entrapment of MRTF-A, without 
detectably changing the MRTF-A/actin interaction as measured by FRET 
(Vartiainen et al., 2007). To test whether nuclear accumulation was sufficient for 
MRTF-A phosphorylation cells were incubated with increasing amounts of LMB for 
30 minutes and there was no reduction in electrophoretic mobility (Figure 3.3A). It 
was a possibility that while bound to actin phosphorylation could still occur but less 
efficiently. Phosphorylation was not detected even after a longer LMB treatment of 
90 minutes. Changes in MRTF-A electrophoretic mobility reflect changes in total 
phosphorylation with low resolution. A small panel of phospho-specific antibodies 
was used to probe for any small changes in phosphorylation at specific sites. Again, 
no phosphorylation was detected upon LMB treatment (Figure 3.3B). 
 Nuclear accumulation is therefore not sufficient for MRTF-A phosphorylation 
but is required for full phosphorylation, provided that actin dissociation occurs. 
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Figure 3.3 Nuclear localisation is not sufficient for MRTF-A phosphorylation 
A. Gel shift assay after LMB treatment. NIH-3T3 cells stably transfected with a 
tetracyclin inducible MRTF-A expression vector, were starved and treated with 
tetracyclin overnight. Cells were then treated with indicated concentrations of LMB 
for 30 or 90 min. Cell lysates were resolved on a 7% polyacrylamide gel and 
MRTF-A was detected by immunoblotting with a specific antibody. B. Lysates 
prepared as explained in (A), were resolved on 4-12% polyacrylamide gradient gels 
and immunoblotting was carried out using antibodies that recognise specific 
phosphorylation sites on MRTF-A. Immunoprecipitated MRTF-A from TPA 
stimulated cells was loaded as a positive control. LMB concentrations used were: 
2.5, 5, 10, 20, 50nM. 
 
3.5 MRTF-A dimerisation and binding to SRF are dispensable 
for phosphorylation 
 
 Transcriptional cyclin dependent kinases (Cdks), including Cdk7, Cdk8 and 
Cdk9, are so called because of their association with transcriptional machinery at 
gene promoters (Lim and Kaldis, 2013). Previous work in our lab, shows that 
MRTF-A phosphorylation is sensitive to Cdk inhibition using the pan-Cdk inhibitor 
Purvalanol A. It was therefore hypothesised that association of MRTF-A with SRF 
could lead to phosphorylation by the transcriptional Cdks. 
 Biochemical and functional assays have demonstrated that interaction with 
SRF in-vivo is abolished by the Y330A mutation (Zaromytidou et al., 2006), while 
dimerisation is dependent on the leucine zipper motif (Miralles et al., 2003). In 
MRTF-A depleted cells, rescue experiments are frequently complicated by 
dimerisation with residual endogenous MRTF-A (Vartiainen, 2008; Pawłowski et al., 
2010). To test whether binding to SRF is required for MRTF-A phosphorylation the 
Y330A and leucine zipper deletion ΔLZ were combined. 
The activity of the abovementioned MRTF-A derivatives was measured in 
an MRTF-A luciferase reporter assay, in order to assess the effectiveness of the 
mutations (Figure 3.4). Cells were depleted of endogenous MRTF-A/B and then 
transfected with the MRTF-A derivatives and reporters. Reporter activity in cells 
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transfected with the Y330A mutants was very low in all conditions tested, 
consistent with their inability to bind SRF. In agreement with previous studies the 
ΔLZ mutant which was SRF binding competent was less able to induce reporter 
activity (Pawłowski et al., 2010; Zaromytidou, 2007), especially after TPA 
stimulation.  
 The MRTF-A derivatives were next tested for their ability to be 
phosphorylated (Figure 3.5A). After serum or CD stimulation, MRTF-A Y330A 
showed no defect in phosphorylation, as observed by a reduction in electrophoretic 
mobility identical to that of wild type MRTF-A (Figure 3.5B). MRTF-A Y330A ΔLZ 
did exhibit faster electrophoretic mobility than MRTF-A Y330A, however this was 
not due to the inability to bind SRF. The faster electrophoretic mobility was also 
seen in the ΔLZ mutant indicating that this was a consequence of the dimerisation 
defect. The leucine zipper deletion decreases the predicted molecular weight of 
MRTF-A from 108kDA to 104kDa, and it is therefore unlikely that the differences 
seen were due to the deletion. In addition, there are no identified phosphorylation 
sites within the leucine zipper and the mutant has no defect in its ability to 
accumulate in the nucleus (Figure 3.5D). 
Because of its poor activity in the reporter assay, MRTF-A ΔLZ was further 
tested for its ability to be phosphorylated. Despite normal nuclear accumulation, 
MRTF-A ΔLZ demonstrated faster electrophoretic mobility than WT in all conditions 
(Figure 3.5C). Just like WT was partially phosphorylated in response to CD and 
TPA treatments with respect to its maximum with FCS stimulation. Sensitivity to 
U0126 was like that of WT. λ-phosphatase treatment revealed that deletion of the 
LZ leads to an apparent molecular weight reduction that can be resolved by SDS-
PAGE (Figure 3.5E). 
Taken together, the data show that MRTF-A phosphorylation is not 
dependent on SRF binding or MRTF-A dimerisation. 
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Figure 3.4 Activation potential of dimerisation defective and SRF binding 
defective MRTF-A 
NIH-3T3 cells were transfected with the p3D.A and ptkRL luciferase reporters (see 
section 2.8) as well as the indicated MRTF-A derivatives. VP16 indicates cells 
transfected with the fusion protein SRF-VP16 which constitutively activates activity 
of the p3D.A reporter. The cells were starved overnight and stimulated with 15% 
FCS, 2µM CD or 100ng/mL TPA for 6 hours. Cell extracts were then assessed for 
luciferase activity. Error bars represent standard error of the mean (SEM) from at 
least two independent experiments. 
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Figure 3.5 Ternary complex formation and dimerisation are dispensable for 
MRTF-A phosphorylation 
A. Schematic representation of MRTF-A showing the regions affected by the 
Y330A point mutation and the LZ deletion. The resulting MRTF-A mutants cannot 
bind SRF and cannot dimerise, respectively. B. Gel shift assay of MRTF-A 
mutants. NIH-3T3 cells were transfected with the indicated MRTF-A derivatives, 
starved overnight and stimulated with 15% FCS or 2µM CD. Cell lysates were run 
on a 7% polyacrylamide gel and MRTF-A was detected by immunoblotting. C. NIH-
3T3 cells were transfected with WT MRTF-A or the ΔLZ mutant which cannot 
dimerise and starved overnight. The cells were subsequently stimulated with 15% 
FCS, 2µM CD or 100ng/mL TPA. Cell lysates were resolved on a 7% 
polyacrylamide gel and MRTF-A was detected by immunoblotting with an anti-Flag 
antibody. An arrow head marks a non specific band. D. Cells were transfected with 
MRTF-A WT or ΔLZ, maintained in 0.3% FCS overnight and stimulated with 15% 
FCS. MRTF-A localisation was assessed by immunofluorescence using an anti-
Flag antibody. At least 100 cells were counted and localisation was scored as 
predominantly nuclear (navy blue), pancellular (lilac) or predominantly cytoplasmic 
(light blue). E. Cells were transfected with the indicated constructs and extracts 
were used for immunoprecipitating MRTF-A. λ-phosphatase treatment was carried 
out where indicated. 
 
3.6  Phosphorylation is required for full activity 
 
Our lab and others have identified multiple phosphorylation sites on MRTF-
A, all of which are S/T-P sites and spread throughout the protein (Figure 3.6A).  
The S/T-P sites were substituted to alanine residues by F Miralles to generate a 
derivative for use in determining the role of phosphorylation of MRTF-A (Figure 
3.6B). This mutant, named “E3”, was able to accumulate in the nucleus normally, 
but exhibited reduced transcriptional activity in response to serum stimulation. 
Further analyses, including validation using specific antibodies led to a set 
of 26 residues that are reproducibly phosphorylated upon MRTF-A activation by 
serum. Based on this set of 26 phospho-acceptor sites, additional 6 residues were 
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mutated to alanine on E3, while 6 residues were repaired back to serines or 
threonines because they were subsequently shown to remain unphosphorylated. 
The resulting derivative named “26ST/A” lacks all phosphorylation sites observed 
in-vivo (Figure 3.6C). The strategy followed for the generation of 26ST/A is shown 
in Figure 3.6D. 
All intermediate derivatives obtained during the generation of 26ST/A from 
E3 were tested in a reporter assay to assess whether a particular residue 
substitution had a drastic effect on activity. Cells were depleted of endogenous 
MRTF-A and transfected with the various ST/A mutant intermediates. The FCS and 
CD induced maxima were all lower than that of MRTF-A WT, but did not fluctuate 
significantly as alterations were made. The baseline activity, however, fluctuated 
with some mutations. After the last alteration was made, the final product, 26ST/A 
appeared identical to the E3 with respect to activity in all conditions tested (Figure 
3.6E).  
During the correction process alanine substitution of S33 (ST/Ac ) appeared 
to cause a significant change in baseline activity. To validate this, the assay was 
repeated, comparing E3, ST/Ac and 26ST/A. Indeed, ST/Ac was as active as the 
E3 and 26ST/A mutants in stimulated conditions, but more active in starved 
conditions (Figure 3.7A). The increased activity in unstimulated conditions suggests 
that the S33A modification affects MRTF-A regulation, in a way that is redundant 
after stimulation. In addition, it appears that in the low ranges of the titration, FCS 
or CD induced activity is not different between WT and ST/As. One explanation 
could be that there is enough endogenous MRTF-A to dimerise with the ectopically 
expressed and is possibly sufficient to induce activity. Once enough ectopic MRTF-
A is expressed, endogenous MRTF is titrated out and significant amounts of 
ectopic MRTF-A dimers begin to form. It is at this point that MRTF-A WT dimers 
continue to provide more activity, whereas the ST/A mutant dimers cannot and 
defects begin to be seen. 
Both E3 and 26ST/A exhibited similar mobility in SDS-PAGE, which did not 
detectably change upon stimulation with FCS or CD (Figure 3.7B). In addition, 
neither E3 nor 26ST/A were defective in their ability to accumulate in the nucleus 
after FCS stimulation (Figure 3.7C). To gain more insight into the reduced activity 
observed with 26ST/A, the 26ST/A mutant was rendered unable to bind actin. In 
the absence of any actin binding localisation would not be regulated. In addition, 
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since stimulation would be unnecessary, any remaining endogenous MRTF-A 
would be sequestered in the cytoplasm or at least in the inactive state.  
Cells were therefore depleted of endogenous MRTF and wild type MRTF-A , 
MRTF-A xxx  or 26ST/A xxx were titrated in. As previously seen, titrating in the wild 
type protein increased baseline activity in starved conditions. Titrating in MRTF-A 
xxx led to a dose dependent increase in reporter activity, while ST/A xxx was 
significantly less effective but not completely inactive (Figure 3.8).  In this 
experimental setup, the inability to become phosphorylated appears to have a more 
drastic effect on reporter activation. It would be interesting to see if deletion of the 
leucine zipper would lead to a complete loss of activity in this context. 
Taken together these data show that phosphorylation of MRTF-A is required 
for full transcriptional activity. 
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Figure 3.6 Generation of a non phosphorylatable MRTF-A derivative 
A-C. Schematic representation of MRTF-A. Top shows all confirmed 
phosphorylation sites. Middle shows a mutant (E3) in which the phosphorylation 
sites shown in red were mutated to alanines. In white are confirmed 
phosphorylation sites that were not known at the time the mutant was made. 
Bottom shows the revised ST/A construct (26ST/A) in which only validated 
phosphorylation sites are mutated to Alanine (red) while some others, mutated in 
E3, were repaired (green). D. Strategy followed to generate the revised MRTF-A 
ST/A. Starting with E3 residues were sequentially mutated or repaired to generate 
the 26ST/A derivative. Changes were cumulative; each progressive derivative 
includes the changes in the previous ones. E. Cells were transfected with the 
luciferase reporter plasmids (p3D.A for MRTF-A activity, ptkRL for normalisation) 
and 20ng of different ST/A MRTF-A mutants (a to j, explained in part D) and their 
activity assayed by luciferase assay after stimulation with 15% FCS, 2µM CD or 
100ng/mL TPA for 6 hours. Error bars represent standard error of the mean (SEM) 
from at least two independent experiments. 
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Figure 3.7 MRTF-A phosphorylation is required for full activity 
A. MRTF-A activity reporter assay. NIH-3T3 cells depleted of endogenous MRTF-A 
using siRNA, were transfected with luciferase reporter plasmids  and the indicated 
MRTF-A derivatives (0.5, 1, 5, 10, 20, 40ng of derivatives). After overnight 
starvation, the cells were stimulated with 15% FCS or 2µM CD. Cell extracts were 
then assessed for luciferase activity. B. Gel shift assay. NIH 3T3 cells transfected 
with the indicated MRTF-A derivatives were starved and stimulated with 15% FCS 
or 2µM CD for 30 min. Lysates were resolved on a 7% polyacrylamide gel and 
MRTF-A derivatives were detected by immunoblotting. C. Cells were transfected 
with MRTF-A WT, E3 or 26ST/A, maintained in 0.3% FCS overnight and stimulated 
with 15% FCS. MRTF-A localisation was assessed by immunofluorescence using 
an anti-Flag antibody. At least 100 cells were counted and localisation was scored 
as predominantly nuclear (navy blue), pancellular (lilac) or predominantly 
cytoplasmic (light blue). Error bars represent standard error of the mean (SEM) 
from at least two independent experiments. 
 
 
Figure 3.8 The defect in ST/A activity is actin binding independent 
MRTF-A activity reporter assay. NIH-3T3 cells depleted of endogenous MRTF-A 
using siRNA, were transfected with luciferase reporter plasmids and the indicated 
MRTF-A derivatives (0.5, 1, 5, 10, 20, 40ng). After incubation in 0.3% FCS 
overnight, cell extracts were prepared and assessed for luciferase activity.  
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3.7 Kinase siRNA screen 
 
To identify the kinases responsible for MRTF-A direct phosphorylation R 
Pawlowski carried out a small molecule inhibitor screen using “Protein kinase 
inhibitor libraries I, II and III” (Calbiochem). The screen included 288 cell-permeable, 
reversible protein kinase inhibitors, most of which were ATP competitive. The 
outline of the strategy followed is shown in Figure 3.9. 
A cell line stably expressing an MRTF-A reporter gene was used to identify 
inhibitors from the library that blocked FCS or CD induced MRTF activity. Effects 
on MTRF-A nuclear accumulation were assessed by immunofluorescence. 14 
inhibitors that blocked both FCS and CD induced MRTF-A activity, without affecting 
nuclear accumulation, were next tested for their ability to inhibit MRTF-A 
phosphorylation.  
Three inhibitors blocked MRTF-A phosphorylation: PI3K inhibitor VIII, 5-
iodotubercidin and indirubin derivative. A subsequent ligand immobilised affinity 
binding assay against a panel of 442 kinases, was then carried out to determine 
the specificity. A small siRNA library against the 20 most promising targets was 
compiled. Criteria used included degree of inhibition by the above inhibitors, 
whether the kinase is constitutively active and is nuclear or pancellular. 
The aim of my studies was to investigate the potential role of these targets 
in MRTF-A regulation. The 20 siRNAs were tested in the MRTF-A reporter assay. 
Out of the 20 siRNA pools, 8 impaired both FCS and CD induction of the reporter 
(Figure 3.10). However, none of those 8 siRNA pools blocked phosphorylation of 
MRTF-A in any of the conditions tested, suggesting that none of the siRNA 
targeted kinases directly phosphorylate MRTF-A (Figure 3.11). siRNA pools 
against CLK2 and CKIa (CSNK1A1), which increased reporter activity, were also 
tested, and depletion of those led to an increase in MRTF-A phosphorylation. I did 
not however investigate those candidates further since I was interested in kinases 
that would directly phosphorylate MRTF-A. 
Depletion of no single kinase, from the panel tested, is sufficient to block 
MRTF-A phosphorylation. Taken together, the data suggest that MRTF-A 
phosphorylation induced by either serum or CD, involves multiple kinases. 
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Figure 3.9 Strategy for identification of kinases that phosphorylate MRTF-A 
Outline of the strategy followed to identify kinases that directly phosphorylate 
MRTF-A. See text for details. 
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Figure 3.10 Kinase siRNA screen 
NIH-3T3 cells stably transfected with the MRTF-A activity reporter were transfected 
with siRNA against the indicated kinases. After starving overnight, cells were 
stimulated with 15% FCS or 2µM CD. Firefly luciferase activity was normalised to 
renilla luciferase activity and plotted as fold change relative to control in starved 
conditions (the dotted line indicates the activity of the control). Arrows indicate the 
eight siRNAs that led to a block in both FCS and CD activation. Error bars 
represent standard error of the mean (SEM) from at least two independent 
experiments. 
 
 
 
 
 
 
 
Figure 3.11 MRTF-A phosphorylation after kinase knockdown 
NIH-3T3 cells were transfected with non-targeting siRNA (CTRL), or siRNA against 
indicated kinases, maintained in 0.3% FCS overnight and stimulated with 15% FCS 
or 2µM CD. Lysates were resolved by SDS-PAGE on a 7% polyacrylamide gel and 
MRTF-A was detected by immunoblotting.  
 
 
Chapter 3 Results 
 
 152 
3.8 Are DYRK kinases involved in MRTF-A regulation? 
 
Previous work in the lab, using the small molecule inhibitor DMAT, implicated 
dual-specificity tyrosine-phosphorylated and regulated kinases (DYRKs) in MRTF-A 
regulation. Since two members of the DYRK family were also targeted in the 20 
siRNA screen, I decided to investigate them in more detail. 
Using siRNA each family member was depleted (DYRK1A, 1B, 2, 3, 4) and 
MRTF activity was followed by qRT-PCR analysis of expression of the target genes 
Vcl and Srf. Only depletion of DYRK1A moderately hindered activation of both 
target genes, after both FCS and CD stimulation (Figure 3.12). Since there is a 
possibility of redundancy, especially between DYRK1A and DYRK1B (Leder et al., 
1999), I also depleted DYRK family members in pairs.  All combinations that 
included DYRK1A, except when paired with DYRK4, caused the greatest inhibition 
in all MRTF-A target genes tested and after both FCS and CD stimulation (Figure 
3.13). The data suggest there is redundancy between DYRK family members with 
respect to MRTF-A regulation. Expression levels could be a contributing factor, and 
only once two family members are depleted MRTF-A activity is impaired. 
I next tested Harmine, a low nanomolar potency inhibitor of DYRK1A and 
DYRK1B (in-vitro IC50 of 33nM and 166nM respectively; over 1µM for other 
DYRKs) (Göckler et al., 2009). 10µM Harmine treatment, led to 50% attenuation of 
Vcl induction but had a weaker effect on Srf (20% and 35% attenuation after FCS 
and CD respectively) (Figure 3.14).  
To test whether overexpression of DYRKs could potentiate MRTF-A activity 
cells were transfected with either wild type or kinase dead versions of DYRK1A or 
DYRK1B (Kinase dead versions are mutated in the ATP binding site).  
Overexpression had no effect on MRTF-A target gene transcription in starved or 
stimulated conditions (Figure 3.15). 
 To confirm that the expressed kinases were functional, they were 
immunoprecipitated from transfected cells for use in kinase assays. First I 
confirmed that an optimal DYRK substrate peptide called DYRKtide could be 
specifically phosphorylated. The DYRKtide was successfully phosphorylated only 
by anti-HA conjugated resin incubated with lysates from cells transfected with HA-
DYRK1A (Figure 3.16A). Appropriate controls were included to ensure that 
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detected activity was not due to kinases non-specifically bound to the resin. In 
addition DYRK1A did not phosphorylate the PKA substrate KEMPtide, indicating its 
specificity. 
DYRK1B phosphorylated the DYRKtide with 30% the efficiency of DYRK1A 
under the assay conditions used (Figure 3.16B). In addition, the kinase dead 
versions did not display any activity, confirming that they are indeed inactive and 
detected activity was dependent on the DYRK kinase domain. 
The immunoprecipitated complexes were also used to test whether they 
could phosphorylate a panel of 15 residue peptides corresponding to MRTF-A 
segments that include validated phosphorylation sites. These sites were predicted 
to be DYRK targets by the GPS 2.0 prediction tool (Xue et al., 2008). One peptide, 
which contains the S949 phospho-acceptor site, was phosphorylated when 
incubated with DYRK1A but not DYRK1B (Figure 3.17A). This phosphorylation site 
is conserved between MRTF family members and throughout vertebrates, and is 
located in the transactivation domain of MRTF-A. Phosphorylation of this peptide 
was 5-fold over background but only 7% of the positive control. A phospho-specific 
antibody that recognises pS949 was not available to confirm this result. The 
immunoprecipitated kinases were also incubated with recombinant MRTF-A. 
DYRK1A but not DYRK1B was able to weakly phosphorylate MRTF-A, however the 
residue(s) concerned was not identified (Figure 3.17B). It is not clear why harmine 
did not inhibit DYRK activity in this in vitro assay. Because harmine is an ATP 
competitive inhibitor, the ATP concentration of the kinase reaction could be lowered 
and higher concentrations of harmine could be tested. 
The data suggest that DYRK kinases are involved in MRTF-A regulation, but 
further work is required to determine whether they directly phosphorylate MRTF-A. 
An S949A derivative could be used in a kinase assay to determine whether S949 is 
a DYRK1A substrate and whether there are more residues phosphorylated. 
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Figure 3.12 Effect of DYRK knockdown on MRTF-A target genes 
NIH-3T3 cells were transfected with siRNA against the indicated kinases, starved 
overnight and stimulated with 15% FCS or 2µM CD. Extracted RNA was used to 
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make cDNA, which was analysed by qRT-PCR analysis of MRTF-A target gene 
expression, using intronic probes. Data presented as target gene/GAPDH 
abundance. For the top panel exonic probes were used to assess depletion of 
siRNA targets and data are presented as fold change relative to before 
knockdown.For the middle and bottom panels intronic probes were used. c is 
control, M is MRTF-A, A is DYRK1A, B is DYRK1B and 1-4 are DYRK1-4 
respectively. Error bars represent standard error of the mean (SEM) from at least 
two independent experiments. 
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Figure 3.13 Combination knockdowns of DYRK family members 
A. Cells were treated as described in Figure 12. Combinations of siRNA are 
explained in B. Efficiency of siRNA depletion of the DYRK target transcripts is 
shown in C. Error bars represent standard error of the mean (SEM) from at least 
two independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 DYRK inhibitor Harmine attenuates MRTF-A target gene induction 
NIH-3T3 cells were maintained in 0.3% FCS overnight and treated for 15 minutes 
with 10 µM Harmine before stimulation with 15% FCS or 2µM CD. Extracted RNA 
was used to synthesise cDNA, which was analysed by qRT-PCR for expression of 
MRTF target genes using intronic probes. Error bars represent standard error of 
the mean (SEM) from at least two independent experiments. 
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Figure 3.15 Effect of DYRK overexpression on MRTF-A target gene 
expression 
A. NIH-3T3 cells were transfected with wild type or kinase dead (KD) DYRK1A or 
DYRK1B. Cells were starved overnight and stimulated with 15% FCS or 2µM CD 
for 30 min. RNA extracts were used to synthesise cDNA for qRT-PCR analysis of 
MRTF target genes using intronic probes. B. DYRK overexpression was confirmed 
using exonic primers. EV is empty vector. Error bars represent standard error of the 
mean (SEM) from at least two independent experiments. 
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Figure 3.16 Expressed DYRK1A and DYRK1B are functional kinases 
A.  NIH-3T3 cells were transfected with HA-tagged DYRK1A. The kinase was then 
immunoprecipitated using anti-HA from the extracts of the FCS stimulated cells. 
Immune complexes were then tested for their ability to phosphorylate either the 
KEMPtide peptide (K, AMPK substrate) or the DYRKtide peptide (D, DYRK 
substrate) in the presence of ATP𝛾32P. A fraction of the reaction was spotted on P81 
paper and activity measured using a scintillation counter. B. Cells were transfected 
with either HA-tagged DYRK1A or DYRK1B wild type or kinase inactive (KD). 
Immune complexes were tested in kinase assays, as in (A). 
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Figure 3.17 DYRK and MRTF-A kinase assay 
A. DYRK1A and DYRK1B immunoprecipitates were prepared as described in 
Figure16 and incubated with peptides corresponding to regions of MRTF that 
include a phosphorylation site. Sites tested were predicted DYRK targets (Xue et 
al., 2008). Predicted phospho-acceptor residue is in red. The two amino-terminal 
arginines shown in blue were added to ensure adsorbtion to the P81 
phosphocellulose paper. A fraction of the reaction was spotted onto P81 
phosphocellulose paper and incorporation of 32P was measured using a scintillation 
counter. B. Immunoprecipitates were incubated with purified MRTF-A in the 
presence of ATP𝛾32P and where indicated 10µM Harmine. Reactions were then 
resolved by SDS-PAGE, transferred and developed using a phosphorimager (Top 
panel) or used in immunoblotting (Bottom panel). The reaction with DYRK1B was 
done in duplicate. MRTF-A, DYRK1A and DYRK1B were detected using specific 
antibodies. 
 
 
3.9 Are cyclin dependent kinases involved in MRTF-A 
regulation? 
 
Previous work in the lab using Purvalanol A implicated CDKs in MRTF-A 
regulation. siRNA depletion of CDK7, CDK8 or CDK9 did not block MRTF-A activity 
in the reporter assay (Figure 3.18A). Flavopiridol is a panCDK inhibitor, regarded 
as a CDK9 inhibitor due to its strong potency towards CDK9. Flavopiridol treatment 
resulted in a dose dependent inhibition of MRTF-A phosphorylation (Figure 3.18B). 
In addition there was a dose dependent decrease in MRTF-A activity in the reporter 
assay (Figure 3.19). Flavopiridol also inhibited transcription of the constitutively 
expressed TK-renilla luciferase construct, as expected, since CDKs are part of the 
basal transcription machinery. Expression of the MRTF-A reporter however was 
exceptionally sensitive to Flavopiridol compared to TK-renilla luciferase, as reporter 
activity was completely blocked at 400nM Flavopiridol while TK-renilla luciferase 
was inhibited by 40%. These data warrant further investigation into the role of 
CDKs in MRTF-A regulation.  
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Figure 3.18 CDK knockdown does not impair MRTF-A reporter activation 
A. NIH-3T3 cells stably expressing the MRTF-A activity reporter were transfected 
with siRNA against the indicated CDKs. Conditions for efficient knockdown of 
CDKs were optimised in a separate experiment. After overnight incubation in 0.3% 
FCS, cells were stimulated with 15% FCS or 2µM CD for 6 hours. Firefly luciferase 
activity was normalised to renilla luciferase activity. Error bars represent standard 
error of the mean (SEM) from at least two independent experiments. B. Cells were 
starved overnight and then stimulated with 2µM CD for 45 min, in the presence of 
increasing amounts of Flavopiridol (50, 100, 200, 400, 600, 1000, 2000nM). 
Lysates were resolved by SDS-PAGE and MRTF-A, pSer2 of Pol II C-terminal 
domain (CTD) and total Pol II were detected using specific antibodies. 
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Figure 3.19 Flavopiridol blocks MRTF-A reporter activation 
NIH-3T3 cells were transfected with the MRTF-A activity reporter, starved overnight 
and stimulated with 2µM CD for 6 hours in the presence of increasing amounts of 
flavopiridol. Cell extracts were then assessed for luciferase activity. (Flavopiridol: 
50, 100, 200, 400, 800, 1000nM). A. Data are presented as firefly/luciferase B. 
firefly luciferase activity. C. renilla luciferase activity.   
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3.10  Summary 
 
The evidence presented in this chapter shows that MRTF-A phosphorylation 
is required for full activity. MRTF-A phosphorylation can occur upon MAPK pathway 
activation, possibly by ERK itself. Actin keeps MRTF-A in a low stoichiometry 
phosphorylation in part by cytoplasmic sequestration. By an unknown mechanism, 
even when MRTF-A is trapped in the nucleus, actin is able to inhibit 
phosphorylation.  In the absence of stimulation, actin dissociation is sufficient for 
phosphorylation of MRTF-A suggesting that nuclear constitutively active kinases 
are responsible. For high stoichiometry phosphorylation actin dissociation and 
MAPK pathway activation are required. I have presented evidence for the 
involvement of CDKs and DYRKs, but also that there is probably a high degree of 
redundancy.  
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Chapter 4. Regulation of MRTF-A by the MAPK 
pathway 
 
 
4.1 Aims 
 
MRTF-A has previously been reported to be regulated in response to ERK 
signalling. In neurones ERK activation was reported to lead to phosphorylation of 
MRTF-A and activation of MRTF-A/SRF target genes (Kalita et al., 2006). In HeLa 
cells ERK activation was reported to lead to phosphorylation and subsequent 
export of MRTF-A (Muehlich et al., 2008). In our system, using NIH-3T3 fibroblasts, 
we also have evidence for ERK signalling to MRTF-A. Treatment with MEK1/2 
inhibitor U0126 affects MRTF-A phosphorylation and binding to SRF (Miralles et 
al., 2003; Esnault et al., 2014). Tetradecanoyl phorbol acetate (TPA) is widely used 
as a means to activate the MAPK pathway and this activation occurs in a PKC 
dependent manner (Griner and Kazanietz, 2007). Unpublished data from R. 
Pawlowski demonstrated that in 3T3 fibroblasts TPA treatment leads to nPKC 
mediated downregulation of RhoA activity and a subsequent increase in G-actin 
concentration. This negative effect of TPA on Rho/actin signalling makes MRTF-A 
refractory to FCS activation. 
In the following chapter I investigate the consequences of ERK signalling on 
MRTF-A and how the MAPK pathway contributes to MRTF-A regulation. 
 
4.2 ERK signalling activates MRTF-A 
 
 To ask whether ERK activation was sufficient to activate MRTF-A, cells 
were stimulated and MRTF-A/SRF target gene expression was monitored by qRT-
PCR using intronic probes (Figure 4.1A). Transcription of Srf, Vcl and Itgb1, which 
depend on MRTF-A for activation, was induced upon TPA treatment, together with 
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the TCF dependent Egr1 gene used as a control. Induction was largely sensitive to 
the MEK1/2 inhibitor U0126. Residual activity after U0126 treatment was similar to 
that of the ERK/TCF regulated Egr1 suggesting incomplete inhibition of ERK rather 
than the contribution of other transcription factors. To confirm this observation I 
additionally tested the TPA treatment on cells transiently transfected with an 
MRTF-A reporter gene. Expression of the reporter gene is entirely dependent on 
MRTF-A and TPA stimulation of the reporter occurred only in the presence of 
MRTF-A (Figure 4.1B).  
 In 3T3 cells TPA treatment downregulates Rho activity and increases G-
actin concentration, which creates inhibitory conditions for MRTF-A (Figure 4.2A). 
Using the Rho-GTP binding domain of Rhotekin active Rho was precipitated from 
cells stimulated by either FCS or TPA. Indeed, as opposed to FCS treatment, TPA 
led to a reduction of available RhoGTP, as judged by recovery of Rho in the 
Rhotekin pulldown experiment (Figure 4.2B). Hence the MRTF-A dependent 
activity observed is occurring despite TPA induced increase in G-actin 
concentrations. These results suggest that TPA influences MRTF-A subcellular 
localisation by mechanisms other than G-actin depletion. The presence of an ERK 
phosphorylation site, S98, within the RPEL domain suggests that this might occur 
through a decrease in the affinity of the RPEL domain towards actin. 
S98 exhibits little phosphorylation in resting conditions and is rapidly 
phosphorylated after TPA stimulation in a U0126 sensitive manner (Figure 4.3). 
Other phosphorylation sites tested exhibited baseline phosphorylation and some 
were induced by TPA. The large change in S98 phosphorylation, and its presence 
within the actin binding RPEL domain, suggested that it might provide a way to 
regulate the actin binding properties of MRTF-A and therefore its localisation. 
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Figure 4.1 TPA induces MRTF-A target gene activation 
A. NIH-3T3 cells were maintained in 0.3% FCS overnight and stimulated with 
100ng/mL TPA for the indicated times, in the presence or absence of 10µM U0126 
. RNA extracts were used for qRT-PCR analysis of MRTF-A target gene expression 
using intronic probes. B. MRTF-A activity reporter assay. NIH-3T3 cells depleted of 
endogenous MRTF-A using siRNA were transfected with luciferase reporter 
plasmids and  3ng/well MRTF-A. After overnight starvation cells were stimulated 
with 15% FCS, 2µM CD or 100ng/mL TPA for 6 hours. Error bars represent 
standard error of the mean (SEM) from at least two independent experiments. 
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Figure 4.2 TPA treatment downregulates Rho activity in 3T3 cells 
A. Schematic depicting the effects of TPA on ERK and RhoA signalling in 3T3 cells 
(R. Pawlowski, unpublished). B. Starved NIH-3T3 cells were treated with 15% FCS 
or 100ng/mL TPA for indicated times. RhoGTP was pulled down on bead-
immobilised GST-rhotekin RBD. Precipitates were resolved by SDS-PAGE and 
probed with an anti RhoA antibody. Whole cell extracts were immunoblotted with 
anti RhoA as a loading control and anti phospho ERK for ERK activation. 
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Figure 4.3 TPA leads to MRTF-A phosphorylation 
NIH-3T3 cells stably transfected with a tetracyclin inducible MRTF-A expression 
vector, were starved and treated with tetracyclin overnight. The cells were next 
treated with 100ng/mL TPA for the indicated times in the presence or absence of 
10µM U0126. Lysates were resolved by SDS-PAGE and MRTF-A was detected 
using an anti flag antibody or the indicated phospho-specific antibodies. 
 
 
4.3 ERK directly binds MRTF-A and phosphorylates S98 
 
 S98 is located at the N-terminal end of Spacer1 (Figure 4.4A). A sequence 
which closely resembles an ERK binding motif (Figure 4.4B) (Sharrocks et al., 
2000) is present N-terminal to this, overlapping RPEL1. The motif is composed of 
the two positive residues RK 70/71, followed by a two-residue spacer and LQL 
74/75/76 (Figure 4.4A). The motif overlaps with RPEL1, sharing the highly 
conserved Leucine 74 that is involved in actin binding.  
 To determine whether this putative ERK binding motif was required for 
phosphorylation of S98, I mutated either the basic or the hydrophobic residues of 
the motif (Figure 4.4C). Because it was previously seen that BSAC is not 
phosphorylated on its S98 equivalent position (F. Miralles, unpublished), I 
exchanged the positive residues in MRTF-A to those found in BSAC (VQ) or to 
Chapter 4 Results 
 
 174 
alanine (AA). This analysis showed that S98 phosphorylation was dependent on 
the motif for phosphorylation. Upon serum stimulation, S98 was phosphorylated 
and mutation of the positive residues to AA greatly reduced phosphorylation 
(Figure 4.4C). Indeed phosphorylation of the serine was not detected in BSAC and 
in MRTF-A RK/VQ S98 phosphorylation was substantially reduced. No 
phosphorylation was detected upon mutation of Leucines 74/76 of the ERK binding 
motif. 
 I next wanted to confirm whether ERK could directly interact with MRTF-A 
using purified components. I used immobilised GST MRTF-A 2-115 as bait and 
successfully precipitated purified ERK2. The interaction was dependent on the 
integrity of both the positive and hydrophobic residues of the ERK binding motif 
(Figure 4.4D). 
 Combined these results show that activated ERK directly binds MRTF-A via 
the ERK binding motif to phosphorylate S98 within the RPEL domain. 
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Figure 4.4 ERK directly binds MRTF-A and phosphorylates Ser98 
A. Schematic representation of MRTF-A. Expanded region containing the ERK 
binding motif (D-domain) and S98 is aligned with that of other MRTF family 
members. RPEL1 is enclosed in a red box and the conserved R, P, E and L 
residues of the RPEL motif are indicated below. Conserved positions of the D-
domain are colored blue. B. The MRTF-A D-domain, aligned with other known D-
domains is presented and the consensus sequence is shown below (‘Multiple 
docking sites on substrate proteins form a modular system that mediates 
recognition by ERK MAP kinase’, n.d.; Garai et al., 2012). Conserved positions are 
shown in blue. Ψ is either Arg or Lys (basic), Φ is Leu, Val, Iso, Phe or Met 
(hydrophobic). C. Cells were transfected with either MRTF-A WT or derivatives 
where key positions of the D-domain were mutated or BSAC, an MRTF-A isoform 
in which the D-domain is divergent. After stimulation, the overexpressed proteins 
were probed for S98 phosphorylation using a phospho-specific antibody against 
pS98. D. ERK2 pull down using immobilised GST-MRTF-A (2-115) as bait. GST-
MRTF-A (2-115) and derivatives with mutated D-domains were immobilised on 
resin and tested for their ability to interact with ERK2. Left: Immunoblot using an 
anti-ERK antibody. Right: coomassie stained gel to show that equal amounts of bait 
were used. ERK2 protein amounts were not sufficient for coomassie staining. 
 
 
4.4 S98 phosphorylation affects actin binding by the RPEL 
domain 
 
 The RPEL domain forms a compact complex with actin (Mouilleron et al., 
2011) and it might be expected that introduction of a negatively charged phosphate 
moiety at S98 would affect complex assembly. I first tested whether S98 
phosphorylation would affect actin binding to RPEL1, which is just N-terminal to 
S98, using the fluorescence anisotropy assay. The assay allows accurate 
measurements of binding affinity, the basic principle of the technique is shown in 
Figure 4.5A. In a previous study, N-terminally fluorophore-labeled peptides 
corresponding to RPEL1 ±5 residues (residues 67-98) and purified actin-LatB were 
Chapter 4 Results 
 
 177 
used (Mouilleron et al., 2008). For comparison, S98 phosphorylation was first 
studied in this context (Figure 4.5B). The Kd of WT RPEL1 was 1.1µM. The Kd of 
the ɑ1AA peptide in which the ɑ1-helix contact points were mutated could not be 
determined due to very low or no binding. The Kd of phospho-S98 and S98A 
peptides, were 0.6µM and 1.7µM respectively (Figure 4.5C). Phosphorylation of 
S98 does not appear to appreciably affect actin-binding affinity. For example the 
“weak” R81A mutation in RPEL1 results in a Kd of 17.7µM ±2.4 (Guettler et al., 
2008). 
 Since S98 was the terminal residue of the 67-98 peptides, longer peptides 
were also used (62-104), in which S98 was followed by an authentic ɑ-carbon 
chain. Again the phosphorylated S98 residue did not affect the Kd of the RPEL1-
actin interaction. There was no difference between the shorter and longer peptides 
(Figure 4.5D). Thus S98 phosphoylation does not affect actin binding in the context 
of the isolated RPEL1. 
 I next tested whether S98 phosphorylation affected actin binding to Spacer1. 
Previously, size exclusion chromatography experiments showed that the Spacer1-
RPEL2 peptide can form a complex with 2 actins and that actin binding to Spacer1 
cannot occur in the absence of RPEL2 (Mouilleron et al., 2011). This was a suitable 
context to investigate the effect of S98 phosphorylation for two reasons. First, if 
S98 phosphorylation affected actin binding to spacer1 there would be a distinct 
change in the complex mass. Second, the resulting complex would be easily 
monitored. This is because the actin would grant the complex good absorption at 
A280, as opposed to peptide alone. Actin alone eluted as a single peak at an 
elution volume corresponding to an apparent MW of 42.4 kDa; the mass of 1 actin 
(Figure 4.6). The deduced MW of the complex formed between S1-R2 was 70.9 
kDa, corresponding to one peptide and 1.5 actins. This apparent stoichiometry did 
not significantly change with the phosphorylated S98 peptide or the S98D 
derivative. Phospho-S98 was therefore unable to affect actin binding to Spacer1, at 
least in the context of the S1-R2 peptide. 
 The RPEL domain binds actin cooperatively to form a 3:1 complex with actin 
bound to RPEL1-Spacer1-RPEL2. This complex is stable enough in solution and 
for size exclusion chromatography. A 5:1 complex can form, but this complex can 
only be detected under conditions where actin is constantly present during 
separation (Mouilleron et al., 2011). Actin interaction with Spacer2 and RPEL3 is 
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not strong enough to survive the process of SEC. I therefore next investigated 
whether S98 phosphorylation can destabilise the 3:1 complex and lead to a lower 
stoichiometry.  
 As previously observed a 3:1 complex formed between actin and the wild 
type MRTF RPEL domain (Figure 4.7A). The S98D derivative however, formed a 
2:1 complex, indicating that 98D was somehow affecting binding of one of the 
actins. To determine whether RPEL1 was the affected actin-binding element, I 
compared the RPEL domain x23, which cannot bind actin via RPEL1, to the RPEL 
x23 S98D. In this case the 98D mutation was first tested as a potential phospho-
mimetic substitution. Both derivatives bound 2 actins; there was no further change 
in actin binding upon aspartate substitution of S98. This suggests that 98D 
abolishes actin binding to RPEL1 (Figure 4.7A).  
 To ensure that the stable trimer formed was by actin binding to RPEL1, 
Spacer1 and RPEL2 and that the only change with S98D was loss of actin from 
RPEL1, I looked at the effect of the S98D substitution in the context of RPEL 12x, 
an RPEL domain derivative which is unable to bind actin through Spacer2 and 
RPEL3. This would preclude the possibility that S98D causes a rearrangement of 
the RPEL-actin complex. RPEL 12x formed a 3:1 complex, and the S98D 
substitution led to the loss of one actin. The results confirmed that S98D abolished 
actin from RPEL1, leaving actin bound to Spacer1 and RPEL2 (Figure 4.7B). 
 Because of the compact assembly formed by the RPEL domain and actin, I 
hypothesised that the integrity of S98 itself could be required for formation of the 
stable complex. In order to investigate this I asked whether RPEL S98A would be 
impaired in actin binding. The S98A derivative formed a trimeric complex with actin 
suggesting the alanine substitution did not affect actin binding properties and that 
integrity of S98 is not required (Figure 4.7C). 
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Figure 4.5 S98 phosphorylation does not affect actin binding in the context of 
the RPEL1 peptide alone 
A. Schematic representation of how the affinity of a peptide for actin can be 
quantified in the fluorescence polarisation assay. Actin is shown in orange and 
labeled peptides are black with yellow fluorophores. Polarised light is used to excite 
the peptide-coupled fluorophores into a high-energy state. Small, highly mobile 
peptides change orientation before returning to ground state and re-emiting light. 
As a consequence of changing orientation, emitted light is depolarised. Binding to 
actin reduces mobility of peptides and hence the light emitted remains more 
polarized compared to the free peptide. Degree of polarisation is proportional to 
amount of complex formation (Heyduk et al., 1996) B. The short and longer RPEL1 
containing peptides used in the fluorescence polarisation assay are shown. 
Residues altered in the derivatives tested are shown with arrows, RPEL1 is 
enclosed in a red box and the conserved RPEL residues are shown below. C and 
D. Anisotropy of indicated FAM labeled RPEL1 peptides measured over a range of 
LatB-actin concentrations. Error bars represent standard error of the mean (SEM) 
from at least two independent experiments. 
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Figure 4.6 S98 phosphorylation does not affect actin binding to Spacer1 
Peptides corresponding to Spacer1-RPEL2 of the RPEL domain were incubated 
with purified actin and analysed by size exclusion chromatography. The elution 
volumes of the complexes, determined by the peaks, were converted to apparent 
molecular weight using the calibration curve (right). Bottom: Coomassie gels show 
the major peaks corresponding to the actin-peptide complexes, and excess 
peptide. 
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Figure 4.7 S98 phosphorylation blocks actin binding to RPEL1 in the context 
of the RPEL domain 
Recombinant RPEL domain and the indicated derivatives were incubated with actin 
and complexes were analysed by size exclusion chromatography. Separate sample 
runs are superimposed in different colours. Conversion of elution volumes to 
apparent molecular weight is shown on the right, along with the corresponding 
apparent stoichiometry of each complex.  
 
 
4.5 ERK promotes MRTF-A nuclear accumulation through S98 
phosphorylation. 
  
Actin binding to the RPEL domain regulates MRTF-A shuttling. Because 
ERK activation leads to S98 phosphorylation, which in turn affects actin binding, I 
tested whether TPA induced MRTF-A activation is dependent on S98. To do this I 
examined the effect of S98A mutation both in MRTF-A and the fusion protein 
MRTF-A (2-204) PK. 
 TPA treatment led to transient nuclear accumulation of MRTF-A (Figure 
4.8A), however, this was not entirely dependent on S98. MRTF-A S98A exhibited 
only a slight impairment in TPA induced nuclear accumulation. The S98D derivative, 
which mimics S98 phosphorylation, exhibited elevated nuclear accumulation in 
resting cells, which was potentiated upon TPA treatment. These results suggest 
that phosphorylation of S98 promotes nuclear accumulation, but is not the only 
event contributing to TPA induced nuclear accumulation. It is possible that the peak 
of nuclear localisation in the case of S98D is lower, because the aspartate 
substitution does not faithfully mimic a phospho-serine. TPA induced nuclear 
accumulation can be attributed to ERK activation, because it was blocked by the 
MEK1/2 inhibitor U0126 (Figure 4.8B). 
Previous studies suggest other phosphorylation sites (S544, T545, S549) 
impinge on MRTF-A regulation (Muehlich et al., 2008). The N-terminal region of 
MRTF-A, including the N-terminus and RPEL domain is sufficient to confer MRTF-
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A like shuttling when fused to the normally cytoplasmic pyruvate kinase (Guettler et 
al., 2008).  
Use of the MRTF-A (2-204) PK fusion allowed investigation of S98, 
independently from the other phosphorylation events. The MRTF-A (2-204) PK 
fusion and its S98A derivative accumulated in the nucleus upon TPA treatment 
indicating that S98 phosphorylation is not required (Figure 4.8C). Accumulation 
was not completely blocked by U0126 (Figure 4.8D) indicating that TPA induced 
nuclear localisation is not accomplished solely through ERK activation. S98 
phosphorylation by ERK is therefore not required for TPA induced nuclear 
accumulation, however, the S98D derivative is predominantly nuclear indicating 
that S98 phosphorylation is sufficient. 
 TPA activates other pathways besides ERK, and inhibits Rho activation, as 
shown above. I therefore induced ERK activation by making use of RafER. RafER 
is a fusion between the Raf kinase domain and the estrogen binding domain of the 
estrogen receptor. The fusion is kept inactive by binding to HSP90 and can be 
activated by tamoxifen (Samuels et al., 1993). Upon tamoxifen addition, an 
increase in S98 and total phosphorylation of MRTF-A was observed, which was 
sensitive to MEK1/2 inhibition (Figure 4.9A). The time dependent increase was 
reflected by nuclear accumulation of either full length MRTF-A or MRTF-A (2-204) 
PK (Figure 4.9B). Together, these experiments show that selective activation of the 
MAPK pathway is sufficient for MRTF-A phosphorylation and nuclear accumulation, 
and suggest that this occurs through phosphorylation of S98. 
 To confirm that nuclear accumulation was occurring via ERK and S98 I co-
transfected cells with constitutively active MEK (MEKR4F) and the S98 derivatives of 
MRTF-A (2-204) PK. In the presence of MEKR4F, the fusion was substantially more 
nuclear, as with TPA (Figure 4.9C). The S98A derivative did not respond to 
constitutive MEK-ERK signalling, in contrast to treatment. This supports the notion 
that TPA induced nuclear accumulation was not simply down to S98 
phosphorylation. Thus S98 phosphorylation can promote nuclear accumulation at 
least in the context of the RPEL domain. The observation that the S98D derivative 
showed relatively high nuclear accumulation in starved conditions, which was not 
TPA or MEKR4F responsive, suggests that S98 phosphorylation is not only 
necessary but also sufficient to promote nuclear accumulation.  
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Figure 4.8 TPA leads to MRTF-A nuclear localisation 
NIH-3T3 cells were transfected with wild type, S98A or S98D derivatives of either 
full length MRTF-A (A and B) or MRTF-A-PK fusion protein (C and D). Following 
overnight starvation, cells were stimulated with 100ng/mL TPA for the indicated 
times in the presence or absence of 10µM U0126. Localisation was determined by 
immunofluorescence using an anti flag antibody. At least 100 cells were counted 
and localisation was scored as predominantly nuclear (navy blue), pancellular 
(lilac) or predominantly cytoplasmic (light blue). Error bars represent standard error 
of the mean (SEM) from at least two independent experiments. 
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Figure 4.9 Activation of the MAPK pathway promotes S98 phosphorylation 
and nuclear accumulation 
A. Cells transfected with RafER were starved overnight and treated with tamoxifen 
for indicated times in the presence or absence of 10µM U0126. Lysates were then 
resolved by SDS-PAGE and analysed by immunoblot using the indicated 
antibodies. B. Cells were co-transfected with RafER and MRTF-A or MRTF-A (2-
204) PK fusion, starved overnight and treated with tamoxifen for the indicated 
times. Localisation was determined by immunofluorescence using an anti flag 
antibody. At least 100 cells were counted and localisation was scored as 
predominantly nuclear (navy blue), pancellular (lilac) or predominantly cytoplasmic 
(light blue). C. Left: Cells were co-transfected with MRTF-A (2-204) PK fusion and 
MEKR4F, starved overnight and stimulated with 100ng/mL TPA as indicated. 
Localisation was determined by immunofluorescence using an anti flag antibody. At 
least 100 cells were counted and localisation was scored as predominantly nuclear 
(navy blue), pancellular (lilac) or predominantly cytoplasmic (light blue). Right: Cells 
were co-transfected with MRTF-A (2-204) PK and constitutively active MEK 
(MEKR4F), starved overnight and stimulated with TPA where indicated. Lysates 
were resolved by SDS-PAGE and S98 phosphorylation was determined using the 
specific antibody. Error bars represent standard error of the mean (SEM) from at 
least two independent experiments. 
 
4.6 Ser33 is basally phosphorylated 
 
 Although MEKR4F and RafER transfections provided more specific MAPK 
pathway activation to investigate S98 phosphorylation, TPA treatment uncovered 
the potential for a further regulatory element within the N-terminal region. Because 
TPA could still affect MRTF-A (2-204) PK S98A localisation, S33 was investigated. 
Like S98, S33 is followed by a proline and is in close proximity to the ERK binding 
site, making it a candidate for the remaining regulation observed. 
 In order to confirm and characterise S33 phosphorylation, a peptide 
corresponding to residues 29-37, which contain S33, was synthesised in its 
phospho-S33 form and used in the immunisation of 3 rabbits (Figure 4.10A). 
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 Serum from each rabbit was incubated with resin-immobilised non-phospho 
peptide, thereby removing antibodies reactive against epitopes irrelevant to the 
phosphate moiety of the antigen. To test reactivity towards pS33, each depleted 
serum was tested in immunoblotting. All three depleted sera recognised MRTF-A 
S33A indicating incomplete depletion (Figure 4.10B). Their reactivity against 
MRTF-A was therefore tested in the presence of excess non-phosphorylated 
antigen, to block any remaining reactivity against non-phosphorylated S33. In the 
presence of excess non-phosphorylated antigen serum1, but not serum 2 or 3, 
recognised MRTF-A only when S33 was intact and presumably phosphorylated 
(Figure 4.11C).  
 To confirm the reactivity observed was indeed against phosphorylated S33, 
the sera were tested in the presence of the phosphorylated form of the antigen 
(Figure 4.11D). The phosphorylated antigen should sequester phospho-specific 
antibodies. In the case of Serum1 the pS33 peptide prevented any detection of 
immunoprecipitated MRTF-A, confirming that Serum1 was suitable for detection of 
pS33 on MRTF-A. 
 Serum1 could therefore be used, in the presence of excess non-phospho-
peptide, to assess S33 phosphorylation. As shown in Figure 4.10A (top panel), S33 
is phosphorylated in resting conditions and phosphorylation increases by 
approximately 3-fold after serum stimulation and 2-fold after TPA stimulation. 
 Because induction of pS33 appeared poor after stimulation I carried out a 
timecourse to investigate the phosphorylation kinetics of S33 after FCS stimulation. 
The data from the timecourse confirm that S33 phosphorylation does not 
dramatically change after stimulation, suggesting it may already be highly 
phosphorylated (Figure 4.11A). The FCS induced increase in pS33 was sensitive to 
ERK inhibition, but not dependent on the identified ERK binding motif (Figure 4.11 
B,C). 
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Figure 4.10 Generation of a pSer33 specific antibody 
A. Schematic representation of the peptide sequence used for the generation of 
pS33 reactive serum. The C-terminal cysteine, shown in green, was used for 
crosslinking and immobilisation of the peptide. B. Cells were transfected with Flag-
MRTF-A or the S33A derivative, starved and then stimulated with 15% FCS or 
100ng/mL TPA for indicated times. Anti-Flag immunoprecipitates were resolved by 
SDS-PAGE. Sera from 3 immunised rabbits, were passed over resin with 
immobilised non-phospho peptide, in order to deplete the serum of antibodies 
which recognise the non-phosphorylated form of the peptide. The depleted sera 
were then tested for reactivity against the abovementioned samples. Each depleted 
serum was tested alone, or C. in the presence of non-phospho peptide or D. 
phospho-peptide, to assess specificity. E. Membranes were probed with an anti-
MRTF-A antibody to assess loading. 
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Figure 4.11 S33 phosphorylation 
A. Cells transfected with MRTF-A were starved overnight and stimulated with 15% 
FCS for the indicated times. MRTF-A was immunoprecipitated using an anti-Flag 
antibody. pS33 and total MRTF-A were then detected by immunoblot analysis. B. 
Cells were treated as in (A) but also with U0126 where indicated. C. Cells were 
transfected with MRTF-A, the S33A derivative or the ERK binding motif mutant 
RK/AA. Cells were starved overnight and treated with 100ng/mL TPA for 30 
minutes. Extracts were then resolved by SDS-PAGE and analysed by immunoblot 
analysis using specific antibodies. 
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4.7 S33 phosphorylation prevents nuclear accumulation 
 
 To determine how S33 phosphorylation affects shuttling of MRTF-A (2-204) 
PK, S33 and S98 were cotransfected with RafER. Alanine substitution of S33 led to 
an increase in nuclear localisation, which is further potentiated by ERK activity 
(Figure 4.12). In contrast the S33D derivative was more cytoplasmic in resting 
conditions and refractory to ERK induced nuclear accumulation. These results 
suggest that S33 phosphorylation prevents nuclear accumulation. In agreement 
with previous data S98D promotes nuclear accumulation. The S33A mutation 
appears to potentiate S98D and RafER induced nuclear accumulation, while S33D 
appears to make MRTF-A (2-204) PK refractory to nuclear accumulation, 
consistent with the observations that S33 is basally phosphorylated but can also be 
phosphorylated further. Together these data show a functionally antagonistic effect 
of pS33 against pS98 on MRTF-A(2-204) PK localisation. In addition these data 
support the previous observation that S33 is basally phosphorylated.  
The observation that ERK mediated phosphorylation of MRTF-A promotes 
its cytoplasmic localisation is in accordance with the findings of Muehlich et al. In 
their view ERK mediated phosphorylation of residues S544, T545 and S549 is 
required for MRTF-A nuclear export by promoting association with actin (Muehlich 
et al., 2008). They showed that TPA treatment does not activate MRTF-A, but 
rather makes MRTF-A refractory to subsequent activation by FCS. In our lab, Rafal 
Pawlowski has shown using PKC and MEK1/2 inhibitors, that ERK activity was 
dispensable for the inhibitory effect of TPA, which is instead caused by nPKC 
mediated RhoA down-regulation (R. Pawlowski, unpublished data). 
 Since the observations with pS33 provide evidence for phosphorylation 
having a negative role on nuclear accumulation I sought to determine whether the 
reported phosphorylation sites co-operate with S33 to promote export. Muehlich et 
al. used human MALmet, which lacks the 92 N-terminal residues including the N-
terminus and RPEL1, but state that similar behaviour was observed for full length 
MRTF-A. The reported residues were therefore substituted to alanines in the 
context of full length MRTF-A and a truncated version (Δ92) that was generated to 
mimic their MALmet (Figure 4.13A).  
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 In our system, using NIH-3T3 cells, alanine substitution of the reported 
residues did not cause constitutive nuclear accumulation in starved conditions; 
instead it looked almost identical to wild type MRTF-A (Figure 4.13B). The 
truncated version designed to mimic their construct, exhibited a baseline that was 
slightly increased in combination with the alanine mutations. Finally, in an attempt 
to replicate their findings, the experiment was carried out in HeLa cells but similar 
results with 3T3 cells were obtained (Figure 4.13C).  
 Taken together, the data show that S33 is basally phosphorylated and 
promotes cytoplasmic localisation of MRTF-A, presumably by promoting export. 
The idea that phosphorylation promotes export has also been reported by others, 
however I cannot replicate their findings and S33 phosphorylation cannot explain 
the effects reported. Since MRTF-A shuttling is regulated at the level of export, in 
the next chapter I address how S98 and S33 impinge on MRTF-A export. 
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Figure 4.12 MAPK activation leads to MRTF-A nuclear accumulation through 
S98 phosphorylation 
Cells were co-transfected with RafER and the indicated MRTF-A (2-204) PK fusion 
derivatives. After overnight starvation cells were treated with tamoxifen for 30 or 60 
min. MRTF-A (2-204) PK localisation was determined by immunofluorescence 
using an anti-Flag antibody. At least 100 cells were counted and localisation was 
scored as predominantly nuclear (navy blue), pancellular (lilac) or predominantly 
cytoplasmic (light blue). 
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Figure 4.13 Alanine substitution of STS544/545/549 does not block export 
A. Schematic of MRTF-A showing derivatives used in this experiment. B. 3T3 cells 
were transfected with wild type MRTF (WT) or STS544/545/549AAA (mut) in the 
context of full length or N-terminally truncated MRTF-A. Cells were then starved 
overnight and stimulated with 15% FCS for 30 minutes. Localisation was 
determined by immunofluorescence using an anti-Flag antibody. At least 100 cells 
were counted and localisation was scored as predominantly nuclear (navy blue), 
pancellular (lilac) or predominantly cytoplasmic (light blue). Error bars represent 
standard error of the mean (SEM) from at least two independent experiments. C. 
Same as in (B) but using HeLa cells.  
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Chapter 5. Identification of a Crm1 NES in the N-
terminus of MRTF-A 
 
 
5.1 Aims 
 
MRTF-A nuclear localisation is regulated primarily at the level of export. 
Decreases in cellular G-actin concentrations result in reduced actin-MRTF-A 
interaction leading to its nuclear accumulation. In the fibroblast model import of 
MRTF-A appears to be constant, as it is not affected by growth factors, although it 
is inhibited in very high G-actin concentrations. MRTF-A export is mediated by 
Crm1 and is dependent on actin binding. Therefore depletion of the actin pool 
results in decreased export rates (Vartiainen et al., 2007). In this chapter I identify a 
Crm1 dependent export signal within the MRTF-A N-terminus, and investigate how 
S33 and S98 may be involved in its regulation. 
 
5.2 Multiple export signals in MRTF-A 
 
I first analysed the MRTF-A primary sequence using the prediction software 
NetNES (http://www.cbs.dtu.dk/services/NetNES/) (la Cour et al., 2004). This 
algorithm takes into account previously identified export signals and their similarity 
to the sequence in question, integrating the apparent high specificity of the hidden 
Markov model (HMM) and the apparent sensitivity of the Neural network (NN) to 
detect potential NES elements. The output returned after submission of a sequence 
shows both scores individually and generates a combined score (which is a 
function of the two) which ranges from 0 – 2.1. A default threshold of 0.5 is set. 
Sequences that score below the 0.5 threshold, have a greater than 0.1 false 
discovery rate. 
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Within the MRTF-A sequence eight regions are given a score by NN, HMM 
or both. The regions identified are shown in Figure 5.1. Two of these regions, 
putative NES 3 and 6, receive a score above the threshold. NES2 was the only 
NES detected within the RPEL domain and also received the lowest score. It is still 
possible than some true NESs receive a low score.  Muehlich et al have confirmed 
NES 3 but not NES 6 as a functional NES in MRTF-A (Muehlich et al., 2008).  In 
addition, Hayashi et al. have also identified NES3 (Hayashi and Morita, 2013), as 
well as a region overlapping with RPEL1 and the ERK binding motif shown in 
chapter 4.  
Previous experiments in the lab showed that gross deletions encompassing 
single or pairs of these NESs did not completely block MRTF-A export. This 
suggested that multiple NES contribute to MRTF-A export, but the mechanism was 
not analysed in detail (R. Pawlowski, unpublished data). 
The N-terminal region of MRTF-A has been shown to be sufficient to confer 
MRTF-A-like shuttling when fused to the normally cytoplasmic protein pyruvate 
kinase (Guettler et al., 2008). In addition R. Pawlowski has shown that the N-
terminal region (residues 2-261) is also able to interact with Crm1 in-vitro. 
Therefore the RPEL domain, and the 66 aminoacids that precede it must contain 
both an import signal, which is known (Pawłowski et al., 2010), and at least one 
export signal. 
In the following sections I will address (i) whether Crm1 mediated export is a 
property of the RPEL domain and (ii) where the Crm1 binding sequences are. 
 
Chapter 5. Results 
 
 201 
 
Figure 5.1 MRTF-A possesses multiple putative classical export sequences 
Schematic representation of MRTF-A. Arrows point at the locations that resemble 
the classical nuclear export signal consensus. Regions detected by NetNES 
prediction software, are aligned below. Coloured in red are the key residues that 
conform to the classical NES consensus shown at the bottom.   
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5.3 The MRTF-A and Phactr1 RPEL domains are not 
interchangeable 
 
 Phactr1, like MRTF-A, possesses an RPEL domain and accumulates in the 
nucleus upon serum stimulation (Wiezlak et al., 2012). The MRTF-A and Phactr1 
RPEL domains both contain an embedded NLS and three highly homologous 
RPEL motifs, separated by spacer sequences (Figure 5.2). It is not known if 
Phactr1 continuously shuttles through the nucleus, however, a Phactr1 mutant 
containing an RPEL domain that cannot bind actin is constitutively nuclear. 
However Phactr1 is not dependent on Crm1 for export, suggesting that although 
both proteins rely on actin binding through similar RPEL domains for their 
localisation they rely on different export machinery. 
 While the Phactr1 RPEL domain can form a trivalent complex by binding 
one actin on each RPEL motif, the MRTF-A RPEL domain can form a pentavalent 
complex by also binding actins via its slightly longer spacers. Despite this 
difference, the actins bound by the RPEL motifs in each RPEL/actin complex share 
near identical relative orientation and proximity to each other (Mouilleron et al., 
2011; 2012). The different dependence of Phactr1 and MRTF-A on Crm1 allowed 
investigation into the relationship between Crm1 and the RPEL domain. 
 When the MRTF-A RPEL domain was transferred to Phactr1, the resulting 
chimera Phactr1(MRTF-R)  (Figure 5.3A, top), accumulated in the nucleus after FCS 
stimulation, but LMB treatment had no effect (Figure 5.3B). LMB sensitivity was not 
transferred along with the RPEL domain, suggesting that it is context specific.  
Phactr1(MRTF-R)  exhibited increased nuclear localisation in starved conditions 
compared to wild type Phactr1. This may reflect the introduction of the strong 
MRTF-A NLS in place of the weaker Phactr1 NLS. Although the two NLS were not 
directly compared, the B2 NLS embedded in the Phactr1 RPEL domain plays a 
secondary role relative to the Phactr1 B1 NLS (Wiezlak et al., 2012). Therefore 
upon transplanting the MRTF-A RPEL the weaker Phactr1 B2 NLS is replaced by 
the stronger NLS of MRTF-A (Pawłowski et al., 2010; Wiezlak et al., 2012).  
 Conversely, when the Phactr1 RPEL domain was transferred to MRTF-A, 
the resultant chimera, MRTF(Phactr-R),  was completely cytoplasmic in starved, FCS 
stimulated and LMB treated conditions (Figure 5.3B). It is possible that concomitant 
Chapter 5. Results 
 
 203 
replacement of the strong MRTF-A NLS for the weak Phactr1 NLS results in very 
inefficient import and so upon FCS treatment or LMB mediated inactivation of Crm1, 
the MRTF(Phactr-R) chimera is very inefficient in nuclear import.  
Taken together, the data show that MRTF-A and Phactr1 RPEL domains 
are not functionally interchangeable, and that Crm1 dependence for export is not a 
property of the MRTF-A RPEL domain itself. However, through actin binding, the 
RPEL domain can affect the function of other elements that define subcellular 
localisation and the mechanism appears to be context specific. MRTF-A regulation 
is at the level of Crm1 mediated export. In Phactr1(MRTF-R), it could be regulation of 
non-Crm1 dependent export, or cytoplasmic anchoring. 
 To gain further insight into the chimeras’ mechanism of shuttling I studied 
their dependence on actin and previously mapped NLS elements. As shown in 
Figure 5.4 A, multiple elements contribute to this chimera’s nuclear import. Serum 
regulation of Phactr1 is abolished by mutation of its B1 element (Wiezlak et al., 
2012). The RPEL motif adjacent to the B1 region was shown to have a minor 
contribution in maintaining cytoplasmic localisation of Phactr1. Cytoplasmic 
localisation of Phactr1 is in fact dependent on its RPEL domain (Wiezlak et al., 
2012). MRTF-A regulation is heavily dependent on the B2B3 elements embedded 
within the RPEL domain(Pawłowski et al., 2010), however MRTF-A shuttling is 
regulated at the level of export in fibroblasts (Vartiainen et al., 2007).  
 Phactr1(MRTF-R) xxx, which cannot bind actin, is constitutively nuclear 
indicating that actin binding is required for cytoplasmic localisation, either by 
promoting export or inhibiting import (Figure 5.4B-2). Inactivation of the MRTF B2 
NLS element within the RPEL domain, led to cytoplasmic localisation, indicating 
that the B2 element contributes to import in starved conditions leading to the high 
levels of nuclear localisation observed (Figure 5.4B-3). Serum regulation is retained, 
indicating that regulation of Phactr1(MRTF-R) is not solely determined on the B2 NLS. 
Moreover, the observation that the derivative lacking B2, which cannot bind actin, is 
constitutively nuclear indicates that cytoplasmic localisation is not solely the result 
of actin inhibition of the B2 element (Figure 5.4B-4).  
Because of the possibility of an NES overlapping the B2 region (NES2 in 
Figure 3.1) B3 was mutated instead, which would diminish import activity 
contributed by the RPEL domain without compromising the putative NES.  Mutation 
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of the B3 element also decreased import but again regulation was maintained 
(Figure 5.4B-5).  
 Mutation of the B1 NLS did not abolish serum regulation (Figure 5.4C-1). 
Regulation in the absence of B1 is still actin dependent, since additional mutation 
of the RPEL domain led to constitutive nuclear accumulation (Figure 5.4C-2). 
Inactivation of B1 in combination with either B2 or B3 NLSs did not abolish 
regulation, confirming that serum induced nuclear accumulation of Phactr1(MRTF-R) is 
not achieved by changes in import (Figure 5.4C-3 & 5).  
Regulation of the Phactr1(MRTF-R) chimera is therefore dependent on actin 
binding to the RPEL domain, however the mechanism is not as simple as 
competition between importin and actin binding to the MRTF-A RPEL domain. 
Although the RPEL embedded NLSs do contribute to nuclear import of 
Phactr1(MRTF-R) they are not required for actin regulation. Actin binding is therefore 
not only masking the NLSs but also impinges on the function of elements outside 
the RPEL domain, to regulate subcellular localisation.  
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Figure 5.2 Alignment of MRTF-A and Phactr1 RPEL domains 
Top: Schematic representation and domain structure of MRTF-A and Phactr1 
proteins. Middle: schematic showing the main elements of the MRTF-A and 
Phactr1 RPEL domains. Bottom: Alignment of the MRTF-A and Phactr1 RPEL 
domain primary sequences. RPEL motifs are enclosed in red boxes and the basic 
elements comprising the NLS of each protein are in grey. Note the shorter spacer 
elements of Phactr1 compared to MRTF-A. 
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Figure 5.3 The RPEL domains of MRTF-A and Phactr1 are not functionally 
interchangeable 
A. Top: Schematic depicting the replacement of the Phactr1 RPEL domain with that 
of MRTF-A to generate the Phactr1(MRTF-R) chimera; junctions are: N-terminal 
(Phactr1) …ASLYTSS//LSERKNV…(MRTF-A), C-terminal: (MRTF-
A)…VGQVNYP//ADAQDYD…(Phactr1) . Bottom: replacement of the MRTF-A 
RPEL domain with that of Phactr1 to generate the MRTF-A(Phactr-R) chimera; 
junctions are: N-terminal (MRTF-A) …RNPNLPP//LAMKVCR… (Phactr1), C-
terminal (Phactr1) …FSDYVEV//IIVGQVN… (MRTF-A). B. Cells were transfected 
with MRTF-A, Phactr1 and the chimeras, starved overnight and treated with 15% 
FCS or 50nM LMB for 30 min. Localisation of each protein was determined by 
immunofluorescence using an anti-Flag antibody. At least 100 cells were counted 
and localisation was scored as predominantly nuclear (navy blue), pancellular 
(lilac) or predominantly cytoplasmic (light blue). Error bars represent standard error 
of the mean (SEM) from at least two independent experiments. 
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Figure 5.4 Cellular localisation of the chimera is determined by actin 
dependent export 
A. Schematic representation of the Phactr1(MRTF-R) chimera with arrows indicating 
the basic elements present, which contribute to nuclear import of the chimera. B 
and C. Cells were transfected with the indicated chimera derivatives, starved 
overnight and stimulated with 15% FCS for 30 min or 50nM LMB for 2 hours. 
Localisation of each protein was determined by immunofluorescence using an anti-
Flag antibody. B1A: inactivation of the Phactr1 N-terminal NLS by alanine 
substitution of R108, R109 and R110. B2A and B3A: inactivation of the basic 
elements that constitute the bipartite MRTF-A NLS. At least 100 cells were counted 
and localisation was scored as predominantly nuclear (navy blue), pancellular 
(lilac) or predominantly cytoplasmic (light blue). Error bars represent standard error 
of the mean (SEM) from at least two independent experiments. 
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5.4 The MRTF-A N-terminus contains a Crm1 dependent export 
signal 
 
Previous work showed that residues 2-204 contain an LMB sensitive export 
signal (Guettler et al., 2008). I therefore tested whether the N-terminus (2-67) 
would confer LMB sensitivity to Phactr1(MRTF-R) (Figure 5.5A). 
Phactr1(MRTF-NR) was more cytoplasmic than Phactr1(MRTF) in starved 
conditions and accumulated in the nucleus after serum stimulation. It also 
accumulated in the nucleus after LMB treatment, indicating that it contains a Crm1 
NES (Figure 5.5B-1, compare with Figure 5.4B-1). In addition, its nuclear 
accumulation was actin dependent as the actin binding deficient mutant 
Phactr1(MRTF-NR) xxx was completely nuclear in unstimulated cells (Figure 5.5B-2). 
As with Phactr1(MRTF-R), nuclear accumulation of Phactr1(MRTF-NR) was 
strongly dependent on the MRTF NLS elements B2 and B3 (Figure 5.5B-3 & 5). 
However its cytoplasmic localisation was actin dependent (Figure 5.5B-2). Mutants 
incompetent to bind actin were still sensitive to LMB, indicating that in this context 
actin binding is not required for Crm1 function (Figure 5.5B-4). 
Interestingly, although the RPEL domain cannot bind actin in this derivative, 
serum regulation was retained, suggesting the Phactr1 N-terminal RPEL motif 
might be regulating B1. Consistent with this idea, additional inactivation of B1, to 
generate Phactr1(MRTF-NR) B1A B2A xxx abolished serum regulation but retained 
LMB sensitivity (Figure 5.5C-4). 
Alternatively, the apparent loss of serum regulation could be due to 
insufficient NLS activity to counter the actin independent Crm1 mediated export 
activity. Phactr1(MRTF-NR) B1A B3A xxx, which is less impaired in import activity is 
also not serum regulated (Figure 5.5C-6), further supporting that actin regulates 
import, at least in part through the B1 element. However, Phactr1(MRTF-NR) B1A is 
regulated in response to serum stimulation, indicating that the B1 element is not 
required for serum regulation (Figure 5.5C-1). 
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Taken together these data suggest that the N-terminus of MRTF-A contains 
a Crm1 dependent export signal, however, in the context of the Phactr1(MRTF-NR)  
chimera residues 2-204 do not exhibit actin dependent Crm1 mediated export. 
 
Chapter 5. Results 
 
 213 
 
Chapter 5. Results 
 
 214 
Figure 5.5 The MRTF-A N-terminus confers Crm1 mediated export 
A. Schematic representation of the Phactr1(MRTF-NR) chimera showing the 
replacement of the Phactr1 RPEL domain with the N-terminus and RPEL domain of 
MRTF-A. B and C. Cells were transfected with Phactr1(MRTF-NR) chimera and the 
indicated derivatives. After overnight starvation the cells were treated with 15% 
FCS for 30 min or 50nM LMB for 2 hours. Localisation of each protein was 
determined by immunofluorescence using an anti-Flag antibody. At least 100 cells 
were counted and localisation was scored as predominantly nuclear (navy blue), 
pancellular (lilac) or predominantly cytoplasmic (light blue).  Error bars represent 
standard error of the mean (SEM) from at least two independent experiments. 
 
5.5 RPEL domain sequences cooperate with the N-terminus for 
export activity 
 
 To investigate the N-terminal export signal in more detail, a NES detection 
assay was used (B. R. Henderson and Eleftheriou, 2000). The assay is based on 
the HIV protein Rev, which shuttles between the cytoplasmic and nucleus, where it 
accumulates in nucleoli. Rev is imported via importin-beta interaction with its 
arginine rich NLS (B. R. Henderson and Percipalle, 1997) and exported via a Crm1 
dependent NES (Fornerod et al., 1997). Rev shuttling ceases upon inactivation of 
its NES resulting in nuclear accumulation. Henderson et al. exploited this 
observation to map NES elements, by insertion of sequences into a NES-
inactivated Rev-GFP derivative (hereafter RevΔ) (Figure 5.6A,B). I used this 
approach to determine the exact location of the N-terminal NES and investigate the 
mechanism that underlies its dependency on actin for Crm1 mediated export. 
Insertion of the MRTF-A RPEL domain alone did not relocalise RevΔ (figure 
5.6D). This domain also contains additional NLS elements, B2 and B3, one of 
which overlaps with a putative NES (NES2, see Figure 5.1). The combined import 
conferred by the RevΔ NLS and B2B3 NLS could mask potential export activity. 
Mutation of either the B2 or B3 NLS element did not result in detectable export 
activity (Figure 5.6D). This result supports the notion that there is no effective NES 
within the RPEL domain. 
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In contrast, inclusion of the MRTF N-terminus, resulted in significant 
relocalisation suggesting that it contains an NES (Figure 5.6E). In addition export 
activity was reduced upon FCS and LMB treatment, consistent with regulated Crm1 
dependent export. To test whether nuclear accumulation is regulated at the level of 
export and not import, the B2 and B3 NLS elements embedded in the RPEL 
domain were inactivated, yielding derivatives where import was driven only by the 
RevΔ NLS. Inactivation of the B2 NLS element resulted in almost entirely 
cytoplasmic localisation in starved conditions, but allowed accumulation in the 
nucleus after FCS stimulation, showing that depletion of G-actin levels reduced its 
export activity. Therefore export is promoted by G-actin. Sensitivity of Rev 
(NT+RPEL) B2A to LMB treatment indicated Crm1 mediated export.  
The partial regulation observed, evident by the weak nuclear accumulation 
after FCS, suggests that export is not entirely blocked by actin depletion. Evidence 
for actin independent mediated export of MRTF-A has been reported previously 
(Guettler et al., 2008). FLIP analysis showed that although MRTF-A (2-204) xxx-
2GFP was nuclear, it was still exported. 
Rev (NT+RPEL) xxx, that cannot bind actin, is entirely nuclear in resting 
conditions (Figure 5.6F). Upon mutation of the B2 element export activity was 
detected indicating that actin independent export was indeed occurring. LMB 
treatment confirmed that Crm1 mediated export could occur in the absence of actin. 
Regulation in response to FCS stimulation was lost however, in agreement with the 
previous observation that actin promotes export (Figure 5.6E).  
Rev (NT+RPEL) B2A xxx nuclear accumulation is more efficient than that of 
its actin binding equivalent, Rev (NT+RPEL) B2A, suggesting that actin binding is 
regulating import in this context.  
Taken together, the data suggest that the N-terminus contains an NES. 
Export activity exhibited by residues 2-204 of MRTF-A (N-terminus+RPEL) is actin 
independent, and can be potentiated by actin binding to the RPEL domain.  
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Figure 5.6 The N-terminus and RPEL domain together provide Crm1 
dependent and actin regulated export 
A. Rev export assay: The schematic shows the Rev-GFP (RevΔ) construct used as 
an export signal reporter. The Rev NLS is shown in a dark grey box and the 
location of the inactivated Rev NES is shown in a yellow box crossed out. The site 
of insertion of a putative NES to be tested is shown by dotted lines. B. Left: 
immunofluorescence images of cells transfected with RevΔ or the positive control 
where the intact NES of Rev is inserted to provide Crm1 mediated export. Right: 
quantification of the localisation of the negative and positive controls. At least 100 
cells were counted and localisation was scored as predominantly nuclear (navy 
blue), pancellular (lilac) or predominantly cytoplasmic (light blue). C-F. Cells were 
transfected with Rev constructs in which either the MRTF-A RPEL domain was 
inserted, or the RPEL domain including the N-terminus (NT+RPEL), or NT-RPEL 
xxx, which doesn’t bind actin. Following serum starvation cells were stimulated with 
15% FCS for 30 min or 50nM LMB for 2 hours. 
 
5.6 Mapping the N-terminal NES 
 
The previous data suggest Crm1 mediated export is independent of actin in 
MRTF-A N-terminal sequences. To test this directly, residues 2-67 were inserted 
into RevΔ. Rev (2-67) exhibited Crm1 dependent export (Figure 5.7B, construct B), 
confirming the N-terminus contains an autonomous NES. However, export activity 
exhibited by Rev (2-67) was markedly lower than Rev (2-204) B2A, suggesting that 
the RPEL domain enhances export activity. Although residues 67-115 did not 
confer export, they enhanced export activity of the N-terminal residues 2-67 (Figure 
5.7B, construct C and D respectively). 
In the Rev assay, weak NESs can restore shuttling but not cause 
relocalisation, as this requires the NES activity to be sufficient to overcome the rate 
of import. Actinomycin D (ActD), prevents nucleolar accumulation of Rev by an 
unclear mechanism that involves nucleolar dissociation (B. R. Henderson and 
Eleftheriou, 2000). ActD therefore lowers the threshold for NES detection. 
Nevertheless, after ActD treatment, residues 67-115 did not exhibit export activity, 
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suggesting that they do not contain an additional autonomous NES (Figure 5.7C 
construct C). In contrast, residues 67-204, corresponding to the RPEL domain, 
relocalised Rev to the cytoplasm in the presence of ActD (Figure 5.7C, construct A). 
Export activity however, was not LMB sensitive. Together, the results suggest that 
a non-Crm1 dependent NES is present between residues 115-204 of the RPEL 
domain. 
The capacity of the above RPEL domain fragments to bind actin 
complicates interpretation of the results. I attempted to map minimal sequences 
within the N-terminal region. Surprisingly, while residues 2-67 confer export activity, 
40-70 and 30-60 showed no activity, but 35-52 were active (Figure 5.8 construct 
A,B,C). Again, these results were more pronounced in the presence of ActD. 
Together these results suggest that there is a Crm1-dependent export signal within 
2-67 and the minimal core for this is 35-52.  
Because previous data from a peptide array implicated Spacer1 sequences 
in Crm1 binding, residues 85-110 and 89-104 were also tested for export activity. 
No export activity was detected with or without ActD (Figure 5.8B construct D and 
E), in agreement with the data presented in figure 5.7C.  
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Figure 5.7 The RPEL domain potentiates the export activity of the N-terminus 
A. Schematic showing the MRTF-A N-terminus + RPEL domain and a summary of 
the different segments tested in the Rev assay. B. Rev assay carried out as 
described for Figure 6, to test the various RPEL fragments for NES activity. Where 
indicated cells were treated with 50nM LMB for 2 hours. At least 100 cells were 
counted and localisation was scored as predominantly nuclear (navy blue), 
pancellular (lilac) or predominantly cytoplasmic (light blue). C. Rev assay testing 
the indicated segments. Where indicated, cells were treated with actinomycin D to 
decrease the activity of the Rev NLS and increase the assay sensitivity to NES 
activity. Error bars represent standard error of the mean (SEM) from at least two 
independent experiments. 
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Figure 5.8 A short sequence containing the N-terminal NES is sufficient for 
export 
A. Summary of RPEL segments tested in the Rev export assay. B. Cells were 
transfected with the indicated derivatives and starved overnight. Actinomycin D was 
added for 6 hours where indicated. LMB was added during the last two hours of the 
experiment. At least 100 cells were counted and localisation was scored as 
predominantly nuclear (navy blue), pancellular (lilac) or predominantly cytoplasmic 
(light blue). 
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5.7 Actin binding to RPEL1 may facilitate export 
 
 RPEL1-Spacer1 (67-115) might facilitate the export conferred by the N-
terminus (2-67) either by enhancing interaction with Crm1 or through its ability to 
bind actin. To determine whether actin binding to RPEL1 was important three 
different ways to perturb actin binding by RPEL1 were employed.  Previous studies 
showed that loss of contact mutations in ɑ1-helix and ɑ2-helix in RPEL1, ɑ1AA and 
ɑ2AAA respectively, severely affect the actin binding capacity of RPEL1. Both 
mutations lead to partial nuclear accumulation of full length MRTF-A. In contrast, 
although mutation of R81 in the R-loop between the two helices, decreases affinity 
of the RPEL1 for actin, it deregulates shuttling of MRTF-A to a lesser extent 
compared to the ɑ-helix mutations (Mouilleron et al., 2008).  
 The ɑ1AA and ɑ2AAA mutations led to a small decrease in export of Rev (2-
115), suggesting that actin binding only weakly promotes export in this context. 
Unexpectedly, the weaker R81A mutation led to an increase in export activity 
(Figure 5.9A). There is therefore no simple correlation with ability to bind actin. 
 Because RPEL1-R81A can still bind actin, I tested whether increasing G-
actin levels would promote actin binding and restore the regulation back to that of 
Rev (2-115). Expression of C3-transferase, which inhibits Rho function and 
increases the proportion of G-actin (Posern et al., 2004), did not however have an 
effect (Figure 5.9B). Further experiments are required to determine if the increased 
export caused by the R81A mutation is due to a change in actin binding or the 
arginine residue per se. An alternative approach could be to co-transfect increasing 
amounts of non-polymerisable actin R62D. 
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Figure 5.9 Presence of RPEL1-Spacer1 potentiates NES activity of the N-
terminus 
A. Rev export assay: Cells were transfected with the indicated Rev constructs, 
starved overnight and treated with 50nM LMB for 1 or 2 hours. B. Cells were co-
transfected with the indicated Rev constructs and C3-transferase. After overnight 
starvation cells were treated for 1 or 2 hours with 50nM LMB. At least 100 cells 
were counted and localisation was scored as predominantly nuclear (navy blue), 
pancellular (lilac) or predominantly cytoplasmic (light blue). Error bars represent 
standard error of the mean (SEM) from at least two independent experiments. 
 
 
5.8 Leucine rich NES in the N-terminus directly binds Crm1 
 
 To map the residues that define the N-terminal NES in detail I carried out an 
alanine substitution scan, moving across the N-terminus in triplets (Figure 5.10A). 
The Rev (2-115) construct was used, as it was the simplest construct exported 
efficiently enough to have a good range.  
 The scan revealed that the three mutants spanning residues 41-49, each of 
which contained sequences of the putative NES, did not exhibit export activity (Fig 
5.10B), consistent with the tested minimal sequence 35-52 in Figure 5.8. This 
sequence, which corresponds to the predicted NES1 in Figure 5.1, resembles a 
typical leucine-rich export signal, although it scored below threshold in the 
prediction. Other residues appeared to affect export, including a triplet of acidic 
residues DDE in positions 20-22 and PPL in positions 65-67. 
 I next investigated whether Crm1 directly interacts with the sequence 
identified. Using purified recombinant proteins GST pulldowns were performed with 
the N-terminus (residues 2-67), the better-exported NT-RPEL1-Spacer1 (residues 
2-115) and the RPEL domain (residues 67-199) (Figure 5.11). Reactions were 
carried out with or without RanGTP, which is required for Crm1-cargo interaction 
(see chapter 1.2). The N-terminus alone was sufficient to interact with Crm1. 
Mutation of residues LSL 46-48, the NES anchor point (ɸxɸ) (Güttler et al., 2010) to 
alanine, abolished this interaction. GST-2-115 recovered Crm1 more efficiently and 
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the interaction was again entirely dependent on the integrity of residues LSL 46-48. 
GST-67-199 was unable to efficiently interact with Crm1 but did indeed recover 
some Crm1 in a RanGTP dependent manner. The efficiencies with which the GST-
baits bind Crm1 reflect their performance in the Rev assay. 
 The role of the sequence identified was examined in the context of shorter 
or longer constructs in the Rev assay (Figure 5.12A). In agreement with the alanine 
scanning results, both 2-67 and 2-115 are completely dependent on NES core 
residues 46-48 for export (Figure 5.12 B). Moreover, these residues are required 
for Crm1 dependent export of Rev (2-204) B2A.  
I have shown previously that the RPEL domain alone (67-204) does not 
show Crm1 dependent export, but promotes export activity of the N-terminal 
sequences and enable actin regulation. Ablation of the N-terminal NES reduced 
export of Rev (2-204) B2A revealing residual Crm1-independent export in 
agreement with Figure 5.7C (construct A). However residual export was not serum 
regulated, suggesting that it is also actin independent, suggesting that actin-
regulated export required the N-terminal NES in this context.  
In summary, these results confirm that a leucine rich export signal within the 
N-terminus of MRTF-A is required for direct interaction with Crm1. This interaction 
is enhanced in the presence of RPEL1-Spacer1 and further enhanced by the entire 
RPEL domain (67-204), which also enables regulation by actin. Rev (2-204) B2A 
exhibits both Crm1 dependent and independent export. A caveat in this context is 
that the B2A mutation, which is necessary for enabling assessment of changes in 
export, possibly affects an overlapping export signal. 
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Figure 5.10 Classical NES element in the N-terminus of MRTF-A 
A. Schematic representation of the Rev-MRTF-A (2-115)-GFP derivative used in 
the alanine scan. The N-terminus is expanded to show the residues across which 
the alanine scan was carried out. Consecutive triplets of residues mutated are 
indicated with brackets below; the location of Ser33 is indicated with a phosphate 
symbol. B. Cells were transfected with the various Rev-MRTF-A-(2-115)-GFP 
derivatives and starved overnight. At least 200 cells were counted and localisation 
was scored as predominantly nuclear (navy blue), pancellular (lilac) or 
predominantly cytoplasmic (light blue). 
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Figure 5.11 Crm1 directly interacts with the MRTF-A N-terminus 
Recombinant GST MRTF-A segments were used in a pulldown with Crm1. AAA 
represents LSL46-48AAA mutation of the N-terminal NES. Top panel is an 
immunoblot using an anti-Crm1 antibody. Bottom three panels are Coomassie 
stained gels showing the GST baits, Crm1 input and RanQ69L input.  
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Figure 5.12 RPEL domain enhances N-terminal NES activity 
A. Summary of the RPEL segments used in the Rev export assay. The location of 
the alanine substitutions intended to inactivate the NES is shown in a grey box. B. 
Cells were transfected with the indicated constructs, starved overnight and treated 
with 15% FCS or 50nM LMB for 30 min and 2 hours respectively. At least 200 cells 
were counted and localisation was scored as predominantly nuclear (navy blue), 
pancellular (lilac) or predominantly cytoplasmic (light blue). 
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5.9 Probing Spacer1 for an export signal 
 
 The spacers in the MRTF-A RPEL domain, and their ability to bind actin are 
important for MRTF-A localisation (Mouilleron et al., 2011). In data presented so far, 
spacer1 alone did not demonstrate export activity but was present in the 
sequences that enhanced export activity of NES1 in the Rev assay and Crm1 
interaction in the pull down. This region bears similarity to a structure based 
consensus for Crm1 binding (Figure 5.13A) described by (Güttler et al., 2010). In 
addition, the presence of S98 in the sequence makes it tempting to speculate that 
its phosphorylation may inactivate the export signal. 
 To investigate whether a NES is present, Rev 2-115 was used. The 
residues reported to be important for the putative NES were substituted to alanine 
(Figure 5.13). Alanine substitution of P94 or L96 individually or in combination, had 
no effect on localisation. Positions of the hydrophobic residues are not all equally 
important, particularly if other hydrophobic residues are sufficiently strong. The 
alanine substitutions may therefore be tolerable. (Güttler et al., 2010) show that in 
certain cases alanine substitutions of each residue does not necessarily abolish 
Crm1 binding. Upon exchange of the critical proline to a serine, a small increase in 
nuclear accumulation was observed. The data therefore do not support the 
presence of an NES in Spacer1.  
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Figure 5.13 Probing Spacer1 for an export signal 
A. Alignment of a putative NES in spacer1 with the Rev-like non-canonical NES. B. 
Cells were transfected with the various Rev constructs with point mutations 
intended to disrupt the putative non-canonical NES. At least 200 cells were counted 
and localisation was scored as predominantly nuclear (navy blue), pancellular 
(lilac) or predominantly cytoplasmic (light blue). 
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5.10  Probing Spacer 2 for an export signal 
 
 Overlapping the NLS B2 region within spacer2, is a set of leucine residues 
which resemble a Crm1 consensus site (Figure 5.14A). This sequence was 
detected by the prediction algorithm but scored significantly below the threshold 
(NES2 in Figure 5.1).  Alanine substitution of the anchor point leucines, L151 and 
L153 led to nuclear localisation of the MRTF-PK fusion (R. Pawlowski, preliminary 
data).  
 Alanine or aspartate substitution of L153, results in opposite effects on full 
length MRTF-A-(2-204)-PK localisation. L153A increases nuclear localisation 
without affecting import (Mouilleron et al., 2011). L153D decreases nuclear 
localisation by affecting import rate and additionally affecting actin binding to 
spacer2. To gain further insight alanine or aspartate derivatives of L153 were 
tested using the Rev assay. 
 Rev 67-204 was nuclear and neither B2A nor 153D affected this localisation 
(Figure 5.14B). In Rev 2-204 the 153A mutation led to nuclear accumulation 
(Figure 5.14C). Since the 153A mutation does not affect import, nuclear localisation 
may be a result of diminished export. It is not clear whether it is through direct 
disruption of the putative NES or indirectly through affecting actin binding to 
spacer2. The 153D mutation led to a small decrease in nuclear accumulation, 
because the acidic substitution is in the NLS and may be affecting importin binding. 
The small defect may reflect a simultaneous loss of export activity. 
 To gain further insight into the effect of L153A, RPEL3 mutated derivatives 
could be used. Actin binding to spacer2 is RPEL3 dependent. Preventing actin 
binding to spacer2 could reveal whether 153A perturbs NES activity. 
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Figure 5.14 Probing Spacer 2 for an export signal 
A. Schematic of MRTF-A RPEL domain. Spacer 2 is expanded to show the 
residues mutated in the following experiment. Spacer 2 mutations were tested in 
the context of the RPEL domain or N-terminus + RPEL as indicated. AAA indicates 
mutation of the NES in the N-terminus. B and C. Rev export assay. Cells were 
transfected with the indicated constructs, starved overnight and treated with 15% 
FCS or 50nM LMB for 30 min and 2 hours respectively. At least 200 cells were 
counted and localisation was scored as predominantly nuclear (navy blue), 
pancellular (lilac) or predominantly cytoplasmic (light blue). 
 
 
5.11  The role of S33 and S98 in regulation of export 
 
As shown in Chapter 4, S33 that is basally phosphorylated blocked nuclear 
accumulation of MRTF-A (2-204) PK. S98 is not phosphorylated in resting 
conditions and its phosphorylation is required for nuclear accumulation of MRTF-A 
(2-204) PK in response to ERK signalling. To investigate how S33 and S98 affect 
export, derivatives were tested in the context of Rev (2-67) and Rev (2-204). In 
both contexts S33D promoted export, while S33A made export less efficient, 
suggesting that phosphorylated S33 facilitates the function of the NES (Figure 
5.15A). 
Substitutions of S98 were less clear. In the context of 2-115, mutations of 
S98 did not affect export (Figure 5.15B). However I have shown that in this context 
S98 is not able to affect actin binding to RPEL1.  
The effects of S33 and S98 were also investigated in the context of Rev (2-
204) B2A (figure 5.15C). As observed with 2-115, in this context S33A was more 
nuclear. S33D did not appear to have an effect, however it appears to be at the 
lower detection limits of the assay. Rev (2-204) B2A is already cytoplasmic in the 
majority of cells and it is possible that higher export levels cannot be detected.  
The S98A and S98D mutations caused a small increase in nuclear 
localisation despite the fact that one mimics phosphorylation and the other is 
phospho-deficient. This may be due to a requirement for serine in that position. 
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Since aspartate substitution of S98 abolished actin binding from RPEL1 in-vitro, it 
could be expected to cause nuclear localisation comparable to that of the mutant 
that cannot bind actin on RPEL1 (ɑ1AA) (Figure 5.15 C). One explanation for the 
difference between ɑ1AA and S98D is that under starved conditions, when G-actin 
concentrations are relatively high, RPEL1 can still bind actin even with the 
disruption by S98D. Mutation of the RPEL1 ɑ-helix appears to be a more severe 
disruption.  
Together the data show that S33 phosphorylation promotes export activity of 
the N-terminal NES and that it is phosphorylated in the absence of stimulation, in 
accordance with the findings in Chapter 4. The effect of S33 is more likely to be 
direct, for example by forming a better substrate for Crm1. The small decrease in 
export observed with S98D is likely to be indirect through affecting actin loading of 
the RPEL domain. 
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Figure 5.15 The role of S33 and S98 in MRTF-A export 
A. Cells were transfected with Rev-MRTF-A-(2-67)-GFP or Rev-MRTF-A-(2-115)-
GFP S33 mutants, starved overnight and treated with 15% FCS or 50nM LMB for 
30 min and 2 hours respectively. B. Cells were transfected with Rev-(2-115)-S98 
derivatives and treated as above. C. Cells were transfected with Rev-MRTF-A-(2-
204)-GFP derivatives and treated as in A. At least 100 cells were counted and 
localisation was scored as predominantly nuclear (navy blue), pancellular (lilac) or 
predominantly cytoplasmic (light blue). Error bars represent standard error of the 
mean (SEM) from at least two independent experiments. 
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Chapter 6. Discussion 
 
 
6.1 Outline 
 
In the present thesis I have analysed the role of phosphorylation as a 
regulatory mechanism of MRTF-A. MRTF-A is phosphorylated on multiple serine 
and threonine residues upon ERK activation or G-actin depletion. I have shown that 
overall phosphorylation of MRTF-A is required for its full capacity to activate 
transcription.  
 Although the phosphorylation sites are spread throughout MRTF-A, S98 is 
the only one located within the RPEL domain. I have shown that S98 is 
phosphorylated by ERK, which promotes MRTF-A nuclear accumulation by 
blocking actin binding to RPEL1. S98 therefore provides a means for ERK 
signalling to affect the ability of MRTF-A to sense Rho-actin signalling. 
Not all phosphorylation positively regulates MRTF-A function. S33 is located 
in the N-terminus of MRTF-A, close to the RPEL domain, and phosphorylation of 
S33 promotes MRTF-A export. The mechanism by which pS33 promotes MRTF-A 
export is likely to involve an adjacent leucine rich region shown to directly bind 
Crm1 and mediate MRTF-A export. This leucine rich region is an NES that 
cooperates with the RPEL domain to confer actin dependent nucleocytoplasmic 
shuttling. 
In the following sections, the impact of MRTF-A phosphorylation on its 
function will be discussed. In addition, evidence will be presented on how S33 and 
S98 phosphorylation impacts how the N-terminus of MRTF-A regulates its 
nucleocytoplasmic shuttling. 
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6.2 Rho and MEK-ERK signalling converge on MRTF-A 
 
FCS stimulation leads to MRTF-A phosphorylation that can be visualised as 
a reduction in electrophoretic mobility. Inhibition of either Rho signalling using C3-
transferase, or MEK-ERK signalling using U0126, attenuates FCS-induced MRTF-
A phosphorylation. Inhibition of both signalling pathways effectively blocks MRTF-A 
phosphorylation (Miralles et al., 2003). Therefore in addition to sensing Rho-actin 
signalling, MRTF-A is also responsive to MAPK signalling.  
MRTF-A thus appears to integrate signalling from the two pathways, which 
can be seen at the level of phosphorylation and activity. Levels of MRTF-A 
transcriptional activity correlate with phosphorylation levels. SRF/MRTF-A target 
gene activity, measured by qRT-PCR, is higher when both pathways are activated 
compared to when each pathway is active alone. MRTF-A phosphorylation levels 
are also highest when both pathways are activated and partial when only one 
pathway is activated. 
 MAPK-mediated MRTF-A phosphorylation in the actin-sensing domain 
provides a mechanism by which the MAPK pathway can cooperate with Rho 
signalling, for MRTF-A regulation. 
 Measuring reduction of electrophoretic mobility does not allow for 
quantitative measurement of phosphorylation, in part because not all 
phosphorylations lead to a reduction in electrophoretic mobility and because the 
average of a cell population of cells is taken into account. Using stable isotope 
labelling by amino acids in cell culture (SILAC) would enable quantitative 
measurements and determination of the phosphorylation kinetics of individual sites. 
It could therefore be possible to distinguish between early (possibly activating) 
phospophorylation events and later (possibly inactivating) ones. 
 
6.3 Actin controls phosphorylation 
 
Phosphorylation of MRTF-A is regulated by actin binding to the RPEL 
domain. Rho activates multiple downstream effectors, however three lines of 
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evidence agree that it is G-actin depletion that results in MRTF-A phosphorylation. 
First, coexpression of an activated form of the formin mDia1, which induces F-actin 
nucleation, is sufficient to cause MRTF-A phosphorylation. Second, direct 
disruption of the actin-MRTF-A interaction by CD is also sufficient for partial 
phosphorylation. Third, MRTF-A xxx, that does not bind actin, is constitutively 
phosphorylated. Constitutive phosphorylation of MRTF-A xxx, in the absence of 
any manipulations of actin, suggests that actin suppresses MRTF-A 
phosphorylation.  
Because actin regulates MRTF-A nuclear export, actin dissociation leads to 
MRTF-A phosphorylation but also simultaneous nuclear accumulation. This raises 
the issue of whether phosphorylation reflects actin dissociation or nuclear 
localisation. However nuclear accumulation without compromising actin binding, 
achieved by LMB treatment, is not sufficient for MRTF-A phosphorylation. 
Considering that the import defective derivative MRTF-A B2A does not become 
phosphorylated after CD treatment, then a nuclear kinase or kinases must target 
MRTF-A. 
Actin can therefore regulate MRTF-A phosphorylation by spatially 
separating MRTF-A from the nuclear kinases and either (i) by blocking access of 
the kinase to MRTF-A or (ii) promoting interaction with a phosphatase that 
continuously dephosphorylates MRTF-A. 
 
6.4 What are the kinases that phosphorylate MRTF-A? 
 
 MRTF-A is phosphorylated by ERK, as well as other kinases, which are 
constitutively active and nuclear. Given that all phosphorylation sites on MRTF-A 
are S/T-P sites, these kinases should be proline-directed kinases. Experiments 
presented in this thesis implicate the Cdk family in MRTF-A phosphorylation. While 
depletion of single Cdk family members did not affect MRTF-A activity, 
pharmacological inhibition of multiple Cdks resulted in inhibition of MRTF-A activity. 
These observations suggest redundancy between the Cdks that phosphorylate 
MRTF-A. 
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 Depletion or pharmacological inhibition of DYRK family members had gene 
specific effects on MRTF-A target genes and also affected transcription of the non-
MRTF-A target Egr1. Although DYRKs phosphorylated full length MRTF-A in-vitro, 
it is not necessarily the case in-vivo. It is therefore unlikely that DYRKs directly 
regulate MRTF-A activity. 
ERKs, Cdks and DYRKs belong to the CMGC kinase group and within the 
family ERKs and Cdks are more closely related (Manning et al., 2002). Although 
not the only determinant of substrate specificity, the three kinase families share 
similar phosphorylation consensus sequences. ERK: Px(S/T)P, DYRK1A: 
RPx(S/T)P, DYRK2/3: Rx(S/T)P and Cdks: (S/T)Px(K/R) (ERK and Cdk: (Pinna 
and Ruzzene, 1996; Songyang et al., 1994; 1996) DYRKs: (Himpel et al., 2000; 
Aranda et al., 2011)). It has previously been reported that Cdks and ERK can 
phosphorylate the same residues on a protein (Aoki et al., 2013; Brumbaugh et al., 
2014; Voong et al., 2008).  
Both Cdks and ERK1/2 have been shown to regulate transcription through 
phosphorylation of the C-terminal domain (CTD) of RNA Pol II (Bonnet et al., 1999; 
Eick and Geyer, 2013). I have shown that ternary complex formation is not required 
for MRTF-A phosphorylation, suggesting that MRTF-A can interact with its 
kinase(s) independently of SRF or promoter association. In addition, inhibition of 
Cdks using flavopiridol, blocked CD-induced phosphorylation of MRTF-A and 
reporter activation. It is therefore conceivable that MRTF-A recruits Cdks to the 
promoters of target genes, and is also phosphorylated by Cdks itself.  
In support of this notion, unpublished data by F. Gualdrini showed that Cdk-
dependent Ser2 phosphorylation of the C-terminal domain of Pol II and productive 
transcription of MRTF/SRF targets require actin dissociation from MRTF-A. A 
similar scenario has been reported for NF-κB, which is required for recruitment of 
Cdk9/CyclinT to the IL-8 gene for TNFα induced transcription (Barboric et al., 2001). 
To investigate whether MRTF-A can directly associate with Cdks, 
coimmunoprecipitation and pull-down experiments could be carried out. However 
these approaches would not provide information on whether MRTF-A recruits the 
kinases to promoters. 
 
Chapter 6. Discussion 
 
 241 
6.5 The role of phosphorylation in MRTF transcriptional 
activity 
 
 To assess the potential role of MRTF-A phosphorylation on transcriptional 
activation of its target genes, an MRTF-A activity reporter was used. The MRTF-A 
activity reporter used contains 3 copies of the Fos SRF binding site that drive 
transcription of the luciferase enzyme. The Fos derived sequences are modified so 
that they are not sufficient for TCF binding (Hill et al., 1995), and thus transcription 
of luciferase is dependent on MRTF-A/SRF signalling. Transcriptional activation of 
the MRTF-A reporter gene by the phosphorylation-deficient derivative E3, in which 
most but not all phosphorylation sites were replaced by alanine, was impaired. The 
26ST/A derivative, in which all phosphorylation sites were replaced by alanine, was 
no more defective, suggesting that there may be a threshold stoichiometry, beyond 
which MRTF-A activity is potentiated. Phosphorylation of MRTF-A on multiple sites 
is therefore required for full transcriptional activation. 
 Although the reporter specifically allows measurement of MRTF-A activity, 
the assay has certain limitations that should be considered. Transcriptional 
activation of MRTF targets, measured by qRT-PCR of introns, is transient and 
occurs over a period of 2 hours after stimulation. In the reporter assay activity is 
quantified indirectly by measuring the amount of luciferase protein produced. The 
measurement is therefore one of the combined processes of transcription and 
translation. As opposed to endogenous targets, the coding sequence in the 
reporter is intronless and is therefore subject to fewer regulatory processes that 
can affect the rate and minimum requirements of transcription (Lynch, 2006). In 
addition, the transiently transfected reporter is not necessarily in a bona fide 
chromatin context and may not be subjected to all regulatory processes that need 
to be overcome in the case of endogenous target genes. For example if MRTF-A 
promotes transcription activation through recruitment of chromatin remodellers, the 
process will be redundant in the reporter context.  
 After depletion of MRTF-A/B, FCS or CD stimulation resulted in effectively 
no reporter activity. Subsequent transfection of MRTF-A led to increased baseline 
activity, which could be a result of titrating out negative regulators. There was no 
appreciable difference between MRTF-A and 26ST/A in unstimulated conditions, 
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suggesting that the two proteins exhibit similar activity in conditions under which 
MRTF-A is basally phosphorylated. Differences in activity were observed in 
stimulated conditions, when MRTF-A would be phosphorylated at high 
stoichiometry. However the 26ST/A derivative was not completely inactive. 
Remaining activity could be a consequence of dimerisation with residual 
endogenous MRTF-A, which can heterodimerise with 26ST/A.  
It was previously reported that after siRNA depletion, residual MRTF-A can 
dimerise with transfected derivatives and contribute to reporter activation 
(Pawłowski et al., 2010). It is especially apparent when comparing the MRTF-A 
Y330A (SRF binding deficient) with or without the leucine zipper (Figure 3.4). 
MRTF-A Y330A appears to act in a dominant negative manner, only when it can 
dimerise with the residual endogenous MRTF-A. 
Interpretation is further complicated by the presence of multiple 
phosphorylation sites, which can affect different regulatory processes, for example 
localisation (Muehlich et al., 2008), transactivation and SRF binding. At least two 
sites, S33 and S98, not only affect localisation, but also exert opposite effects. 
26ST/A xxx, is not regulated at the level of localisation and was considerably less 
able to stimulate reporter activity. 
In the context of xxx, regulation of phosphorylation is uncoupled from 
nuclear accumulation. The possibility of dimerisation however remains and it would 
therefore be interesting to test whether deletion of the leucine zipper would abolish 
the remaining activity of 26ST/A xxx. Partially phosphorylated MRTF-A xxx, can be 
further phosphorylated by activation of the MAPK pathway (Figure 6.1A). 
Preliminary data show that activation of the MAPK pathway potentiates MRTF-A 
xxx activity (Figure 6.1B).  
Phosphorylation therefore promotes MRTF-A activity. Further work is 
required to determine whether phosphorylation is essential for transcriptional 
activity rather than merely enhancing it. To avoid heterodimerisation with 
endogenous MRTF-A, MRTF-A/B KO MEFs could be transfected with MRTF-A xxx 
or 26ST/A xxx. In the absence of possible heterodimerisation, a defect in 
endogenous gene activity in 26ST/A xxx transfected cells, would strongly support a 
positive regulatory role for phosphorylation. In addition, chromatin 
immunoprecipitation can be carried out, to assess whether phosphorylation affects 
ternary complex formation. 
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 In this study, comparison between different MRTF-A derivatives involved 
transient transfection. This approach leads to a population of cells expressing 
different levels of MRTF-A derivatives, which are pooled before transcriptional 
activity is assessed. The importance of MRTF-A abundance in target gene 
expression is evident in Figures 3.4 and 3.7. Future work should involve generation 
of cell lines stably expressing comparable levels of MRTF-A derivatives. This can 
be accomplished by fluorescence assisted cell sorting (FACS) after which cells can 
be grouped according to expression of MRTF-A GFP. Additionally complications 
arising from cell heterogeneity can be circumvented using single cell analysis, such 
as single cell RNA sequencing. 
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Figure 6.1 MAPK signalling promotes full phosphorylation and activation of 
MRTF-A 
A. Cells transfected with the indicated constructs were maintained in 0.3% FCS 
overnight and stimulated with 15% FCS as indicated. Cell extracts were resolved 
by SDS-PAGE on a 7% polyacrylamide gel and MRTF-A was detected by 
immunoblotting. B. MRTF-A activity reporter assay. NIH-3T3 cells depleted of 
endogenous MRTF-A using siRNA, were transfected with p3D.A and ptkRL 
luciferase reporter plasmids and the indicated MRTF-A derivatives. After incubation 
in 0.3% FCS overnight, cell extracts were prepared and assessed for luciferase 
activity. Error bars represent standard error of the mean (SEM) from at least two 
independent experiments. 
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6.6 Regulation of MRTF-A nuclear accumulation by ERK 
 
Activation of ERK by TPA treatment leads to MRTF-A nuclear accumulation, 
phosphorylation, and activation of MRTF-A. The data presented in this thesis show 
that MRTF-A accumulates in the nucleus upon TPA treatment, despite elevated G-
actin levels. The nuclear accumulation observed, at least in part, required ERK 
mediated phosphorylation of S98 in the RPEL domain. In the MRTF-A-(2-204)-PK 
fusion protein, the N-terminus of MRTF-A including the RPEL domain, can be 
studied separately from the other phosphorylation sites and regulatory elements in 
the rest of the protein. This allowed investigation of the mechanism by which ERK 
signalling affects how the N-terminus contributes to MRTF-A shuttling. Specific 
activation of ERK, using the constitutively active MEK derivative MEK R4F or the 
tamoxifen-inducible RafER fusion protein, resulted in S98-dependent nuclear 
accumulation of MRTF-A-(2-204)-PK. Phosphorylation of S98 blocks actin binding 
to RPEL1 and promotes nuclear accumulation of MRTF-A.  
TPA treatment also leads to a two-fold increase in S33 phosphorylation, 
however S33 phosphorylation promotes export of MRTF-A from the nucleus. S33 is 
basally phosphorylated in unstimulated conditions. Substitution to alanine promotes 
nuclear accumulation, while aspartate substitution prevents nuclear accumulation 
by potentiating export. 
It has previously been shown that TPA stimulation leads to MRTF-A 
phosphorylation (Muehlich et al., 2008). In contrast to the data presented in this 
thesis, Muehlich et al. proposed that phosphorylation promotes export through 
increased actin binding. The authors showed that MRTF-A STS544/545/549AAA, 
in which the three residues they mapped were substituted to alanine, was 
constitutively nuclear. According to their view, phosphorylation of these sites is 
required for actin association and nuclear export. This implies that basal 
phosphorylation of these sites is involved in the maintenance of cytoplasmic 
localisation of MRTF-A in unstimulated cells. The relevance of their findings to 
signalling is therefore unclear. Because the experiments presented were carried 
out in HeLa cells, we wanted to confirm this observation in our NIH-3T3 system.  
Contrary to their observations, I found that MRTF-A STS544/545/549AAA 
was cytoplasmic in starved conditions and accumulated in the nucleus after 
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stimulation both in 3T3 and HeLa cells. The experiments presented by Muehlich et 
al. were carried out using an N-terminally truncated MRTF-A, MRTF-A(met),  
starting at Spacer1 (Muehlich et al., 2008). I therefore generated an analogous 
derivative by deletion of the first 92 residues (N-terminus + RPEL1) of full length 
MRTF-A. The truncation itself led to an increase in nuclear accumulation, 
consistent with the loss of the N-terminal Crm1-dependent MRTF-A nuclear export 
signal described below. However, again, nuclear accumulation was not further 
increased by alanine substitution of S544, T545 and S549. 
Muehlich and colleagues also reported that in 3T3 cells TPA treatment 
blocks reporter activation by subsequent FCS stimulation (Muehlich et al., 2008). In 
their view, this reflects ERK-mediated phosphorylation of S544, T545 and S549, 
leading to heightened nuclear export, and therefore antagonising the effects of 
serum (Muehlich et al., 2008). In contrast, other work (R Pawlowski), found that 
blockade of ERK signalling does not relieve the blockade of the serum response 
and that instead TPA blocked FCS activation because of PKC-mediated 
downregulation of RhoA activity and consequent high G-actin levels.  
In this thesis I present evidence that ERK activity impinges on MRTF-A 
regulation, by phosphorylating S98 in the RPEL domain, which is the major 
regulatory domain in MRTF-A. In addition ERK can also phosphorylate other sites 
in MRTF that contribute to full activity of MRTF-A. 
 
6.7 S98 phosphorylation affects actin binding to RPEL1 
 
MRTF-A shuttling is controlled by actin, which is sensed via the N-terminally 
located RPEL domain (Miralles et al., 2003; Vartiainen et al., 2007). The RPEL 
domain however, is not the only element contributing to MRTF-A shuttling, as 
deletions of C-terminal sequences affect MRTF-A localisation (Miralles et al., 2003). 
Gene fusion experiments showed that the MRTF-A N-terminal sequences and 
RPEL domain are sufficient to confer MRTF-A-like shuttling (Guettler et al., 2008; 
Mouilleron et al., 2008). Data presented in this thesis show that, at least in the 
context of these fusions, S98 phosphorylation affects shuttling conferred by the 
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RPEL domain. Since S98 is located within the RPEL domain itself, I investigated 
the effect of S98 phosphorylation on actin binding. 
Size exclusion chromatography and fluorescence polarisation assays 
showed that phosphorylation of S98 did not alter actin binding to the isolated 
RPEL1 or Spacer1-RPEL2 peptides, but instead prevented recruitment of actin to 
RPEL1 in complexes formed with the intact RPEL domain. The aspartate 
substitution can at least in part mimic phosphorylation of S98.  
Although RPEL3 exhibits a low affinity for G-actin, its mutation results in 
severe deregulation of MRTF-A, indicating that the interaction is crucial for MRTF-A 
regulation. However the contribution of RPEL3 to regulation of MRTF-A by actin, is 
dependent on actin binding to RPEL1, Spacer1 and RPEL2 (Mouilleron et al., 
2011; Guettler et al., 2008; Mouilleron et al., 2008). 
Direct destabilisation of actin binding to RPEL1 through mutation of actin 
contact residues results in partial deregulation of MRTF-A (Guettler et al., 2008; 
Mouilleron et al., 2008). S98 phosphorylation would provide a subtle way of altering 
the regulatory properties of MRTF-A. Indeed, the BSAC isoform of MRTF-A lacks 
both the N-terminal NES and the ERK docking site that is required for S98 
phosphorylation. 
By lowering affinity of the RPEL domain for actin, S98 phosphorylation could 
increase the threshold at which RPEL/actin assembly occurs. S98 phosphorylation, 
could therefore act as a timer, by making MRTF-A refractory to actin reassociation, 
thereby prolonging nuclear accumulation and activity. A similar case is that of 
WASp activation. WASp activation involves release from an autoinhibitory 
conformation by initial binding of Cdc42 and PIP2 (Rohatgi et al., 2000).  
Subsequent phosphorylation of Y291 by Src family kinases acts as a mechanism of 
molecular memory, prolonging WASp activity (Torres and Rosen, 2003). 
The mechanism by which actin binding to RPEL1 is inhibited, is likely to 
involve occlusion of RPEL1, that requires sequences that are only present in the 
context of the whole RPEL domain. Introduction of a negative charge may cause 
intramolecular rearrangements that cause occlusion of RPEL1 thereby preventing 
actin binding.  
Phosphorylation of serine or threonine residues can have strong effects on 
the conformation and function of a protein, primarily through two types of 
interaction, (i) interaction of the negatively charged phosphoryl group with the main 
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chain nitrogens at the beginning of a polar alpha helix and (ii) interaction of the 
phosphate group with the side chain of arginine residues which form strong 
electrostatic interactions (L. N. Johnson and Lewis, 2001). 
S98 is in close proximity to the α2 helix of RPEL1. A simple model for how 
S98 inhibits actin binding would be that phospho-S98 coordinates with the RPEL1 
α2 helix, thereby disrupting the sharp turn in spacer1 and destabilising the 
interaction with actin. Alternatively, phospho-S98 could coordinate to the arginines 
of the RPEL1 motif making it inaccessible to actin. However, if either case were 
true, loss of actin binding would have been observed with the RPEL1 and RPEL1-
Spacer1 peptides. 
Instead, the observation that inhibition of actin binding can occur in the 
context of the whole RPEL domain supports a model where sequences required for 
RPEL1 occlusion are downstream of Spacer1. It is possible that S98 
phosphorylation enables additional contacts with actin bound to RPEL2 (See 
Figure 6.2), thereby preventing the RPEL1 motif from adopting the necessary 
orientation to bind actin. 
Because the S98D derivative of the RPEL domain formed a stable complex 
with two actin molecules in-vitro, it appears that actin binding downstream of 
RPEL1 is unaffected. Actin binding by Spacer2 and RPEL3 is not stable enough to 
endure the separation process in size exclusion chromatography (SEC). It 
therefore remains possible that the S98 phosphorylation affects formation of the 
pentameric complex.  For detection of the pentameric complex by SEC, actin 
needs to be present in the running buffer during the separation (Mouilleron et al., 
2011) and it would be interesting to evaluate the effects of phospho-S98 or S98D in 
this assay.  
In cells, inability to form the import defective pentameric assembly could 
result in MRTF-A activity in conditions that would normally be inhibitory. For 
example MRTF-A import is blocked at tensional homeostasis and it has been 
proposed that the block is a result of a high G/F actin ratio (McGee et al., 2011). 
Because MRTF-A is itself part of the homeostatic loop, it would be interesting to 
test whether in the presence of higher basal MAPK activity homeostasis is 
achieved at higher tension (Salvany et al., 2014; Esnault et al., 2014). 
A simple way to test whether S98 phosphorylation raises the threshold for 
pentameric complex assembly, would be to test MRTF-A (2-204)-PK serum 
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induced nuclear accumulation, against a gradient of G-actin. MRTF-A (2-204)-PK-
S98A, which cannot be phosphorylated, would be more susceptible to import 
blockade, and nuclear accumulation should be blocked at a lower concentration 
compared to wild type MRTF-A (2-204)-PK. 
 
 
Figure 6.2 Potential mechanism by which S98 phosphorylation blocks actin 
binding to RPEL1 
S98 phosphorylation blocks actin binding to RPEL1 only in the context of the entire 
RPEL domain. Addition of the phosphate moiety may promote conformational 
changes that inhibit RPEL1 from adopting the necessary conformation to bind 
actin. 
 
6.8 MRTF-A export 
 
 While disruption of actin binding by CD or RPEL mutations, substantially 
reduces MRTF-A export, as measured by FLIP, it does not completely block it 
(Vartiainen et al., 2007). These observations have led to the idea that actin 
functionally cooperates with Crm1, but the NES involved and the mechanism of 
cooperativity have not been described. 
 N-terminal sequences of MRTF-A are sufficient for regulation, but C-terminal 
sequences also contribute to MRTF-A localisation. Miralles et al. showed that 
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deletion of the C-terminus (leaving MRTF-A 1-563) renders MRTF-A constitutively 
nuclear, indicating that sequences that promote export are present in the C-
terminus. In addition, deletion of the N-terminus (leaving MRTF-A 200-1021) also 
led to constitutive nuclear accumulation, suggesting that export-promoting 
sequences are also present in the first 200 residues (Miralles et al., 2003). 
Muehlich et al. have reported a NES in the Q-box (residues 356 -377), mutation of 
which leads to constitutive nuclear localisation (Muehlich et al., 2008). Hayashi et al. 
reported two regions, one within the α1 helix of RPEL1 (residues 73-78) and 
another in the Q-box (residues 356 -377) (Hayashi and Morita, 2013). They show 
that both regions individually bind Crm1 and mutation of both reduces Crm1 
association by 80% (Hayashi and Morita, 2013).  
 MRTF-A subcellular localisation is therefore defined by the net effect of 
multiple sequences that affect import and export. Regulation of shuttling however is 
managed by actin binding to the RPEL domain.  
 
6.9 The MRTF-A RPEL domain is not sufficient for Crm1-
mediated export 
 
 Phactr1 subcellular localisation, like MRTF-A, is regulated by actin binding 
to its RPEL domain and in both cases actin competes with importins for binding to 
the RPEL domain (Wiezlak et al., 2012). Phactr1 however, is not exported by Crm1. 
Structural analysis and comparison of how the two RPEL domains bind actin 
revealed that the difference is that the 6-residue-shorter spacers of Phactr cannot 
bind actin. Otherwise, the relative orientation and distances between the actins 
bound to RPEL1, 2 and 3 of each RPEL domain, are almost identical (Mouilleron et 
al., 2012). Since in both proteins a triple RPEL repeat is required for regulation, 
they allowed investigation of the relationship between Crm1 dependence and the 
RPEL domain. 
 In agreement with previous observations (Maria W, unpublished), when the 
RPEL domain of MRTF-A was replaced with that of Phactr1, the resulting chimera 
was cytoplasmic and did not accumulate in the nucleus after serum stimulation or 
LMB treatment, even for prolonged periods of time. While this shows that the RPEL 
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domain of Phactr1 cannot functionally replace that of MRTF-A, it remains unclear 
whether the failure of the chimera to respond to Crm1 blockade reflects the weaker 
Phactr1 NLS or a true functional difference. 
The reciprocal exchange, replacing the Phactr1 RPEL by that of MRTF-A, 
allowed greater insight. The chimera showed greater basal levels of nuclear 
accumulation compared to Phactr1, which could be reduced by mutation of the 
NLS elements, without loss of regulation. Export however was Crm1 independent. 
The RPEL domain alone therefore is not sufficient to confer Crm1 mediated export. 
The Phactr1 chimera containing the N-terminus + RPEL domain was indeed 
LMB sensitive, suggesting that an NES is present in the N-terminus. The chimera 
was dependent on actin for cytoplasmic localisation, however Crm1 mediated 
export was independent of actin.  
 
6.10  A nuclear export signal in the N-terminus 
 
 The inability of the RPEL domain alone to confer Crm1 mediated export 
suggested that the N-terminus (2-67) contained an NES. The Phactr1 chimera 
containing the N-terminus + RPEL domain was indeed LMB sensitive, consistent 
with the presence of an NES in the N-terminus. 
 Analysis of the MRTF-A amino acid sequence using the NES prediction 
software NetNES suggested the presence of an NES in the N-terminus of MRTF-A, 
between residues 37-48. Being located on a terminal unstructured region of a 
protein is also a characteristic of NES sequences (Mouilleron et al., 2011; Güttler et 
al., 2010). An Alanine scan across the N-terminus of MRTF-A revealed an NES, 
the minimal core of which is amino acids 35-52. In the context of amino acids 2-67 
the NES exhibited more efficient export, probably due to the presence of S33 that 
promotes export. The phospho-specific pS33 antibody could be used to test 
whether S33 is phosphorylated in Rev 2-67 and not Rev 30-60. The export activity 
exhibited by the Rev 2-67 was entirely dependent on the integrity of the leucine rich 
sequence. 
 Consistent with these data, GST-2-67 was able to directly bind Crm1 in a 
Ran-dependent manner in-vitro and the Crm1 interaction was abolished by 
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mutation of the leucine rich sequence. Since the N-terminus does not bind actin 
(Vartiainen et al., 2007), its function must be affected by the RPEL domain, which 
does bind actin. 
 
6.11  The N-terminus and RPEL domain cooperate to confer 
actin regulated shuttling 
 
Insertion of the N-terminus, (2-67) into RevΔ, conferred Crm1 dependent 
export, which was enhanced by inclusion of C-terminal sequences extending into 
the RPEL domain. To investigate how the RPEL domain promotes export and 
allows regulation by actin, a variety of MRTF-A sequences were inserted into the 
Rev construct. In some experiments, the NLS of MRTF-A was inactivated, 
eliminating the possibility of actin regulated import.  
Although residues 67-115 that correspond to RPEL1-Spacer1, did not 
exhibit any export activity, they potentiated that of residues 2-67. In agreement with 
this, GST-2-115 associated better with Crm1 compared to GST-2-67 in-vitro, in the 
absence of actin. These results suggest that the N-terminal NES interacts with the 
hydrophobic groove of Crm1 and the sequences C-terminal can form additional 
contacts with Crm1. Such additional interactions were previously reported in the 
case of Snurportin/Crm1 binding (Monecke et al., 2009). Furthermore, in a 
subsequent study Snurportin (residues 15-360) was fused to the PKI NES, which 
stabilised interaction between the NES and the hydrophobic groove of Crm1 
(Güttler et al., 2010).  
Consistent with the observation that RPEL sequences per se enhance 
interaction with Crm1 in-vitro, loss of contact mutations in RPEL1 did not abolish 
the enhancement in export activity, as assessed in the context of Rev (2-115) GFP. 
Interestingly, mutation of R81 enhanced export activity.  
The R81A mutation lowers affinity of RPEL1 for actin (Guettler et al., 2008), 
but resulted in an opposite effect to that of the other mutations which abolish actin 
binding. The data suggest that weaker actin binding to RPEL1 promotes Crm1 
binding.  
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The RPEL domain is unstructured in solution and forms transient α-helices 
(Mizuguchi et al., 2014; Mouilleron et al., 2008). Actin binding stabilises formation 
of the helices observed in the actin-RPEL motif structures (Mouilleron et al., 2008). 
Actin binding to RPEL1 may occlude the sequences that potentiate Crm1 binding, 
but promote presentation of the N-terminal NES and stabilise the conformation 
required to enhance Crm1 binding. Less stable actin binding to RPEL1 may allow 
more efficient exchange of those sequences between actin and Crm1 (Figure 6.3). 
While residues 67-115 enhanced export activity of the N-terminus, 67-204 
B2A enhanced export activity even further. In addition, fusion of 67-204 B2A to the 
N-terminal NES enabled regulation of export activity by actin. Therefore, actin 
regulation of Crm1-dependent export requires all actin-binding elements of the 
entire RPEL domain.  
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Figure 6.3 Binding of Crm1 to the N-terminal NES is facilitated by RPEL1-
Spacer1 
The N-terminal NES can autonomously bind Crm1 but C-terminal sequences 
facilitate binding. Based on this and other observations described in this thesis, the 
following model can be proposed. (i) In the absence of actin, the N-terminus 
switches between an open and closed conformation by association with RPEL1 
sequences. (ii) In the open conformation Crm1, shown in green, is able to bind the 
NES and mediate export. The process can be “catalysed” by actin. (iii) Actin 
binding to RPEL1 stabilises the open conformation (iv) thereby making the NES 
more readily accessible to Crm1. (v) In a second step actin is displaced from 
RPEL1 and additional contacts are formed between Crm1 and RPEL, leading to 
formation of a stable export complex. The steps that could be affected by S33 and 
S98 phosphorylation are indicated. The R81A mutation, which weakens affinity of 
the RPEL1-actin interaction, could promote exchange of the RPEL1 sequences 
from actin to Crm1. 
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6.12  The role of phosphorylation in the N-terminal region of 
MRTF-A 
 
 S98 phosphorylation promotes MRTF-A nuclear accumulation in response 
to ERK signalling. Nuclear accumulation observed after TPA stimulation or RafER-
mediated activation of ERK is more pronounced in the context of the isolated N-
terminus compared to the full-length protein. This is due to the fact that in the full 
length protein the relative contribution of the RPEL domain is smaller than in the 
MRTF-A-(2-204)-PK fusion. 
 TPA stimulation leads to increased G-actin levels, which may mask the 
effects of S98 phosphorylation. However when RafER was used to activate ERK, 
nuclear accumulation of full length MRTF-A was also weak. In starved cells G-actin 
levels are relatively high because of low Rho activity. It is therefore possible that G-
actin concentration was too high for phosphorylation of S98 to exert an effect.  
 It would be interesting to test this hypothesis by comparing localisation of 
MRTF-A-(2-204)-PK and MRTF-A-(2-204)-PK S98D across a range of G-actin 
levels. By lowering the affinity of the RPEL domain for actin, pS98 may allow 
MRTF-A nuclear accumulation at higher G-actin levels, enabling MRTF-A to be 
activated in response to smaller decreases in cellular G-actin levels (Figure 6.4). In 
addition S98 phosphorylation could impair formation of the pentameric MRTF-
A/actin complex, thereby preventing import inhibition at G-actin concentrations that 
normally would be inhibitory.  
 As described in section 1.3.7, nuclear actin dynamics can be regulated. A 
change in the F/G actin ratio could differentially affect actin binding proteins in the 
nucleus, depending on their affinity for actin. For example, a brief change in nuclear 
G-actin may not affect a protein stably bound to an actin monomer. One may 
speculate that ERK activity could increase the presence of MRTF-A in the nucleus, 
and in a brief, transient decrease in nuclear G-actin levels, more MRTF-A would be 
readily activated. 
 In a recent publication, Aoki et al. showed that cell density affects stochastic 
ERK activity pulses (Aoki et al., 2013). Sequencing of RNA from cells subjected to 
pulsatile ERK activity revealed an enrichment in SRF binding sites in pulse-induced 
genes. One could therefore speculate that ERK activity pulses could activate MRTF 
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in two ways. ERK could phosphorylate S98 and promote actin dissociation and 
nuclear accumulation. In addition, ERK could phosphorylate other phosphorylation 
sites on MRTF-A thereby potentiating activation of target gene expression.  
 In the absence of stimulation, MRTF-A is nuclear in a small proportion of 
cells. Because cell density was shown to be inversely related to ERK activity pulses, 
I tested whether cell density could affect the proportion of nuclear scoring cells. 
Preliminary data show that indeed the proportion of cells with nuclear MRTF-A-(2-
204)-PK decreases as cell density increases (Figure 6.5). In addition MRTF-A-(2-
204)-PK S98D is unaffected by cell density. However, nuclear localisation of 
MRTF-A-(2-204)-PK S98A is affected, suggesting that ERK activity is not the only 
determinant of localisation of the fusion. Further investigation is needed to 
determine whether this is solely an effect of ERK pulses and why the S98A 
derivative is affected. For example, immunofluorescence experiments can be 
carried out to test for coincident ERK activity and MRTF-A-(2-204)-PK nuclear 
accumulation. In addition S33 phosphorylation should also be taken into account. 
Furthermore, if the increase in MRTF-A-(2-204)-PK nuclear accumulation is ERK 
dependent, it should be tested for U0126 sensitivity. 
 S33 is also present in the N-terminal region of MRTF-A, in close proximity to 
the NES. S33 is phosphorylated in starved conditions and promotes MRTF-A 
export. The mechanism by which pS33 promotes MRTF-A export was not 
determined. However, since S33 mutants had affected export in the context of the 
isolated N-terminus (2-67) in the Rev assay, it is likely that S33 directly enhances 
Crm1 binding to the N-terminal NES. Alanine substitution of S33 led to moderate 
nuclear accumulation, in agreement with the observation that S33 is 
phosphorylated. S33A also potentiated nuclear accumulation of S98 
phosphorylation, suggesting that the mechanism of how S98 affects steady state 
involves accessibility of Crm1 to the N-terminal NES. 
 Multiple studies have shown that proteins such as ERF (Le Gallic et al., 
2004) , HIF1α (Mylonis et al., 2006) and CIITA (Voong et al., 2008) depend on 
ERK-mediated phosphorylation for promotion or inhibition of Crm1-mediated export. 
However it was not determined whether phosphorylation directly affected Crm1 
binding to the NES, or whether conformational changes led to masking/unmasking. 
 The finding that phosphorylation of MRTF-A promotes export, is in 
agreement with Muehlich and colleagues (Muehlich et al., 2008). However S33 was 
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not present in the MRTF-A derivative used in their studies and cannot be involved 
in their observations. In addition, in the context of MRTF-A-(2-204)-PK where pS33 
affects localisation, their proposed sites (S544, T545, S549)  are absent.  
  
 
 
 
Figure 6.4 Effect of S98 phosphorylation on regulation of MRTF-A localisation 
S98 phosphorylation blocks actin binding to RPEL1, which could affect the overall 
affinity of the RPEL domain for actin. Lowering the affinity of the RPEL domain for 
actin would allow for nuclear accumulation of MRTF-A at higher G-actin 
concentrations. Thus, the MAPK pathway can affect sensitivity of MRTF-A to Rho-
actin signalling. 
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Figure 6.5 Effect of cell density on MRTF-A (2-204) PK localisation 
NIH-3T3 cells, seeded at different confluencies were transfected with wild type, 
S98A or S98D derivatives of MRTF-A (2-204) PK fusion protein. Localisation was 
determined by immunofluorescence using an anti flag antibody. At least 100 cells 
were counted and localisation was scored as predominantly nuclear (navy blue), 
pancellular (lilac) or predominantly cytoplasmic (light blue). Error bars represent 
standard error of the mean (SEM) from at least two independent experiments. 
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6.13  Conclusions 
 
In this thesis, I have shown that MRTF-A is subject to regulatory 
phosphorylation, which impinges on at least two levels: localisation and 
transactivation efficiency. Phosphorylation on multiple sites is required for maximal 
MRTF-A activity. Amongst 26 phosphorylation sites, scattered across MRTF-A, 
S33 and S98 are located in the N-terminus and RPEL domain respectively.  
S98 phosphorylation abolishes actin binding to RPEL1 and promotes 
nuclear accumulation. S98 is phosphorylated by ERK, which requires an ERK 
docking site located N-terminal to S98. Thus, S98 represents a mechanism by 
which ERK signalling can affect how MRTF-A senses Rho signalling; the major 
regulatory pathway of MRTF-A. 
In contrast, S33 phosphorylation promotes MRTF-A export, probably by 
enhancing the interaction between Crm1 and the leucine rich NES which was 
identified in this study. Although the mechanism by which actin promotes MRTF-A 
export was not elucidated, I have shown that the RPEL domain itself does not 
possess a Crm1-dependent NES, but is able to cooperate with the N-terminal NES 
to confer actin and Crm1 dependent export. 
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